The regulation of myeloid cell survival: Emerging roles for the pro-survival protein HAX1 by Sadiku, Pranvera

  
The regulation of myeloid cell 
survival: Emerging roles for the 
pro-survival protein HAX1 
 
Pranvera Sadiku 
Academic Unit of Respiratory Medicine 
Department of Infection and Immunity 
University of Sheffield 
 
Thesis submitted for the degree of Doctor of Philosophy 
September 2014 
 
 
 1 
Abstract 
The regulation of myeloid cell apoptosis is critical in both the control of 
inflammation and homeostasis. HAX1, a ubiquitously expressed multifunctional 
protein is thought to play a key role in cell survival. HAX1 mutations in the 
human result in premature apoptosis of bone marrow myeloid progenitor cells 
and a profound PMN (peripheral blood neutrophils) deficiency, suggesting 
HAX1 plays a critical role in PMN homeostasis. Human PMN are genetically 
intractable and Hax1 homozygous mice have been shown to die at 14 weeks of 
age. The molecular pathways in which HAX1 is involved are therefore yet to be 
elucidated. We hypothesised that HAX1 would play a critical role in constitutive 
cell death through effects on mitochondrial membrane stability and that hax1 
deficient zebrafish embryos would have defective PMN development and 
survival.   
 
HAX1 expression was studied in primary PMN (prepared from venous blood of 
healthy volunteers), myeloid leukaemia cell line PLB-985 and wild type 
zebrafish embryos by western blotting, RT-PCR and in situ hybridisation. HAX1 
was knocked down in the human myeloid leukaemia cell line PLB-985 and hax1 
deficient zebrafish mutants were created in an MPO driven GFP transgenic line 
using antisense morpholino oligonucleotides (MO) or TALEN technology. 
 
PLB-985 and primary PMN express multiple HAX1 isoforms at the mRNA level, 
including the full-length isoform. I present data revealing the modulation of 
HAX1 in response to inflammatory stimuli in PLB-985 and show that HAX1 
expression decreases during constitutive ageing of PMN. Zebrafish express 
multiple isoforms of hax1, providing novel evidence for alternative splicing of the 
gene in the model organism. hax1 MO injected embryos exhibit a reduction in 
PMN numbers, which may be due either to a loss of Hax1 or to the concomitant 
developmental delay observed. The hax1 targeting TALEN generated efficiently 
modified the hax1 gene and was successfully transmitted through the germline. 
Preliminary data suggest that the HAX1 knockdown in PLB-985 cells and the 
hax1 homozygous mutation generated in the zebrafish are not important in 
PMN lifespan. 
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1 General introduction 
1.1 Immunity 
The mammalian immune system consists of various cell types and signalling 
cascades essential in maintaining homeostasis and defence against 
pathogenic microorganisms. The immune system can be arbitrarily divided 
into two components, innate and adaptive immunity. The innate immune 
system is the first line of defence against pathogens. It is primarily mediated 
by the professional phagocytes polymorphonuclear neutrophils (PMN) and 
macrophages (Silva 2010). These cells recognise microorganisms through a 
limited number of pattern recognition receptors (PRRs), which are highly 
conserved among species from plants to mammals (Takeuchi & Akira 2010). 
This is in contrast to adaptive immunity, which utilises a large repertoire of 
specific receptors found on B and T lymphocytes and is capable of 
generating ‘immunological memory’ (Zinkernagel et al. 1996). An acquired 
immunity response is highly specific and is mediated in the later phase of 
infection. It is characterised by the clonal expansion of lymphocytes bearing 
antigen-specific receptors.  
 
1.2 Inflammation 
1.2.1 Leukocyte recruitment 
Inflammation and the clinical symptoms and signs of inflammatory disease 
were first described by the Roman Cornelius Celsus, in the first century. The 
four key signs of inflammation were defined as: redness, swelling, heat and 
pain (Rather 1971). It was later established that an imbalance of these four 
“cardinal signs” leads to the development of disease. In the second century 
A.D., impaired function was identified as the fifth “cardinal sign” of 
inflammation (Rather 1971). Robert Koch and Louis Pasteur later went on to 
hypothesise that microorganisms are a major cause of an inflammatory 
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response. It is now accepted that a controlled inflammatory response is 
initiated as a host defence mechanism against pathogens.  
 
1.2.2 Pattern recognition receptors 
Inflammation is characterised by increased blood flow, vascular dilation, 
capillary permeability and leukocyte recruitment to the site of infection or 
injury. It is in part initiated by the tissue resident macrophages and mast cells 
that act as sentinels and recognise highly conserved pathogen-associated 
molecular patterns (PAMPs). This “pattern recognition” event occurs through 
PRRs such as Toll-like receptors (TLRs) and nucleotide binding 
oligomerisation domain receptors (NLRs), expressed by macrophages and 
mast cells (Takeda et al. 2003; K. S. Kobayashi et al. 2005). TLRs are the 
most well characterized PRRs and play a major role in the recognition of 
both endogenous and exogenous stimuli (Takeda et al. 2003). They 
recognise PAMP signals across Gram positive and negative bacteria and 
viruses (Takeda et al. 2003). 
 
PRRs can also recognise and bind to danger associated molecular patterns 
(DAMPs) such as ATP (adenosine triphosphate) and mRNA (messenger 
ribonucleic acid) released from damaged or stressed cells (Gallucci & 
Matzinger 2001; Kariko et al. 2004). This enables the immune system to not 
only distinguish between ‘self’ and ‘non-self’ but also between ‘healthy’ and 
‘damaged self’. PRR ligation results in the activation of a signalling cascade, 
which culminates in the activation of a number of transcription factors 
including NF-κB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) and interferon-regulatory factor (IRF) (Baldwin Jr. 1996; Kawai & Akira 
2007).  
 
PRR signalling results in the production of numerous inflammatory factors 
(Medzhitov 2008). These include chemokines, cytokines and pro-
inflammatory lipid mediators that can elicit local and systemic inflammatory 
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responses, which highlights the role of PRRs in leukocyte recruitment. 
Leukocytes are recruited to sites of infection and inflammation through 
functional gradients of chemokines, which are cytokines with 
chemoattractant function and in addition to leukocytes are also produced by 
endothelial, stromal and epithelial cells (Kumar & Sharma 2010). This 
process is known as chemotaxis. 
 
Leukocyte recruitment from the circulation into tissues is essential for the 
development and appropriate maintenance of an inflammatory response. 
The type and length of the response are governed by the inflammatory 
trigger (Medzhitov 2010). The fate of inflammation is regulated by 
neutrophils, macrophages, mast cells and dendritic cells, which sense the 
pro-inflammatory signals and in turn release inflammatory mediators to 
regulate the duration and amplitude of the response. Neutrophils are among 
the first leukocyte type to accumulate at the inflamed tissue (Nathan 2006). 
During inflammation, these cells combine their anti-infectious role with a pro-
inflammatory role (Weiss 1989; Ward & Lentsch 1999). 
 
1.3 PMN 
PMN were first discovered by Elie Metchnikoff as migrating and 
phagocytosing cells in starfish larvae in response to inserted rose thorns 
(Cavaillon 2011). The cells are on average 10 μm in diameter and have a 
characteristic lobulated-chromatin dense nucleus (Korchak et al. 1983). They 
belong to a group of leukocytes known as granulocytes that are 
characterized by the presence of granules in the cytoplasm. Based on the 
histological properties of the granules, granulocytes can be divided into PMN, 
eosinophils and basophils. PMN constitute 60 % of the circulating leukocyte 
population in the blood (Smith 1994). They are produced in the bone marrow 
and it is estimated that in the human, between 5 x 1010 and 10 x 1010 are 
formed each day (Summers et al. 2010).   
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1.3.1 PMN terminal differentiation 
PMN production and differentiation from hematopoietic stem cells in the 
bone marrow is modulated by two cytokines known as granulocyte colony-
stimulating growth factor (GCSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Cannistra & Griffin 1988). The cells first appear 
in the human marrow cavity at 10-11 weeks post-conception (Slayton et al. 
1998) and mature to become terminally differentiated cells within 14 days 
(Haylock et al. 1992). The majority of a PMN’s life is spent in the bone 
marrow and under physiological conditions only 2 % of the cells are found in 
the circulation (Semerad et al. 2002).  
 
PMN terminal differentiation, termed granulopoiesis, begins during the 
myeloblast and promyelocyte stages at which point proliferation is switched 
to differentiation (Glasser & Fiederlein 1987). During the promyelocytic cell 
stage, in addition to losing the ability to undergo cell division, the cells form 
the first granules known as azurophilic granules. These granules are defined 
by a high content of myeloperoxidase, defensins and proteases such as 
PMN elastase (Borregaard et al. 1993; Pham 2006). Differentiation of 
promyelocytic cells progresses into the development of myelocytes and 
metamyelocytes (Glasser & Fiederlein 1987). During these states, nuclear 
segmentation is initiated and the cells form secondary granules required for 
respiratory burst and bactericidal activity (Borregaard & Cowland 1997). 
Metamyelocytic cells differentiate into band PMN, which in turn go on to 
become segmented neutrophils (Glasser & Fiederlein 1987). Segmented 
PMN have segmented nuclei and form secretory and tertiary granules 
characterised by a high content of enzymes such as gelatinase and 
lysozyme (Borregaard & Cowland 1997). During stress and infection the rate 
of PMN differentiation can increase by 10-fold (Cannistra & Griffin 1988).  
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1.3.2 PMN migration to the site of infection/injury 
PMN circulate in the blood in a relatively functionally quiescent state until 
stimulated by an infection (Southgate et al. 2008). These cells exist in 
numerous subpopulations in various states of activation ranging from the 
inactive resting state to the fully activated state (Gallin 1984).  Primed PMN 
acquire a state of pre-activation and this enables them to produce a more 
powerful response once fully activated.  
 
PAMP binding induces sentinel cells to produce numerous pro-inflammatory 
cytokines including interleukin-1β (IL-1β), tumour necrosis factor-α (TNF- α), 
chemokines and other lipid mediators (Zeytun et al. 2010). These act to 
rapidly recruit PMN to the inflammatory peripheral tissues. PMN 
extravasation occurs in the postcapillary venules and pulmonary capillaries 
(Downey et al. 1993). Their recruitment has been shown to involve both 
selectin and integrin dependent mechanisms (Adams & Shaw 1994; 
Springer 1994).  
 
A multistep sequential adhesion cascade is initiated on contact of free-
flowing PMN to the activated vascular endothelium. It is thought that the 
vasculature acts as a fast-track system for PMN whereby PMN approach the 
injured or infected site as closely as possible within the blood vessel 
(McDonald et al. 2010). During the first step of the PMN adhesion cascade 
known as tethering, PMN become transiently adherent to the endothelium 
(Springer 1994). Tethering results in rolling of PMN along the endothelium, 
which involves PMN L-selectins and E- and P-selectins expressed on the 
endothelial wall (Lawrence & Springer 1991; Lawrence & Springer 1993; 
Phillips et al. 1995; Moore et al. 1995; McEver & Cummings 1997). During 
the rolling step, PMN transmigration into the inflammatory site is promoted 
through the production of chemoattractants such as platelet-activating factor 
(PAF) and Interleukin-8 (IL-8) (Walz et al. 1987). These are immobilised on 
the luminal surface of endothelial cells via glycosaminoglycans (Premack & 
 25 
Schall 1996; Matsumoto et al. 1997). Chemoattractant production results in 
the activation of PMN, which in turn leads to firm adhesion to the endothelial 
cells. This occurs through PMN β2-integrins (Zimmerman et al. 1992). In 
order to prevent cytotoxic damage to the host, PMN activation appropriately 
occurs in regions proximal to the inflammatory site (Swain et al. 2002).  
 
Following PMN activation, β2-integrins bind to their physiological ligand 
Intercellular Adhesion Molecule 1 (ICAM-1) with enhanced affinities allowing 
firm adhesion to occur (Sligh  Jr. et al. 1993; Stewart & Hogg 1996). Once 
PMN have firmly bound to the endothelium, numerous surface molecules 
including Platelet Endothelial Cell Adhesion molecule 1 (PECAM-1), ICAM-1, 
CD44 and CD47 facilitate transmigration to the peripheral tissue (Diamond et 
al. 1990; Muller et al. 1993). PMN movement across the endothelial cell 
layer and basement membrane is also known as diapedesis and has been 
shown to almost always occur through the endothelial cell borders (Sumagin 
& Sarelius 2010; Woodfin et al. 2011).  
 
Once into the interstitial tissue, PMN migrate to the site of injury or infection 
along a gradient of immobilised chemoattractants and this process is known 
as haptotaxis (Foxman et al. 1999). PMN sense the gradients through G-
protein-coupled-seven-transmembrane glycoprotein receptors and receptors 
for the chemoattractant, C-X-C chemokines (Premack & Schall 1996; 
Yokomizo et al. 1997). The ligation of these receptors to the 
chemoattractants results in the activation of numerous signalling cascades 
regulating PMN degranulation, reactive oxygen (ROS) production, 
cytoskeletal organisation, cell adhesion and motility (Cox et al. 1997; Thelen 
& Didichenko 1997; Nobes & Hall 1999). 
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1.3.3 The role of PMN in infection 
The principal role of PMN is to destroy invading microorganisms at sites of 
infection through binding and ingestion, a process known as phagocytosis, 
and degranulation in areas where phagocytosis of pathogens is not possible 
(Bellocchio et al. 2004; Lotz et al. 2004; Brinkmann et al. 2004). Granule 
proteins and chromatin are also released by PMN that form extracellular 
fibres known as neutrophil extracellular traps (NETs) (Brinkmann et al. 2004). 
NETs bind Gram positive and Gram negative bacteria and prevent their 
spreading while simultaneously ensuring a high exposure to anti-microbial 
granule contents for destroying the pathogen. PMN antimicrobial activity is 
caused primarily by the production of ROS and the antimicrobial and 
hydrolytic proteins found in their granules (Spitznagel 1990; Quinn & Gauss 
2004). Following PMN activation, oxygen consumption of the cell increases 
dramatically and this process is termed the respiratory burst (Babior 1984). It 
involves the enzymatic complex, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (DeLeo & Quinn 1996). This complex 
generates superoxide anion (O2-), which in turn can react with other 
molecules to form ROS including hydrogen peroxide, which are critical in the 
killing of ingested microorganisms (Babior 1984; Nathan 1987)). Proteins 
such as myeloperoxidase present in PMN granules amplify the toxic effects 
of the hydrogen peroxide through the generation of hypochlorous acid and 
chloride anions (Klebanoff 1968).  
 
In addition to their ability to phagocytose, PMN can also resolve infections 
through the release of ROS and granules containing degradative enzymes 
(Dransfield & Rossi 2004; El Kebir & Filep 2010). PMN responses to 
infection can therefore result in considerable damage to host tissues 
themselves (Melley et al. 2005). This means that PMN apoptosis has to be a 
finely controlled process by extrinsic and intrinsic factors in order to maintain 
a balance between PMN defence functions and safe clearance (Savill, 
Wyllie, et al. 1989; Bianchi et al. 2006; Luo & Loison 2008).  
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1.3.3.1 PMN granule content and action against pathogens 
Human PMN are characterised by the existence of multiple granules varying 
in morphology and size (Borregaard & Cowland 1997). Whilst some PMN 
granules such as the azurophilic granule predominantly contain antimicrobial 
and degradative enzymes that are released into the phagolysosome, others 
are specifically destined for extracellular release (Cowland et al. 1995; 
Lollike et al. 1995). Azurophilic granules contain numerous antibiotic proteins 
including myeloperoxidase and serine proteases (Fouret et al. 1989). These 
compartments are though to be mobilised upon phagocytosis of pathogens. 
Furthermore, the contents of these granules result in the activation of 
numerous cells including epithelial cells, macrophages and lymphocytes 
(Owen & Campbell 1999).  
 
Other PMN granules are myeloperoxidase negative and can be divided into 
secondary and tertiary granules (Kjeldsen et al. 1992). These differ in their 
secretory and content properties. Secondary granules are known as specific 
granules and contain high levels of potent antimicrobial agents such as the 
peptidoglycan cleaving protein lysozyme and lactoferrin, which binds to iron 
and can also cause irreversible damage to bacterial cell membranes 
resulting in cell lysis (Cramer et al. 1985; Lollike et al. 1995; Chapple et al. 
1998). Conversely, tertiary granules are also known as gelatinase granules 
as a result of comprising the highest content of gelatinase (a 
metalloprotease) out of all of the different granule types (Kjeldsen et al. 
1992). These granules contain numerous metalloproteases, stored in an 
inactive form and capable of degrading structural and extracellular matrix 
components upon proteolytic activation (Lazarus et al. 1968; Kjeldsen et al. 
1992; Borregaard & Cowland 1997).  
 
1.3.3.2 PMN apoptosis 
Circulating PMN have a short life span, estimated to be between 8 and 20 
hours (Savill, Henson, et al. 1989; Luo & Loison 2008). The short-half life of 
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circulating PMN is a result of constitutive apoptosis, which is essential for the 
resolution of inflammation and maintenance of homeostasis (Luo & Loison 
2008). PMN that have been recruited to tissue where they are required to 
resolve infection, live longer in order to maximise their immunologic potential 
(1-4 days) (Elbim & Estaquier 2010).  
 
Apoptosis is the major mechanism regulating PMN number, and the 
mechanisms controlling apoptosis will be discussed in section 1.6 (Shi et al. 
2001). PMN undergoing apoptosis are unresponsive to extracellular stimuli 
and express signals that target the cells for recognition and phagocytosis by 
scavenger receptors expressed by macrophages (Savill et al. 1990; Haslett 
et al. 1994; Savill & Haslett 1995). Prolonged PMN lifespan can result in the 
increased disease severity of numerous non-infectious inflammatory 
diseases including chronic obstructive pulmonary disease (COPD), chronic 
lung disease, rheumatoid arthritis and asthma (Kotecha et al. 2003; Pletz et 
al. 2004; Filep & El Kebir 2009; Wong et al. 2009; Brown et al. 2009; 
Moriceau et al. 2010; Baines et al. 2010).  Concomitant with delayed 
apoptosis, the prolonged production of pro-inflammatory mediators by tissue 
neutrophils also contributes to the perpetuation of inflammation. In contrast, 
accelerated PMN apoptosis can lead to a reduction in PMN number and may 
prevent efficient responses to invading pathogens (Carlsson et al. 2004; 
Klein et al. 2007). A precise balance between PMN defence properties and 
safe clearance is therefore crucial for the maintenance of homeostasis. 
 
The constitutive rates of apoptosis in PMN are tightly regulated compared to 
other leukocyte types. It has been shown that PMN can undergo apoptosis 
even in the absence of extracellular signals (Filep & El Kebir 2009). 
Apoptosis can also however, be accelerated by some cytokines and death 
receptor ligand binding on the surface of the cells, although this is not 
thought to be an important mechanism of PMN cell death (van Raam et al. 
2006). Although it remains controversial, it is thought that the mitochondria of 
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PMN play a crucial role in regulating the programmed cell death pathways in 
these cells (Maianski et al. 2004). PMN survival can be extended by 
inflammatory cytokines such as TNF-α, GM-CSF and LPS while 
simultaneously preserving cellular function (Lee et al. 1993). 
 
1.4 Inflammation resolution 
The primary goal of an acute inflammatory response is elimination of 
infectious agents with spontaneous resolution, in turn restoring homeostasis 
and limiting excessive host tissue damage (Van Dyke & Kornman 2008). 
Once the pathogen has been cleared, there is a progressive decrease in 
PMN recruitment due to an increase in the secretion of anti-inflammatory 
cytokines and a return of endothelial cells to their resting state.  There is also 
a switch in expression from anti-inflammatory to pro-resolution endogenous 
lipid mediators such as protectins, lipoxins and maresins that act as “stop 
signals” (Bannenberg & Serhan 2010). These inhibit PMN chemotaxis, 
adhesion and transmigration (Diamond et al. 1999; Bannenberg & Serhan 
2010).  
 
The induction of PMN apoptosis plays a key role in inflammation resolution. 
It has been shown that following phagocytosis of bacteria, PMN apoptosis is, 
in some cases, significantly accelerated (Kobayashi et al. 2003). Apoptosis 
results in impaired PMN functional capacity causing reduced chemotaxis, 
phagocytosis, degranulation and respiratory burst, therefore limiting further 
inflammation (Whyte, Meagher, et al. 1993; S. D. Kobayashi et al. 2005). 
The subsequent ingestion of PMN by macrophages (efferocytosis) is the 
major mechanism for PMN clearance at the site of inflammation (Savill & 
Haslett 1995; Savill 1997). Apoptotic PMN express phosphotidylserine on 
their cell surface, which triggers their recognition and phagocytosis by 
macrophages (Savill et al. 1993; Homburg et al. 1995). In human and mice, 
removal of PMN also occurs in the bone marrow, spleen and in the liver, in 
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Kupffer cells (Savill, Wyllie, et al. 1989; Savill et al. 2002; Furze & Rankin 
2008).  
 
Efferocytosis is critical in inflammation resolution not only by removing the 
source of the inflammation but also by a phenotypic switch to a pro-
resolution phenotype consistent with inflammation resolution and tissue 
repair (Fadok et al. 1998).  For example, the production of pro-inflammatory 
cytokines such as GM-CSF, IL-1β, IL-8 and leukotriene C4 is inhibited in the 
phagocytosing macrophages and anti-inflammatory genes such as TGF-β 
(transforming growth factor β) and PAF are expressed (Fadok et al. 1998; 
Gerber & Mosser 2001).  Although it has been shown in mice that Fas ligand 
(FasL)/Fas death receptor mediated apoptosis is not essential for regulating 
PMN lifespan during an acute inflammatory response (Fecho & Cohen 1998), 
macrophages can trigger PMN apoptosis by expressing FasL on their 
surface and releasing soluble FasL, which binds to the Fas receptor on PMN 
(Brown & Savill 1999). This however is not thought to be an important 
mechanism of PMN death but may be considered as an anti-inflammatory 
response (Renshaw et al. 2000).  
 
Emerging evidence exists for a new route of inflammation resolution. This 
involves a mechanism known as retrograde chemotaxis or reverse migration. 
The use of the zebrafish tissue injury model has shown that during this 
process, PMN migrate away from the wound or infection site and back into 
the vasculature (Mathias et al. 2006). PMN velocity and directionality were 
shown to be the same to and from the wound highlighting that the reverse 
migration is an active process and not due to random mobility. Elks et al. 
were later able to show that a delay in reverse migration contributes to 
delayed inflammation resolution in response to hypoxia, previously thought 
to result only from reduced PMN apoptosis (Elks et al. 2011). Evidence for 
the existence of retrograde chemotaxis in humans has been generated by 
Buckley et al., who have shown that about 0.25 % of PMN from healthy 
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donors and 1-2 % of PMN in patients with systemic inflammation exhibited a 
reverse transmigration PMN phenotype as determined by a distinct profile of 
cell-surface receptors generated from in vitro data (Buckley et al. 2006).  
 
1.5 PMN in disease 
1.5.1 Inflammatory disease 
PMN form part of the first line of defence against invading pathogens and as 
such do not have the ability to differentiate between ‘self’ and ‘non-self’. 
Their non-specificity and powerful toxic defences can therefore cause 
considerable damage to the surrounding normal tissue. Persistence of PMN 
can result in increased damage to the host tissue and impair the wound 
healing. Delayed PMN apoptosis has been shown to result in exacerbated 
and prolonged inflammation (Gilroy et al. 2004). This can have severe 
pathological consequences.  
 
Delayed PMN apoptosis has been identified as a component of many 
diseases. The inappropriate suppression of apoptosis has been shown to 
correlate with the disease severity and outcome. In patients with acute 
respiratory distress syndrome (ARDS), reduced PMN apoptosis is thought to 
be mediated by enhanced GM-CSF production (Matute-Bello et al. 1997). 
This is also the mechanism implicated in supressing PMN apoptosis in 
sepsis and acute coronary artery disease. Persistent pulmonary neutrophilia, 
as detected in bronchoalveolar lavage (BAL) fluid from neonates with 
respiratory distress syndrome, has been shown to be associated with the 
development of chronic lung disease in adolescence (Kotecha et al. 2003).  
 
COPD is one of the leading causes of death in the world. The main 
causative factor is cigarette smoke (Franklin et al. 1956). The disease is 
characterised by persistent local and systemic inflammation, which result in 
impaired lung function and ultimately lung failure. The PMN is the most 
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abundant cell type situated in the bronchial wall and lumen of COPD patients 
(Martin et al. 1985; Pesci et al. 1998). There are also enhanced levels of 
primed circulating PMN (Koenderman et al. 2000; Oudijk et al. 2006). 
Although the mechanisms underpinning dysregulated neutrophil function in 
COPD patients are not fully know, a reported delay in PMN apoptosis in 
COPD patients may be due to enhanced activation of NF-κB (Brown et al. 
2009).  
 
Supressed PMN apoptosis is also known to play a role in the destruction of 
cartilage and bone in rheumatoid arthritis (Mohr et al. 1981). This occurs in 
the synovial fluid of rheumatoid arthritis patients where PMN are the most 
abundant inflammatory cells, along with higher levels of lactoferrin, an iron 
chelating glycoprotein present in the secondary granules of PMN (Furmanski 
& Li 1990; Wong et al. 2009). It was later shown that lactoferrin itself acts as 
a PMN survival factor in rheumatoid arthritis and may be responsible for the 
extended PMN survival in the rheumatoid joint (Wong et al. 2009). 
 
1.5.2 Accelerated PMN apoptosis 
Transient increase in PMN survival during infection is essential for the 
optimal elimination of pathogens. Accelerated PMN death therefore, can 
result in impaired anti-microbial function and recurrent infections. Severe 
congenital neutropenia is a type of immunodeficiency characterised by 
severe neutropenia with absolute PMN counts below 0.5 x 109/l (Haddy et al. 
1999). The disease is associated with recurrent systemic bacterial infections 
due to an insufficient number of circulating PMN. These disorders result 
mostly from genetic defects in genes such as PMN elastase (ELA2), growth 
factor independent transcription repressor (GFI1), glucose-6-phosphatase 3 
(G6PC3) and HCLS-(hematopoietic cell-specific Lyn substrate 1) associated 
protein X1 (HAX1) (Klein et al. 2007; Boztug et al. 2009; Boztug & Klein 
2011). Some pathogens can also shorten PMN lifespan through their ability 
to accelerate PMN apoptosis in order to impair PMN-mediated defences 
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(Colamussi et al. 1999; Allen et al. 2005; Elbim et al. 2009). For example, 
the cystic fibrosis pathogen Pseudomonas aeruginosa produces pyocyanin, 
which attenuates recruitment into the lung by causing increased PMN 
apoptosis and resulting in persistent colonisation (Allen et al. 2005).  
 
1.6 Molecular mechanisms of apoptosis 
The term ‘apoptosis’ was first coined by Kerr et al. to described active, 
inherent programmed cell death as an essential mechanism for tissue 
homeostasis and as a distinct process from necrotic cell death (Kerr et al. 
1972).  Apoptosis occurs in two distinct stages. In the first stage the nucleus 
and the cytoplasm condense leading to cell fragmentation, but with plasma 
membranes still preserved. During this phase chromatin condensation and 
nuclear fragmentation occur. These morphological changes define apoptosis 
(Kroemer et al. 2005). In the second stage, the apoptotic bodies formed are 
rapidly engulfed by resident phagocytic cells preventing the release of 
cellular contents into the surrounding area and without affecting the tissue 
function and architecture. The activation of precursor caspases is required 
for the manifestation of apoptotic features in both the intrinsic and extrinsic 
pathways (Fuentes-Prior & Salvesen 2004). Caspases are cysteine 
proteases that cleave after an aspartate residue (Yuan et al. 1993).  
 
1.6.1 The extrinsic Apoptotic pathway 
The extrinsic cell death pathway is initiated by extracellular signals and 
involves death receptor-mediated interactions (Locksley et al. 2001). 
Members of the tumour necrosis factor (TNF) cytokine family such as TNF-α 
and FasL can bind to their receptors on the PMN and induce apoptosis (Liles 
et al. 1996). Trimeric ligand binding to the transmembrane death receptors 
recruits adaptor proteins and engages signal transduction via cytoplasmic 
‘death domains’ (Ashkenazi & Dixit 1998; Lavrik et al. 2003). For example, 
FasL and TNF- α binding to their corresponding receptors results in the 
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recruitment of adaptor proteins including Fas associated death domain 
(FADD) adaptor protein, which in turn associates with procaspase-8 
(Kischkel et al. 1995). The protein complex formed is known as the death-
inducing signalling complex (DISC). It results in the activation of caspase-8, 
which in turn cleaves caspase-3 which then go on to cleave hundreds of 
substrates in the cell including a DNAse, which degrades chromatin (Scaffidi 
et al. 1998)  
 
1.6.2 Intrinsic (mitochondrial) apoptotic pathway 
In most vertebrate cells, programmed cell death occurs through the intrinsic, 
or mitochondrial, pathway of apoptosis (Green & Kroemer 2004). During 
various forms of intracellular stress such as DNA damage, cytokine 
deprivation and viral infection the outer mitochondrial membrane becomes 
permeabilised (Hakem et al. 1998; Adams 2003). This results in the release 
of the mobile electron transporter cytochrome c (cyt c) into the cytoplasm 
and recruitment of the initiator caspase-9 via Apaf-1 (apoptosis protease 
activating factor) (Liu et al. 1996; Susin et al. 1996; Zou et al. 1997). This in 
turn leads to the formation of the apoptosome, a macromolecular complex in 
which precursor caspase-9 is activated due to allosteric change and 
dimerization. Once caspase-9 is activated, it cleaves executioner caspase-3 
and -7 and in turn triggers the execution phase of apoptosis (Adams 2003).  
 
Whether PMN contain fully functioning mitochondria is subject to controversy 
(Borregaard & Herlin 1982; Fossati et al. 2003). However, studies have 
shown that tubular networks, which form mitochondria, although limited in 
number, can be visualized in PMN (Bainton et al. 1971; Maianski et al. 2002; 
Fossati et al. 2003). Mitochondria of human PMN are unique in that they are 
thought to mainly play a role in apoptosis and are not involved in generating 
energy for the cell in the form of ATP (Maianski et al. 2004). Mitochondria 
also control apoptosis by acting as sensors of endogenous factors such as 
intracellular ions Ca2+ and K+ (van Raam et al. 2006; Giacomello et al. 2007).  
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Loss of mitochondrial membrane potential has been identified as an early 
marker of apoptosis (Fossati et al. 2003) and indeed maintenance of the 
mitochondrial membrane potential is essential in delaying apoptosis during 
infection (Taneja et al. 2004).  
 
1.6.3 The regulation of the mitochondrial apoptotic pathway by the 
Bcl-2 protein family 
Apoptosis of PMN and other cell types is controlled by a balance between 
pro- and anti-apoptotic members of the Bcl-2 (B cell lymphoma 2) family. 
These proteins regulate the integrity of the mitochondrial membrane (Adams 
& Cory 1998). By definition, each member of the Bcl-2 family contains at 
least one BH domain (Bcl-2 homology) out of four (BH1-4) (Zha et al. 1996). 
The formation of homo- and hetero-dimers between Bcl-2 family members is 
crucial for the fine control of the programmed cell death pathway (Zha et al. 
1996; Adams & Cory 1998). The regulation of apoptosis by these proteins is 
complex and not well understood. There are two main subfamilies of Bcl-2 
proteins: pro-apoptotic and anti-apoptotic proteins which although share BH 
domain sequences, are structurally and functionally distinct (Adams & Cory 
1998). 
 
1.6.3.1 Pro-apoptotic proteins 
These Bcl-2 proteins promote apoptosis by using their BH3 domain to bind 
to anti-apoptotic proteins and inhibit their effects (Zha et al. 1996; Adams & 
Cory 1998). The first pro-apoptotic Bcl-2 protein member to be identified was 
alternatively spliced Bax (Bcl-2 associated x protein), which exists in a single 
membrane and two cytosolic forms (Oltvai et al. 1993). Bax was shown to 
bind to Bcl-2 and act as an antagonist of the protein. In an IL-3 (Interleukin 3) 
cytokine dependent cell line, overexpression of Bax was shown to result in 
accelerated apoptosis (Oltvai et al. 1993).  Conversely, mice deficient in pro-
apoptotic Bax and Bak (Bcl-2 associated antagonist/killer) were shown to be 
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unable to induce apoptosis when exposed to cell death stimuli and therefore 
are essential for this process to occur (Wei et al. 2001). These findings 
highlighted the requirement for the balance between pro- and anti- apoptotic 
Bcl-2 protein members in the control of cell fate.  
 
Pro-apoptotic proteins act by utilising their BH3 α-helical region in order to 
bind into a cleft formed by the BH1, BH2 and BH3 domains of anti-apoptotic 
proteins (Zha et al. 1996; Adams & Cory 1998). The BH3 domain is essential 
for the pro-apoptotic function of the Bcl-2 family (Zha et al. 1996; Adams & 
Cory 1998). The proteins have been shown to function by causing the 
release of pro-death factors such as cyt c and Apaf-1 into the cytoplasm 
(Shimizu et al. 1999; Wei et al. 2000). 
 
The BH3 only protein Bad (Bcl-2 associated agonist of cell death) is the 
dominant transcript in PMN but other pro-apoptotic proteins Bax, Bak and 
Bik (Bcl-2-interacting killer) have also been shown to be expressed 
(Moulding et al. 2001). A study on mice deficient in Bim (Bcl-2 like 11) 
demonstrated that granulocyte numbers were increased several fold as a 
result of extended cell survival in comparison to control mice (Bouillet et al. 
1999). The pro-apoptotic Bcl-2 family members in PMN have been shown to 
be extremely stable with long half-lives emphasising the ability of PMN to 
rapidly undergo apoptosis (Moulding et al. 2001). 
 
1.6.3.2 Anti-apoptotic proteins 
The Bcl-2 anti-apoptotic proteins are essential for cell survival and bind to 
pro-apoptotic Bcl-2 members to inhibit their function (Adams & Cory 1998). 
These pro-survival proteins inhibit the release of pro-apoptotic factors such 
as cyt c and Apaf-1 from the mitochondria into the cytosol in order to prevent 
programmed cell death (Susin et al. 1996; Yang et al. 1997; Kluck et al. 
1997).  Although they have been shown to be functionally redundant as the 
overexpression of any of the members protects cells from apoptosis, genetic 
 37 
studies have revealed the differential expression of the proteins in different 
cell types (Susin et al. 1996; Adams 2003). 
 
The pro-survival Bcl-2 proteins utilise the BH1 and BH2 domains to bind pro-
apoptotic Bcl-2 members (Yin et al. 1994). These domains are essential for 
their function and are also used in homodimerisation with a BH4 domain on 
the second molecule (Zha et al. 1996). It has been proposed that anti-
apoptotic proteins also regulate the voltage dependent anion channel 
(VDAC) that in turn modulates mitochondrial membrane potential and the 
release of cyt c from the mitochondria (Shimizu et al. 1999). 
 
The Bcl-2 protein was the first member to be identified in a t(14:18) 
chromosomal translocation where its overexpression in humans causes 
follicular lymphomas (Tsujimoto & Croce 1986). The protein is essential for 
the survival of mature lymphocytes (Veis et al. 1993; Hamasaki et al. 1998). 
The pro-survival proteins Bcl-x (Bcl-2 associated x protein) and Mcl-1 are 
both indispensable in embryonic development since mice deficient in Mcl-1 
fail to implant whereas Bcl-x deficiency in mice results in an embryonic lethal 
phenotype (Motoyama et al. 1995; Rinkenberger et al. 2000). Conversely, 
the A1 protein is required for PMN survival (Veis et al. 1993; Hamasaki et al. 
1998). 
 
PMN express three anti-apoptotic proteins Mcl-1, A1 and Bcl-x but unlike 
other cell types they do not express Bcl-2 (Rinkenberger et al. 2000; 
Moulding et al. 2001). Mcl-1 and A1 are thought to be regulated at the 
protein stability level and have been shown to undergo rapid turnover in 
PMN (Moulding et al. 2001).  Mcl-1 is the key anti-apoptotic protein in PMN 
with high levels of expression shown in freshly isolated PMN (Derouet et al. 
2004). Its levels inversely correlate with the number of apoptotic PMN 
(Moulding et al. 1998). The more recently identified pro-survival protein, 
HAX1, has been shown to have weak homology to the anti-apoptotic Bcl-2 
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proteins (Suzuki et al. 1997). Its structure and function will be discussed in 
the following paragraphs.  
 
1.7 HCLS-1 associated protein X1 (HAX1) 
HAX1 was first identified as a novel 35 kDa protein interacting with HS1 
(hematopoietic cell-specific Lyn substrate) in B lymphocytes (Suzuki et al. 
1997). HS1 is a substrate of Src tyrosine kinases and is specifically 
expressed in cells of hematopoietic lineage. HAX1 binding to the amino 
terminal of the HS1 protein was thought to implicate HAX1 in B lymphoma 
cell signal transduction. Since its identification, it has been established that 
the HAX1 gene is ubiquitously expressed in human and murine tissues and 
the protein is primarily localized in the mitochondria and to a lesser extent in 
the endoplasmic reticulum and nuclear envelope (Suzuki et al. 1997; Hippe 
et al. 2006).  
 
Importantly, autosomal recessive mutations of the HAX1 gene resulting in 
HAX1 deficiency cause Kostmann disease (severe congenital neutropenia), 
a condition characterized by impairment of myeloid differentiation and a lack 
of circulating PMN in the blood (Klein et al. 2007). This finding provides 
strong evidence for the function of HAX1 as a key modulator of myeloid cell 
survival and homeostasis. Therefore, further study into the role of HAX1 
protein could enhance our understanding of this field.  
 
1.7.1 HAX1 genetic organization, transcription and conservation 
The human genome contains two HAX1 genes (Lees et al. 2008). The first is 
located on chromosome 1 (1q21.3) within the epidermal differentiation 
complex and the second is a processed pseudogene found on chromosome 
X (Xq28). The HAX1 gene on chromosome 1 contains seven exons in total 
and has been shown to give rise to eight studied transcript variants through 
alternative splicing and intron retention (Lees et al. 2008). Most of the 
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alternative splicing in humans results from an internal splice site in exon 2, 
which generates transcripts without various regions of the exon. Lees et al. 
show that the mRNA sequence for HAX1 006 contradicts a previously 
published sequence for the same isoform (Lees et al. 2008). This does not 
necessarily mean that one of the sequences is incorrect. It is likely that there 
are other HAX1 isoforms, which are yet to be identified. Lees et al. who 
identified additional PCR products resulting from the retention of the introns 
also support this notion.  
 
At least six of the isoforms out of the eight are transcribed in any one 
particular tissue with no significant differences in the patterns of expression 
between different cell types. Transcripts of HAX1 001, HAX1 003, HAX1 
005, HAX1 006 and HAX1 008 were shown to be expressed in all cell types 
whereas the rest of the isoforms HAX1 002, HAX1 004 and HAX1 007 are 
only expressed in certain cell types. The existence of these isoforms adds a 
level of regulation to HAX1 expression and also may account for the many 
different roles of HAX1, which is to be expected for a protein with numerous 
cellular functions.  
 
The HAX1 gene is highly conserved between human, mouse, rat, 
chimpanzee and macaque highlighting its essential function in the cells of 
these organisms (Jeyaraju et al. 2009). Similar sequences have also been 
found in the zebrafish, Danio rerio. The mouse Hax1 cDNA shares 86 % 
identity with the human HAX1 cDNA (Hippe et al. 2006). However, there are 
two Hax1 genes in the mouse genome and they encode only three distinct 
variants of Hax1. Seven alternatively spliced Hax1 variants have been 
identified in the rat up to date with similar splicing to that of the human gene 
(Grzybowska et al. 2006). Elevated levels of Hax1 mRNA are seen in the 
liver, kidney and testis of mice and in the testis of rat (Grzybowska et al. 
2006; Hippe et al. 2006). However in the human, mRNA levels are the 
highest in skeletal muscle (Lees et al. 2008).  
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HAX1 
Isoform 
Predicted  
protein 
 size 
Expression and roles 
001 31.6 kDa 
>Ubiquitously expressed  
>Mutations in the 5’ region of exon 2 
result in neutropenia only 
002  
28.6 kDa 
Expressed in PBMCs, oral 
keratinocytes and some fibroblasts 
003  
14.2 kDa 
Ubiquitously expressed 
004  
26.1 kDa 
>Expressed in fibroblasts, oral 
keratinocytes and some PBMCs 
>Mutations in the 3’ region of exon 2 
result in neutropenia and neurological 
and neuropsychological abnormalities 
005 32.4 kDa Ubiquitously expressed 
006  
21.8  kDa 
>Expressed in fibroblasts, PBMCs 
and some oral keratinocytes 
>Expressed in cell lines: breast 
carcinoma, colon adenocarcinoma 
and melanoma cell lines 
007  
10 kDa 
Expressed in PBMCs, oral 
keratinocytes and some fibroblasts 
008  
7.5 kDa 
Ubiquitously expressed 
 
Table 1.1 Difference in the expression and mutation of HAX1 
isoforms in human (Information extracted from Lees et al. 2008). 
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1.7.2 Molecular and physiological roles of HAX1 protein 
1.7.2.1 Domain structure, function and cellular localisation 
The human HAX1 gene was first isolated from a B lymphoma cDNA library 
and cloned into yeast cells for use in a yeast two-hybrid system identifying 
the binding partners of hematopoietic lineage cell-specific protein 1 (HS1) 
(Suzuki et al. 1997). Suzuki et al described HAX1 as a hydrophilic protein 
with no significant homology to any other proteins. Fig. 1.1 shows the HAX1 
putative domain organisation and some of its binding partners.  
 
Some similarity was shown to Nip3, a protein, which interacts with 
adenovirus EIB 19-kDa protein and Bcl-2(Suzuki et al. 1997). A putative 
PEST sequence (aa 104-117) was also identified, which indicates that the 
protein can be rapidly degraded in a regulated manner. It was proposed that 
HAX1 contains two BH domains, BH1 (aa 37-56) and BH2 (aa 74-89) and a 
putative hydrophobic transmembrane domain (aa 261-271) at the C-terminus 
(Suzuki et al. 1997). Another feature of HAX1 is an acid box (amino acids 
30-41) with unknown function, identified by analogy with the fibroblast growth 
factor receptor (Lees et al. 2008). 
 
Although the existence of the BH domains is supported by some recent 
studies, contradictory reports have demonstrated that the proposed BH 
domains are not recognised even when using relaxed thresholds in 
conserved protein domain searches (Chao et al. 2008; Jeyaraju et al. 2009; 
Fadeel & Grzybowska 2009). In addition to this, the predicted secondary 
structures for these regions are highly disordered in HAX1 whereas the bona 
fide BH domains are well structured with hairpin motifs formed by 
hydrophobic α-helices (Jeyaraju et al. 2009). Furthermore, the putative BH 
domains of the HAX1 sequence are poorly conserved in mammals and no 
conservation of the sequence is found in distantly related species (Jeyaraju 
et al. 2009).  
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Figure 1.1 Domain structure organization of human HAX1 and sites of interaction with other proteins 
The dominant human HAX1 isoform is composed of 297 amino acids (Suzuki et al. 1997). The locations of the two putative BH 
domains (BH1 and BH2), PEST sequence, putative transmembrane domain (TM) and acid-box are shown. Sites of interactions 
between HAX1 and other proteins identified to date are indicated. Caspase-3 and Granzyme-B cleavage sites on HAX1 are 
also indicated by the thick black arrows. Most of the interactions of HAX1 with other proteins occur at the C-terminus of the 
protein. The schematic figure draws information from numerous studies on the interactions and cleavage of HAX1 referenced 
throughout the text.  
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There is also some controversy as to whether HAX1 is an integral 
mitochondrial membrane protein or a peripherally associated one. Chao et al 
reported that HAX1 is localised on the inner and outer mitochondrial 
membrane with the protein exposed to the intermembrane space (Chao et 
al. 2008).  However, other researchers disagree and have emphasised that 
the putative transmembrane domain does not contain enough hydrophobic 
amino acids in order to span the lipid bilayers (Jeyaraju et al. 2009; Fadeel & 
Grzybowska 2009). A long stretch of a minimum of 20 mostly hydrophobic 
residues is required to form an α-helix which is capable of spanning the lipid 
bilayers and no such region is found anywhere in the HAX1 sequence. 
Although HAX1 is selectively concentrated at the mitochondria, it has been 
shown that some HAX1 has also been detected in the nuclear envelope, 
sarcoplasmic and endoplasmic reticulum in different cell types of human and 
mouse models (Suzuki et al. 1997; Gallagher et al. 2000; Hippe et al. 2006; 
Zhao et al. 2009). This differential localisation is likely to reflect the different 
roles and binding partners of HAX1 in different cell types.  
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1.7.2.2  HAX1 putative binding sites for RNA 
Regulated RNA metabolism is maintained through multiple specific and 
non-specific protein-RNA interactions. In vitro as well as in vivo studies in 
yeast, rat and HeLa cells have revealed that HAX1 binds to mRNA (Al-
Maghrebi et al. 2002; Sarnowska et al. 2007).  So far only two HAX1 
binding targets have been identified. The first is a stem loop structure in 
the highly conserved 3’ untranslated region (UTR) of the cytoskeletal 
protein vimentin involved in cell migration (Al-Maghrebi et al. 2002). The 
second HAX1 target was shown to be an evolutionary conserved hairpin 
motif at the UTR region of the mRNA encoding for DNA polymerase β 
(Sarnowska et al. 2007). HAX1 binding regions on DNA polymerase β 
and vimentin mRNA are not evolutionarily conserved and the protein 
products of their mRNAs are functionally and structurally distinct (Al-
Maghrebi et al. 2002; Fadeel & Grzybowska 2009). It can therefore be 
speculated that HAX1 binding and regulation is different for each mRNA 
and that there may be many other HAX1 mRNA binding targets in the 
cell. 
 
1.7.2.3 Regulation of cell migration by HAX1 
Over the past few years, a number of studies have generated evidence 
linking HAX1 function to cell motility. Gallagher et al reported that HAX1 
interacts with polycystic kidney disease protein 2 (PKD2) and showed 
that HAX1 co-localizes with this protein in the cell body as well as cellular 
processes and lamellipodia (Gallagher et al. 2000). In the same study, a 
link between PKD2 and the cytoskeleton was established by the finding 
that HAX1 interacts with cortactin, an HS1 protein family member and an 
F-actin associated protein expressed in most tissues except for lymphoid 
cells (Suzuki et al. 1997; Gallagher et al. 2000). In a second study, it was 
shown that HAX1 interacts with Gα13, the α-subunit of the heterotrimeric 
G protein 13 involved in stimulating cell migration (Radhika et al. 2004). 
HAX1 forms a quaternary complex with Gα13, Rac and cortactin where 
HAX1 is predicted to sequester Gα13 from cell adhesion signalling 
pathways and tethering it to the cytoskeleton (Radhika et al. 2004). A 
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third study investigating the HAX1 involvement in cell migration reported 
HAX1 binding to the β6 cytoplasmic tail of the integrin αvβ6, which 
regulates clathrin-mediated endocytosis of this integrin (Ramsay et al. 
2007). Silencing of HAX1 with short interfering RNAs led to reduced Gα13- 
and αvβ6- mediated cell migration in Gα13 expressing NIH3T3 cells and in 
oral squamous cell carcinoma cell lines, respectively (Radhika et al. 
2004; Ramsay et al. 2007).  
 
Phosphorylated growth factor receptor-bound protein 7 (Grb7), a cell 
migration protein has also been reported to interact with HAX1 in 
mammalian cells (Siamakpour-Reihani et al. 2010). Grb7 is an adaptor 
protein involved in cell migration and although it is known that it mediates 
signal transduction through a focal adhesion kinase pathway, its specific 
downstream binding partners are unknown. Overexpression of Grb7 has 
been shown to result in increased cell migration and the development of 
metastases (Tanaka et al. 1998).  HAX1 also binds to the cytoskeletal 
protein Pelota (PELO), which is involved in cytoskeleton organization, cell 
growth and spreading (Burnicka-Turek et al. 2010). Cell migration is 
important in both the movement of PMN during inflammation and in 
metastatic cancers. HAX1 has been shown to be upregulated in a 
number of cancers (Ramsay et al. 2007). The above-mentioned studies in 
addition to the evidence for the HAX1/vimentin mRNA interaction provide 
a connection between HAX1 protein and signalling pathways of cell 
migration, however these studies do not present any mechanisms of 
specific HAX1 action and no such interactions have been described for 
PMN. Further study in this area may shed new light into how these 
mechanisms work. 
 
1.7.2.4 Interactions with viral proteins 
Viral protein function and their use to hijack and manipulate host cell 
proteins are slowly being revealed. Viruses utilise any means possible to 
manipulate host cell regulatory pathways in their favour. Studies into 
HAX1 interactions with virus-encoded proteins provide data on binding of 
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proteins from four different viruses. The first two viral proteins to be 
identified as HAX1 binding partners were EBNA-LP (Epstein-Barr virus 
nuclear antigen leader protein) and EBNA5 (Epstein-Barr virus nuclear 
antigen 5) (Kawaguchi et al. 2000; Dufva et al. 2001). Both of these 
proteins had previously been thought of as nuclear proteins involved in B-
cell immortalization but the interaction with HAX1 suggested a function for 
these proteins in the cytoplasm. K15 protein of Kaposi’s sarcoma-
associated herpes virus or herpes virus 8 is another protein shown to 
bind to HAX1 (Sharp et al. 2002).  Infection of HeLa cells with K15 did not 
have any effects on the HAX1 blocking of Bax-induced apoptosis 
indicating that HAX1 may act in a Bax-independent fashion.  Human 
immunodeficiency virus (HIV) type 1 viral protein R (Vpr) has also been 
reported to bind to HAX1 and dislocate it from the mitochondrial 
membrane, resulting in membrane permeability and apoptosis. HAX1 
also binds to a second HIV protein, Rev, delocalising the viral protein 
from the nucleus into the cytoplasm (Modem & Reddy 2008). HAX1 
overexpression was shown to unexpectedly inhibit Rev function by 
preventing RNA binding.  
 
The last protein identified so far to bind to HAX1 is the Hepatitis C virus 
(HCV) core protein (Banerjee et al. 2009). In the same study, HAX1 
presence was shown to increase tumour suppressor gene p53 
expression upon anticancer drug treatment of HepG2 cells. It is unknown 
why or how this occurs but it suggests a further link for HAX1 to cell cycle 
check points.  
 
Many pathogens hijack and modulate host cell apoptosis pathways to 
their own benefit. The virus-encoded proteins known to bind to HAX1 in 
vitro as well as in vivo are mostly involved in suppressing apoptosis in 
order for efficient viral replication to occur. It may therefore be reasonable 
to assume that these proteins utilize HAX1 as a strategy of ambushing 
the apoptotic machinery. However, a direct biological significance of 
HAX1 interactions with the virus-encoded proteins is yet to be revealed.   
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1.7.2.5 HAX1 involvement in cell fate 
The weak homology and similar cellular distribution of HAX1 to Bcl-2 
proteins led Suzuki et al to hypothesize that HAX1 plays a role in 
promoting cell survival by interacting with proteins distributed in the 
mitochondria region (Suzuki et al. 1997). Their preliminary data showed 
that overexpressed HAX1 protected the T-lymphoma cell line, Jurkat from 
apoptosis in response to apoptosis inducing stimuli. Subsequent studies 
have supported this hypothesis (Sharp et al. 2002; Li et al. 2009; Jitkaew 
et al. 2009). Consistent with these findings, HAX1 silencing by siRNA 
caused human melanoma A375 cells to undergo apoptosis (Li et al. 
2009). HAX1 knockout mutations in mice are lethal, with failure of mice to 
survive longer than 14 post-natal weeks (Chao et al. 2008). This is 
because of a failure to eat or drink due to loss of motor coordination and 
activity. In addition, extensive apoptosis of neurons and lymphocytes 
occurs.  
 
HAX1 downregulation occurs in response to apoptosis signals and it is 
thought to trigger the induction of caspase-dependent apoptosis in 
immortalised human B cell lines (Jitkaew et al. 2009). HAX1 
overexpression was also shown to reduce Bax-mediated apoptosis to 
background levels in HeLa cells (Sharp et al. 2002). HAX1 
overexpression has been reported in several tumours including in breast 
cancer, lung cancer and melanoma (Trebinska et al. 2010). These 
findings support a role for HAX1 in the inhibition of apoptosis and the 
involvement of this protein in carcinogenesis.  
 
1.7.2.6 Interactions with factors involved in the apoptotic pathway 
As described earlier in the text, loss of mitochondrial membrane potential 
leads to the release of protein factors such as cyt c and the serine 
protease HtrA2 (Omi) from the intermembrane space into the cytosol. 
This results in the activation of caspase-9, which in turn activates 
caspase-3. HAX1 has been shown to interact with Omi, a mitochondrial 
serine protease that translocates to the cytosol and cleaves inhibitor of 
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apoptosis proteins (Verhagen et al. 2002), caspase-9 and caspase-3 
(Cilenti et al. 2004; Han et al. 2006; Chao et al. 2008). In vitro and in vivo 
studies have shown that HAX1 is also a target of Omi (Cilenti et al. 2004). 
The degradation of HAX1 occurs early in the apoptotic process, while 
Omi is still localized to the mitochondria (Cilenti et al. 2004). However, 
detailed information on the HAX1 cleavage products is not provided.  
 
In a subsequent study, inhibition of apoptosis in lymphocytes was shown 
to require interactions of HAX1 with the mitochondrial proteases Parl 
(presenilin- associated, rhomboid-like) and Omi (Chao et al. 2008). The 
authors of this study proposed a model in which HAX1 binding to Parl led 
to the presentation and cleavage of Omi by Parl. Mature Omi prevents 
the accumulation of pro-apoptotic Bax. It was suggested that reduced 
levels of processed Omi in HAX1 knockout mice and the similarity of the 
phenotypes of HAX1 and Omi deficient mice provide some proof for this 
mechanism (Jones et al. 2003). However, an article by Jeyaraju et al 
claims that the interaction of HAX1 to Parl is an in vitro artefact (Jeyaraju 
et al. 2009). The authors also argue that the two proteins are confined to 
distinct cellular compartments and that Parl does not require presentation 
of proteins by HAX1. In support of this, HAX1 deficiency does not 
completely abolish the expression of mature Omi (Chao et al. 2008). The 
proposed actions of HAX1 implicated in the regulation of programmed cell 
death are illustrated in Fig. 1.2. 
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Figure 1.2 HAX1 involvement in the apoptotic pathway 
A simplified diagram of the mitochondrial apoptotic pathway and the role 
of HAX1 in this process. HAX1 binds to and is cleaved by factors involved 
in apoptotic signalling. It binds to pro-survival proteins enhancing their 
activity and preventing the activation of the caspases. Intracellular stress 
leads to the inhibition of anti-apoptotic proteins such as Bcl-2 and Bcl-x 
by the pro-apoptotic Bcl-2 proteins (Adams 2003). This causes the 
release of several apoptotic factors into the cytoplasm including cyt c, AIF 
(apoptosis inducing factor) and Omi (Liu et al. 1996; Kluck et al. 1997; 
Yamaguchi et al. 2003) and this results in the activation of Apaf-1 
(apoptosis protease activating factor) (Zou et al. 1997). In turn, Apaf-1 
activates the caspase cascade, which ultimately leads to cell death (Zou 
et al. 1997). Omi and caspase 3 cleave HAX1 abolishing its pro-survival 
effects (Cilenti et al. 2004; Lee et al. 2008). Information from different 
studies has been drawn for this figure and is referenced in the text. 
 50 
HAX1 has been identified as a binding target of caspase-9 in cardiac 
myocytes (Han et al. 2006). Overexpression of HAX1 inhibited caspase-9 
activation while silencing of the HAX1 gene using siRNA resulted in 
significant apoptosis of adult cardiac myocytes. In a separate study, 
suppression of HAX1 by siRNA in HepG2 cells did not have any effect on 
caspase-9 processing upon induction of apoptosis, suggesting cell-
specific roles of HAX1. A study by Lee et al identified the association of 
HAX1 with caspase-3 (Lee et al. 2008). Caspase-3 cleaves HAX1 in vitro 
at Asp 127, which is found in the N-terminal region of the protein. As both 
caspase-9 and -3 are cytoplasmic proteins it becomes difficult to 
understand how these interactions occur when the interacting proteins 
are confined to different cellular compartments. Han et al suggested that 
the HAX1/caspase-9 interaction in cardiac myocytes occurs at the 
mitochondrial membrane as a result of some translocation of caspase-9 
to the mitochondria (Han et al. 2006).  
 
Two recent studies have reported HAX1 binding to XIAP (X-linked 
inhibitor of apoptosis protein) and granzyme B (Han et al. 2010; Kang et 
al. 2010). XIAP inhibits apoptosis by preventing the activation of 
caspases (Srinivasula & Ashwell 2008). The interaction of HAX1 with this 
protein is believed to inhibit apoptosis by suppressing the 
polyubiquitinylation of XIAP therefore enhancing the stability of the 
protein and preventing it from proteosomal degradation.  XIAP deficient 
mice fail to produce a distinct phenotype indicating that the HAX1 
interaction may not be essential for inhibition of apoptosis by HAX1. This 
could also be explained by the possible existence of a compensatory 
mechanism from other IAPs in the cell suggesting that other IAPs may 
also be acting by interacting with HAX1 (Harlin et al. 2001).  Granzyme B 
is the second serine protease to cleave HAX1. The protein also cleaves 
Bid (BH3 interacting domain death agonist) into tBid therefore directly 
activating downstream apoptotic proteins resulting in the loss of the 
mitochondrial membrane potential.  
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1.7.3 Roles of HAX1 in PMN 
1.7.3.1 Involvement of HAX1 in Ca2+ signalling  
Changes in calcium concentration in the cell are an important determinant 
of apoptosis (Giacomello et al. 2007). HAX1 has been reported to interact 
with key regulators of Ca2+ homeostasis (Vafiadaki et al. 2007; Vafiadaki * 
et al. 2009; Vafiadaki et al. 2009). Phosphalamban (PLN) and the 
sarco(endo)plasmic reticulum (SR) Ca2+ transport ATPase (SERCA2) are 
such proteins which bind HAX1 (Vafiadaki et al. 2007; Vafiadaki * et al. 
2009). The protective effects of HAX1 increased in the presence of PLN 
whereas overexpression of SERCA2 abolished these effects in response 
to hypoxia-induced cell death. HAX1 overexpression has been shown to 
reduce SERCA2 pump activity in cardiomyocytes and led to reduced 
calcium cycling and contractility (Zhao et al. 2009). In a recent study, 
iterative similarity searches identified novel insect HAX1 homologs which 
are parvalbumin-like Ca2+ binding proteins (Kokoszynska et al. 2010). 
The findings suggest that there is a putative single EF-hand calcium 
binding protein in HAX1. These data further support a role for HAX1 in 
Ca2+ homeostasis and cell survival. This is particularly interesting 
because calcium homeostasis is an important factor in PMN apoptosis 
(Whyte, Hardwick, et al. 1993).  
 
1.7.3.2 The importance of HAX1 in PMN apoptosis 
As previously mentioned, HAX1 deficiency in humans has been shown to 
cause severe congenital neutropenia (SCN) (Klein et al. 2007). Further 
studies have shown that HAX1 isoform-dependent phenotypes may exist. 
Lees et al identified isoforms 001, 002 and 005 as the isoforms likely to 
be responsible for myeloid survival (Lees et al. 2008). Another study 
associated isoform 001 with severe congenital neutropenia whereas 
mutations in isoform 002 were linked to neurologic symptoms including 
neurodevelopmental delay and epilepsy (Germeshausen et al. 2008). 
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Hax1 SCN results from reduced levels of anti-apoptotic Bcl-2 proteins 
and extensive cyt-c release into the cytoplasm in bone marrow myeloid 
progenitor cells leading to premature apoptosis (Carlsson et al. 2004).  
Klein et al. isolated CD34+ cells from patients with SCN, transduced them 
with vectors encoding HAX1 and differentiated the cells in vitro to become 
myeloid precursor cells (Klein et al. 2007). These cells displayed 
significantly delayed loss of mitochondrial membrane potential in 
response to valinomycin when compared with cells transduced with a 
control marker gene and those from healthy individuals. Peripheral blood 
PMN from patients with SCN were also shown to undergo accelerated 
apoptosis compared to PMN from healthy donors. Consistent with these 
findings, PMN from SCN patients were shown to be associated with 
constitutive release of cyt c from mitochondria as well as defective Bcl-2 
protein expression (Carlsson et al. 2004). The Klein et al study provides 
strong support for a unique role of HAX1 in PMN since although it is a 
ubiquitously expressed gene, it does not have the same effects leading to 
extensive apoptotic death in any other cell type.  
 
There are a number of mechanisms by which HAX1 could regulate PMN 
numbers. As discussed earlier, the protein could be directly involved in 
modulating apoptosis through the maintenance of the mitochondrial 
membrane stability. Conversely, the protein may be involved in the GM-
CSF signalling pathway, which is vital in the regulation of PMN production 
and differentiation. One could also speculate that HAX1 plays a role in 
the migration of the PMN out of the bone marrow and therefore, 
mutations of the gene result in persistence of the cells in the bone 
marrow leading to increased apoptosis. 
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1.8 Zebrafish as a model of PMN inflammation 
Zebrafish (Danio rerio) have emerged as a good model organism due to 
their high fecundity, high stocking densities and optical clarity of the 
embryos and larvae (Lieschke & Currie 2007). Zebrafish embryo 
development is rapid with a functional heart and circulating blood cells 
developing within the first 30 hours post fertilisation (hpf) (Stainier et al. 
1993). The transparent zebrafish larvae allow excellent visualization of 
fluorescent proteins in cellular processes (Renshaw et al. 2006). The 
generation of the Tg(mpx::GFP)i114 (myeloperoxidase::green fluorescent 
protein) transgenic line has allowed visualisation of PMN through GFP 
expression under the PMN-specific myeloperoxidase promoter (Renshaw 
et al. 2006). This has meant that zebrafish can be used as an in vivo 
model for the genetic analyses of inflammatory responses.  
 
Zebrafish PMN (sometimes called heterophils) are visible in the 
circulation 48 hours post fertilisation (hpf) (Lieschke et al. 2001). The cells 
are functionally orthologous to their human counterpart, in that they 
contain granules, are the first cell type to migrate towards the 
wound/infection site and phagocytose bacteria (Lieschke 2001; Colucci-
Guyon et al. 2011). The zebrafish innate immune system exists in 
isolation from the adaptive immune system until approximately 4 weeks 
post fertilisation when the latter is established allowing segregation of 
pathways and molecular mechanisms involved in the two immune 
systems (Trede et al. 2004).  
 
Using time-lapse imaging, zebrafish PMN have been shown to migrate to 
the wound site (sterile inflammation) (Mathias et al. 2006). During the 
resolution of the local inflammatory response the cells migrate back into 
the vasculature (Mathias et al. 2006; Colucci-Guyon et al. 2011). Direct in 
vivo quantitation of the tissue neutrophil lifespan has demonstrated that 
the resting PMN cell has a half-life of approximately 5 days (Dixon et al. 
2012). 
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Many different tools and genomic resources have been established for 
use in the zebrafish in order to genetically manipulate the organism 
(Trede et al. 2004; Martin & Renshaw 2009). The genetic tractability of 
the organism has enabled the use of both forward-, through random ENU 
mutagenesis, and reverse-genetic approaches. Microinjection of 
morpholinos or mRNA (messenger ribonucleic acid) into the transparent 
larvae in the early stages of development can result in transient 
downregulation or overexpression, respectively (Hammerschmidt et al. 
1999; Nasevicius & Ekker 2000). Alternatively, stable overexpression and 
knockdown can also be achieved through the use of cell-specific 
promoters and tol2 transposon system. Conversely, the recently 
established knockout technology using zinc finger (ZF) and transcription 
activator-like effector (TALE) nucleases can be utilised for selective gene 
knockout.  
 
A further advantage of using zebrafish as model organisms is the high 
molecular and genetic similarity to humans (Eimon et al. 2006; Lieschke 
& Currie 2007). The zebrafish genome sequencing project has led to the 
annotation of most of the genome (http://www.sanger.ac.uk/resources/ 
zebrafish/genomeproject.html). It has been shown that the zebrafish 
genome contains structural and functional homologs of most of the Bcl-2 
protein family and caspases, which control the mitochondrial apoptotic 
pathway (Kratz et al. 2006). Morpholino oligonucleotides have been used 
to show that like the human, zebrafish innate immunity also involves the 
cytosolic adaptor protein MyD88 (myeloid differentiation factor 88), which 
has a central role in innate and adaptive immunity (Van Der Sar et al. 
2006).  
 
Progress has also been made in the study of monogenic disease 
affecting the PMN. For example, Deng et al developed models of Rac2 
disease (Ras-related C3 botulinum toxin substrate 2) demonstrating 
defects in PMN migration and proliferation (Deng et al. 2011). In a second 
study using a WHIM (Warts, Hypogammaglobulinemia, Infections, and 
Myelokathexis) syndrome model where the G-protein-coupled chemokine 
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receptor CXCR4 was mutated, it was shown that zebrafish PMN are 
trapped in the bone marrow (Walters et al. 2010).  These findings 
establish that zebrafish are a relevant model for studying programmed 
cell death and inflammation. In addition, further support comes from 
protein sequence analysis of human and zebrafish Hax-1, which shows 
that the two orthologues have evolved from a common ancestor (Fig. 
1.3).  
 
 
 
 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Evolution of the Hax-1 protein. ClustalW 2.1 Protein sequence alignment of Hax-1 from a number of different 
species in the form of a phylogenetic tree.  
Zebrafish (Danio Rerio), Chimpanzee (Pan troglodytes), Cow (Bos taurus), Dog (Canis familiaris) Chromosome 7, Gorilla (Gorilla 
gorilla), Guinea Pig (Cavia porcellus), Horse(Equus caballus), Human (Homo sapiens), Macaque(Macaca mulatta), Mouse (Mus 
musculus), Pig(Sus scrofa), Rat(Rattus norvegicus), Zebra Finch(Taeniopygia guttata). The protein sequences were deduced from 
ENSEMBL. 
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1.9 Hypothesis, aims and Objectives: 
The regulation of myeloid cell apoptosis is vital in both the control of 
inflammation and homeostasis. Persistence of PMN has been shown to 
be involved in the pathogenesis of numerous pulmonary diseases 
including COPD and acute respiratory distress syndrome.  PMN have an 
exquisitely short half-life in the circulation due to constitutive apoptosis 
however, PMN longevity can increase several fold following migration into 
the tissue in response to injury or infection. PMN survival is dysregulated 
in inflammatory diseases, where PMN persist in the tissue and cause 
significant tissue damage. Currently, there are no effective therapeutic 
regimes that can effectively reduce PMN numbers in the tissue in order to 
resolve inflammatory disease. Further investigation into the mechanisms 
which regulate PMN apoptosis will lead to a better understanding of the 
molecular pathology of inflammatory diseases and may aid identification 
of new therapeutic targets.  
 
HAX1 is a ubiquitously expressed gene with predominant localisation in 
the mitochondrial membrane. In a study by Klein et al it was shown that 
homozygous recessive mutations of the HAX1 gene in the human result 
in Severe Congenital Neutropenia, a disease associated with premature 
apoptosis of bone marrow myeloid progenitor cells and a profound PMN 
deficiency. This suggests that HAX1 plays a pivotal role in PMN 
homeostasis and survival. The evidence generated thus far from other 
studies on HAX1 function infers that HAX1 is a very complex protein with 
a multitude of roles in multiple important cellular processes. These 
multiple roles of HAX1 in cellular processes make it an important target 
for further research. Although it is not clear how HAX1 functions in 
apoptosis and survival of cells, there is strong evidence emphasizing its 
importance in PMN and pathology. Therefore, our aim is to increase our 
understanding of the roles of HAX1 in myeloid cells, specifically PMN, in 
order to gain a better understanding of how PMN survival is controlled, 
with an overall aim of improving therapeutic strategies for PMN 
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inflammatory diseases. I hypothesise that HAX1 plays a critical role in 
PMN survival and homeostasis. More specifically I hypothesise that: 
a.) HAX1 expression is modulated during induced and constitutive cell 
death  
b.) HAX1 deficient zebrafish will have defective PMN development 
and survival 
 
The main objectives of this thesis are:  
a.) To determine the expression and regulation of HAX1 in primary 
neutrophils and PMN-like cell line PLB-985 
b.) To define the effects of HAX1 knockdown on the mitochondrial 
stability of myeloid cells using flow cytometry 
c.) To establish in vivo models of zebrafish Hax1 deficiency using 
morpholino, ZFN and TALEN technology and investigate the effects on 
PMN development and survival. 
  
A range of techniques will be utilised in order to establish the role of 
HAX1 in myeloid cells using in vitro and in vivo models. My aim is to 
modify the techniques already in use in order to create a working model 
for studying HAX1 function in the zebrafish. Western blotting and RT-
PCR will be used in order to identify HAX1 expression patterns during 
resting and stimulation of cells. HAX1 function will also be investigated in 
PLB-985 cells (myeloid leukaemia cell line) through knockdown studies 
using HAX1 siRNA technology. In order to study the effects of loss of 
Hax1 in zebrafish embryos, a hax1 splice morpholino will be used to 
knockdown hax1 mRNA expression. hax1 knockout will be attempted 
using both CoDa (context-dependent assembly) zinc finger nuclease and 
TALEN (transcription activator like effector nuclease) mutagenesis 
approaches in order to study the effects of hax1 gene mutation and loss 
of Hax1 function in the zebrafish.  
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2 Materials and Methods  
2.1 In-vitro techniques 
2.1.1 Reagents 
Reagents used were purchased from Sigma-Aldrich, Poole, UK unless 
otherwise stated. qVD-OPh was purchased from R&D Systems, 
Abingdon, UK. GM-CSF was purchased from PeproTech, London, UK.  
Pyocyanin was prepared by Dr Lynne Prince (Usher et al. 2002), heat 
killed E. coli and heat killed S. aureus (SH1000, obtained from Professor 
Simon Foster (Dept. of Molecular Biology and Biotechnology, University 
of Sheffield, Sheffield, UK) were prepared from overnight cultures which 
were heat-treated for 10 min at 100 °C. All restriction enzymes and 
buffers were from NEB, (Biolabs, Hertfordshire, England) unless 
otherwise stated. The ON-TARGETplus Cyclophilin B (Cyc B) control 
siRNA (D-001820-01, human NM_000942) and the HAX-1 ON-
TARGETplus SMARTpool siRNA (L-012168-01-0005, human HAX1, 
NM_001018837) were from Thermo Fisher Scientific, Lafayette. CO, 
USA.  
 
2.1.2 Mammalian cell culture  
Adult PMN (polymorphonuclear neutrophils) were harvested from 
peripheral venous blood of healthy volunteers (under the approval of 
South Sheffield Regional Ethics Committee) using either an OptiprepTM 
(Axis-Shield, Upton, Huntingdon, UK) or Percoll® (Sigma-Aldrich, Poole, 
UK) gradient.  
 
2.1.3 Leukocyte isolation and purification  
4.4 ml of the anti-coagulant, trisodium citrate (3.8 %) from single use 
sterile ampulets (Martindale Pharmaceuticals, Essex, UK) were added 
per 35.6 ml of blood. In order to separate the blood cells from the blood 
plasma and platelets, the lid was covered in parafilm and the tube spun at 
350 g for 20 min at room temperature (RT). Once spun, the upper 
platelet-rich plasma layer (PRP- upper phase) was harvested gently, 
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taking care not to disturb the interface. The upper platelet-rich plasma 
was then spun for 20 min at 800g to pellet the platelets leaving the 
platelet-poor plasma (PPP) supernatant. The PPP was then transferred to 
a fresh tube.   
 
2.1.3.1 Dextran sedimentation 
6 ml of 6 % dextran T-500 (3g dextran powder in 50ml 0.9% saline, 
Sigma-Aldrich, Poole, UK) was added to the erythroid/cell-rich layer 
(lower interphase) and the volume was made up to 50 ml with sterile 
0.9% saline and the tube was inverted to mix, avoiding formation of air 
bubbles. The lid was loosened and the cells were undisturbed for 20-30 
min at RT to allow the sedimentation of the red blood cells to occur. 
Following dextran sedimentation the upper white cell layer was harvested 
carefully and spun at 320 g for 6 min. The supernatant was discarded and 
the leukocyte pellet was then subjected to either an Optiprep™ (Axis‐
Shield, Huntingdon, UK) or a Percoll ® gradient (Sigma-Aldrich, Poole, 
UK). 
 
During the centrifugation of the leukocyte pellet, 1X Hanks Buffered 
Saline Solution (HBSS) was made fresh each time from 10X stock. For 
one tube of blood a total volume of 50 ml of 1X HBSS was made; 45 ml 
of Baxter Sterile Irrigation water (Baxter Healthcare Corp., Deerfield, 
Illinois, USA) were added to 5 ml of 10X HBSS. Three drops of Sodium 
Bicarbonate were added to adjust the pH to ~7. 
 
2.1.3.2 Construction of the Optiprep™ gradient 
The white cell soft pellet generated in section 2.1.3.1 was gently 
resuspended in 2 ml of 20% PPP in HBSS without Ca2+ and Mg2+ 
(GIBCO HBSS- from Life Technologies) and topped up to 6 ml.  
OptiprepTM (4 ml) was added to the cells to make the volume 10 ml. After 
gently inverting to mix, 10 ml of the 1.095 Optiprep™ layer (3 ml 
OptiprepTM + 8.036 ml of 20 % PPP in HBSS) was carefully overlaid over 
the 10 ml of the white cell layer followed by a further 10 ml of the 1.080 
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OptiprepTM (3 ml Optiprep + 10.435 ml of 20 % PPP in HBSS). The final 
layer was formed by the addition of 10 ml 20% PPP in HBSS. The 
gradient was centrifuged at 1978 g for 30 min at 20 °C without the brake.  
A single gradient was used to isolate PMN from up to 80 ml of blood. 
 
 
 
 
 
 
 
 
 
 
This yielded three populations of cells: the erythrocyte layer at the bottom 
of the tube, the PMN layer in the middle phase and PBMCs (peripheral 
blood mononuclear cells) in the upper phase.  
 
2.1.3.3 Construction of the plasma-Percoll® gradient 
The pelleted leukocytes from section 2.1.3.1 were resuspended in 1.5 ml 
of PPP. The Percoll® gradient solutions were prepared. The lower phase 
(51 %) was made up by adding 1.02 ml of 90 % Percoll® (1ml of 100 % 
Percoll was added to 9ml 0.9 % saline) and 0.98 ml PPP. The upper 
phase (42 % Percoll®) was made up by adding 0.84 ml of 90 % Percoll® 
to 1.116 ml of PPP. The lower phase (2ml total volume) was placed in the 
bottom of a 15 ml polystyrene centrifuge tube. A fresh sterile Pasteur 
pipette was then used to carefully overlay the upper phase on top, tilting 
the tube slightly whilst doing so. The white cell soft pellet generated in 
section 2.1.3.2 and resuspended in 1.5 ml PPP was then overlaid onto 
the upper phase. The gradient was subsequently spun at 320 g for 11 
min without a brake at RT. A single gradient was used for isolation of 
PMN from up to 80 ml of blood. The centrifugation of the plasma-Percoll® 
gradient also yields three layers of cells with the erythrocytes residing at 
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the bottom of the tube, the PMN at the interphase between the 51% and 
42% Percoll® layers and the PBMCs at the top of the 42% layer.  
 
 
 
2.1.3.4 Harvesting the gradient 
A Pasteur pipette was used to collect the cells from just above the 
interface avoiding any extra liquid from the gradient layers. The cell layers 
were transferred to fresh 50 ml falcon tubes and washed in HBSS 
(without Ca2+ and Mg2+) to remove any contaminating gradient material 
as follows. Each tube was made up to 40 ml with 20 % PPP in HBSS. A 
cell count was then carried out using a haemocytometer. The cells were 
then pelleted at 320 g for 6 min and either further purified as described in 
section 2.1.3.5 or resuspended in pre-warmed supplemented RPMI 1640 
media. 
 
2.1.3.5 Ultrapurification of PMN using a negative magnetic 
selection 
In order to further purify the PMN and remove residual contaminating 
cells, the PMN layer from either purification method in sections 2.1.3.2 
and 2.1.3.3 was subjected to a negative magnetic selection column using 
a custom antibody cocktail (Stem Cell Technologies, Meylan, France). 
Column buffer was prepared by adding 1 ml of FCS to 49 ml HBSS 
(without Ca2+ and Mg2+). The cells were resuspended in column buffer at 
1x108 cells per ml of buffer. 65 µl of antibody cocktail (Sabroe et al. 2002) 
were added and the cells were incubated at RT for 15 min with 
occasional gentle swirling followed by a further 15 min incubation with 
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magnetic colloid beads added at 50 μl/1x108 cells (Stem Cell 
Technologies, Meylan, France). During this incubation a magnetic 
MACS® Separation (Miltenyi Biotec, Surrey, UK) column was pre-
equilibrated with 10 ml column buffer. The cells were subsequently run 
through the column, which bound to the colloid beads attached to 
antibody with contaminating cells. Any remaining PMN in the column 
were washed off with an extra 10 ml column buffer. The ultrapure PMN 
were then counted using a haemocytometer, spun and resuspended in 
RPMI 1640 media.  
 
2.1.4 Cytospin analysis of PMN purity and death  
To determine the purity and assess PLB-985 and PMN apoptosis 
morphologically, 50-100 µl of cells at 5x106/ml were cytocentrifuged onto 
microscope slides and visualised by light microscopy. Duplicate cytospins 
slides were prepared for each treatment. Cells were added to chambers 
and spun at 300g for 3 min (Shandon Cytspin 3, Thermo Scientific, 
Hemel Hempstead, UK). Cytospins slides were fixed with 100 % 
methanol and stained with Quick- Diff stains (Gentaur, London, UK). The 
slides were mounted with DPX (Fisher Scientific, Loughborough, UK) and 
covered with cover slips. The slides were observed under a Zeiss 
Axioplan microscope using the 100x oil immersion lens. PMN, PBMC and 
eosonophils were distinguished on the basis of their morphology and 
PMN apoptosis was assessed on the basis of characteristic 
morphological changes. Healthy PMN have multi-lobed nuclei and are 
round whereas apoptosing cells loose their nuclear morphology and 
shrink. A total count of 300 PMN or 100 of PLB-985 cells was recorded 
for each slide unless otherwise stated. A purity count was carried out on 
the untreated control at 0 h where a total of 600 cells were scored on the 
basis of cell type from the two slides.  
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Figure 2.1 PMN Apoptosis 
 
 
 
A micrograph of PMN cells from cytocentrifuge preparations. During 
apoptosis PMN shrink and undergo chromatin condensation. PMN were         
scored as healthy (red arrow) and apoptotic (blue arrow) based on 
morphological changes. 
 
2.1.5 PLB-985 cell maintenance 
PLB-985 cells - human acute myeloid leukaemia cell line (from the 
German Collection of Microorganisms and Cell Cultures – DMSZ) were 
grown in 1640 RPMI medium containing 10% FBS (Autogen Bioclear, 
Wiltshire, UK) and 100 U/ml Penicillin and 100 U/ml Streptomycin 
(Pen/Strep) at 37 ̊C in a humidified atmosphere of 5 % CO2 in tissue 
culture incubator (Sanyo, Loughborough, UK). PLB-985 cells were 
maintained between 2x105 cells/ml to 2x106 cells /ml of media. Cells were 
grown in 75 cm2 culture flasks until they reached 80% confluence and 
then passaged. To induce differentiation to a PMN-like morphology, cells 
were cultured in medium supplemented with various reagents at 3 x 105 
cells per ml for a number of days. 
 
2.1.6 Mycoplasma testing of PLB-985 
Mycoplasma tests were carried out by the department lead technician on 
the cell culture medium on a monthly basis using EZ-PCR mycoplasma 
test kit, which uses mycoplasma specific primers to detect DNA by PCR 
(Geneflow, Staffordshire, UK). Tests were carried out according to 
manufacturer’s instructions. 
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2.1.7 PLB-985 differentiation into PMN-like cells 
PLB-985 cells were seeded at 0.5 x 106 cells/ml one day prior to transfer 
into differentiation media. The next day the cells were pelleted at 200 g 
for 2 min and re-suspended in differentiation media at 0.3 x 106. The cells 
were in the log phase of growth at this stage.  The differentiation stimuli 
tested were: 0.5 μM Retinoic Acid (RA), 0.75 μM RA, 1 μM RA, 1 μM RA 
and DMF (dimethylformamide), 1 μM RA and 1.25 % (v/v) DMSO 
(dimethyl sulfoxide) and 1.25 % DMSO. The cells were incubated in 24 
well plates in a total of 1 ml volume per well for 5 days at 37 ̊C in a 
humidified atmosphere of 5 % CO2 in tissue culture incubator (Sanyo, 
Loughborough, UK).  Two cytocentrifuge slides were prepared on each 
day. A cell count was carried out using a haemocytometer and 1x106 
cells were lysed for protein on day1 -5 of the differentiation process as 
described in section 2.1.10.1. 
 
2.1.8 Transfection of PLB-985 cells 
PLB-985 cells were seeded at 4 x 105 cells/ml one day prior to the 
transfection to ensure cells were equilibrated. The cells were transfected 
using the Nucleofector V system from Amaxa Biosystems according to 
manufacturer’s manual. Briefly, after centrifugation at 300 g for 3 min, 4 x 
106 cells were gently resuspended in 100 μl of nucleofection solution 
containing 3 μg of siRNA and transfections were performed with the 
program C-023. The siRNA target sites are shown in Fig. 2.2. 
Immediately following transfection, the PLB-985 cells were transferred to 
RPMI 1640 media at a final concentration of 3 x 105. The cells were 
incubated at 37 ̊C with 5 % CO2 for 10 or 24 h. At 10 h or 24 h after 
transfection, the cells were harvested and either lysed for RNA (described 
in section 2.1.15), protein extraction (section 2.1.10.1) or processed for 
flow cytometry (section 2.1.9). Cytospins of the cells were prepared at 
each time-point in order to assess cell death.  
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Figure 2.2 Identification of human HAX1 siRNA target sites 
The HAX1 ON-TARGETplus SMARTpool siRNA (L-012168-01-0005, human HAX1, NM_001018837) used for the gene knockdown in 
the PLB-985 cell line targets four different sites of the mRNA. HAX1 001 sequence is shown with alternating exons displayed in upper- 
and lowercase. The siRNA target sites found on exon 2  (red, pink) exon 3 (blue) and exon 7 (yellow) are highlighted. 
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2.1.9 Detection of changes in mitochondrial inner transmembrane 
potential (Δψm) in PLB-985 cells 
A distinctive feature of early-programmed cell death is mitochondrial 
membrane instability resulting in commitment of cells to undergoing 
apoptosis. Changes in mitochondrial membrane potential were detected 
using a 5,5′, 6,6′-tetrachloro-1, 1′, 3,3′ tetraethylbenzimidazolo-
carbocyanine iodide (JC-1; Sigma-Aldrich). Two x 106 PLB-985 cells from 
each control, mock (nucleofection solution only) or HAX1 siRNA 
transfected conditions were pelleted and resuspended in complete RPMI 
media at 1 x 106/ ml. The cells were transferred to a 24 well plate at 1 x 
106 cells per well. Cells were treated with valinomycin [3 or 5 μM] for 3 h 
in order to induce the collapse of mitochondrial membrane potential of 
these cells.  Cells were then pelleted and resuspended in 300 μl of RPMI 
1640 media without serum and antibiotics containing 10 μM JC-1 dye. An 
unstained untreated PLB-985 cell control was also prepared by 
resuspension in just the serum- and antibiotic-free media. The samples 
were left to stain for 15 min at 37 °C. This was followed by washing in 1ml 
PBS and resuspension in 300 μl of PBS. The samples were kept on ice 
until analysed by flow cytometry. Loss of Δψm was demonstrated by a 
gain of fluorescence on the FL-1 channel of a FACS Calibur flow 
cytometer (BD Biosciences - Pharmingen). At least 10000 cells were 
analysed for each experimental condition. Analyses of data was carried 
out by the flow cytometry analysis software FloJo (software version 9.3.2 
(Tree Star, Inc.).  
 
2.1.10 Protein extraction      
2.1.10.1  Preparation of whole cell lysates 
PLB-985 and PMN cells from section 2.1.3 were washed with ice-cold 
Dulbecco A PBS (Oxoid, Hampshire, England). The cells were then lysed 
in 10 µl of PI cocktail (protease inhibitor), PMSF (phenylmethylsulfonyl 
fluoride) and DFP (Diisopropyl fluorophosphate) containing water (see 
below) per 106 cells. The sample was vortexed vigorously and an 
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equivalent volume of hot SDS-PAGE loading buffer (Appendix 7.1.1) was 
added. The sample was boiled for ~5 min and stored at -80°C until 
required. 
PI, PMSF and DFP containing water (500 µl)   Volume (µl) 
PMSF (100mM)       5                
DFP (100mM)       5                            
PI (Roche Complete protease inhibitor cocktail (Roche 20                    
Applied Science, Lewes, UK) dissolved in 1.5 dH2O)                                     
dH2O         470  
 
2.1.11 Western Blotting 
Protein extracts from Section 2.1.10.1 were analysed by western blotting. 
The samples were first subjected to SDS-PAGE gel electrophoresis using 
either a 12 or 15 % SDS-PAGE resolving gel. The proteins were then wet 
transferred to Immobilon-P 0.45 µM PVDF (Polyvinylidene fluoride) 
transfer membrane (Merck Millipore, Billerica, MA). The membrane was 
then immunostained with a primary antibody against the preferred 
protein. This was followed with immunostaining with a secondary 
antibody conjugated to horseradish peroxidase (HRP). The proteins were 
visualised using the EZ-ECL enhanced chemiluminescence detection kit 
for HRP (Geneflow, UK). 
 
2.1.11.1 SDS-PAGE Electrophoresis 
The gel running apparatus (Protean 2 gel assembly, Bio-Rad, Berkeley, 
CA) was wiped clean and assembled. Acrylamide gels were made by 
mixing the reagents listed in Appendix 7.1.2. APS (Ammonium persulfate) 
and TEMED (Tetramethylethylenediamine) were added just before the 
gel was ready to be poured. The gel was overlaid with 100 % isopropanol 
in order to remove any air bubbles. Once the gel had set, the isopropanol 
was washed off with distilled water. Stacking gels were made by adding 
together the reagents listed in Appendix 7.1.3. Combs were inserted to 
form wells and the gels were left to set for ~15 min. Once the gels had 
set, the gel apparatus was dismantled and the gels were transferred to 
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gel tanks. The gels were immersed in running buffer (Appendix 7.1.4) and 
the combs were carefully removed. Whole cell lysates were loaded into 
individual lanes alongside 15 µl of ColorPlus Prestained Protein Ladder, 
Broad Range (10-230 kDa) (New England Biolabs, UK) to allow sizing of 
the proteins. The gels were run at 120-180 volts using a PowerPac 300 
from BioRad until the blue dye reached the gel front. The gel was 
removed from the gel apparatus carefully using flat- end tweezers and 
immersed in 1X transfer buffer (Table 5) for ~ 5 min.  
 
2.1.11.2 Wet protein transfer 
Proteins were transferred using the Geneflow wet transfer Kit. PVDF 
membrane was immersed in 100 % methanol for ~ 5 min in order to 
activate the membrane. It was then transferred to transfer buffer (1X) 
(Appendix 7.1.5). In a plastic tray containing 1X transfer buffer, two 
transfer buffer soaked fibre pads were placed on the black side of the gel 
holder cassette. One piece of filter card was then placed on top of this 
followed by the gel and the PVDF membrane on top. Any bubbles were 
removed using tweezers and gloved hands. The second piece of filter 
card was then placed on top of the PVDF membrane followed by another 
two transfer buffer soaked fibre pads. Lastly, the cassette was closed 
using the red side of the cassette. The gel holder cassette was then 
placed in the buffer tank and the transfer was run at 100 V for 70 min. 
Ponceau S (0.1 % w/v in 5 % acetic acid) staining was used to assess the 
protein transfer and the protein loading. 1X TBS (Tris Buffered Saline) 
buffer (Appendix 7.1.6) was used to wash off the stain. The membrane 
was then blocked with blocking buffer for 1 ½ – 3 h (depending on 
antibody used) at RT.   
Blocking Buffer (5% Marvel non-fat milk powder in TBS Tween (Appendix 
7.1.7):   
 1 g Marvel milk powder + 20 ml 1X TBS Tween (0.1% Tween-20)
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2.1.11.3 Immunostaining of PVDF membrane 
Blocked membranes were then transferred to a 50 ml Falcon tube 
containing diluted primary antibody in 4 ml of blocking buffer and 
incubated overnight at 4 ̊C on a rolling platform.  Concentrations and 
dilutions of primary antibodies are listed in Appendix 7.2.1. After 
incubation with primary antibody, the membrane was washed with 1X 
TBS-Tween three times for 10 min each time on a shaker at RT. The 
membrane was then incubated with secondary antibody (Appendix 7.2.2) 
conjugated to HRP in 5 ml of blocking buffer on an orbital rotator for 1 h 
at RT. After incubation with secondary antibody, the membrane was 
washed again three times with 1X TBS-Tween for 10 min each time with 
shaking.  
 
2.1.11.4 Chemiluminescent detection of immobilized proteins 
(Western blotting) 
Detection of specific proteins on the immunoblot was carried out using 
the EZ-ECL Chemiluminescence Detection Kit according to the 
manufacturer’s specifications. The membranes were exposed to a 
Hyperfilm™ chemiluminescence film (GE Healthcare Life Sciences, 
Uppsala, Sweden) in a Hypercassette™ (GE Healthcare Life Sciences, 
Uppsala, Sweden) The membranes were sealed in plastic film and stored 
at 4 ̊C. 
 
2.1.12 Stripping and re-immunostaining of western blot membranes 
Stored membranes were blotted in water for 2 min. The membranes were 
then stripped in 0.2 M sodium hydroxide for 15 min on a shaker. This was 
followed by two 5 min washes with water and two 5 min washes with 1X 
TBS-Tween on a shaker. The membrane was blocked for 1 ½ - 3 h in 
blocking buffer. Immunostaining was carried out as described on section 
2.1.11.3. 
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2.1.13 Western Blot Densitometry Analysis  
Western blots were scanned and images saved in TIFF format. Bands 
were analysed using Image J (free software, Rasband, 1997) following 
online instructions (http://www.navbo.info/DensitometricAnalysysNIH 
image.pdf) and have been labeled as relative fold change from the 
untreated control. In occasions where relative band density was 
calculated, the band density is displayed as a percentage of the actin 
control band.  
 
2.1.14 Total RNA (ribonucleic acid) extraction and assessment of 
RNA quality 
Total RNA was extracted from ultrapure PMN (5-10 x 106 cells), PLB-985 
(0.5-1 x106cells) cells and 10-100 zebrafish embryos using TRI reagent 
(Sigma-Aldrich, Gillingham, Dorset, United Kingdom) according to the 
protocol supplied by the manufacturer. 200 µl of TRI-reagent were used 
for 20 or less embryos and 1ml for more than 50 embryos and the 
embryos were forced through a needle to ensure full lysis. Total RNA was 
resuspended in 30 µl of sterile H2O for injections. The RNA was 
quantified using a Nanodrop™ 1000 spectrophotometer (Thermo 
Scientific).  The 260/280 and 260/230 ratios were also noted down to 
evaluate the purity and quality of the RNA. The RNA was then 
immediately either converted to cDNA (Section 2.1.16) or stored at -80 ̊C. 
For some experiments the quality of the RNA was also assessed by RNA 
agarose gel electrophoresis.  Agarose gel (50 ml) was prepared by 
adding 0.5 g of RNA agarose to 38.5 ml of dH2O and boiling in the 
microwave. 5 ml of 10X MOPS (3-(N-morpholino) propanesulfonic acid) 
and 8.5 ml of formaldehyde were then added to the agarose in a fume 
hood and the gel was poured and left to set. The gel was immersed in 1X 
MOPS running buffer and the comb was removed. RNA (2 µl) loading 
buffer was added to 1 µl of RNA and the total 3 µl were loaded into each 
lane. The gel was run at 70 V for 10-20 min.  
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2.1.15 RT-PCR (Reverse-transcription polymerase chain reaction) 
All RT-PCR reagents, buffers and enzyme used were from Promega, 
Biotec (Madison, WI) unless otherwise stated. Unless otherwise stated 
PCR was carried out using Taq polymerase. 
 
2.1.15.1 Reverse Transcription of mRNA into cDNA (Deoxy-
ribonucleic acid) 
RNA (29 µl, containing between 1-3 µg of RNA) was added to 1 µl of 
oligo dT15 (deoxythymidine) primer and heated to 70 ̊C for 5 min in a PCR 
machine. Control tubes containing only water were also prepared. While 
primer annealing was occurring, RT master mix was made for the number 
of samples plus two extra, as some master mix is lost during pipetting.  
 Master Mix (per tube):  
● 5 X MMLV RT Reaction Buffer    10 µl 
● RNAsin       1.25 µl 
● 100 mM dNTPs (deoxynucleotide thriphosphates)  1.25 µl 
● MMLV Reverse Transcriptase    2 µl 
● Nuclease- free H2O      5.5 µl  
Total volume:       20 µl 
20 µl of RT master mix were then added to the 30 µl of the sample and 
the samples were gently mixed by pipetting and placed in the PCR 
machine. Negative RT control tubes containing no MMLV RT were also 
set up in order to assess whether there is any contaminating genomic 
DNA in the sample. The tubes were incubated at 40 ̊C for 1 h and the 
reaction was inactivated by heating for 2 min at 94 ̊C. The cDNA was 
then used as a template for amplification by PCR or stored at -20 C̊ until 
required. 
 
2.1.15.2 Amplification of human and zebrafish cDNA by PCR using 
Taq polymerase 
Two microlitres of cDNA generated as described in section 2.1.11.3 were 
subsequently used in the PCR amplification unless otherwise stated. The 
following were combined in a PCR:  
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Master Mix (made for number of samples + 2 extra tubes) 
● 10 X PCR Reaction Buffer (without MgCl2)  5 µl 
● 25 mM MgCl2      1.5 µl 
● 10 mM dNTPs      1 µl 
● 10 mM Forward Primer     0.7 µl 
● 10 mM Reverse Primer     0.7 µl 
● Taq (DNA Polymerase- 5u/ µl)    0.25 µl 
● Nuclease- Free H2O     13.85 µl 
Total volume:       23 µl 
 
The master mix (23 µl) was added to 2 µl of cDNA from the RT reaction 
(Section 2.1.11.3) and the sample was mixed gently. Negative PCR 
control tubes were also prepared containing H2O instead of cDNA. 
Elongation factor 1- α (EF1-α) (zebrafish samples) and Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (human samples) primers were 
used as positive control PCR primers. Zebrafish and human primer 
sequence and optimal annealing temperatures are shown in 7.3. EF1-α 
and GAPDH are ubiquitously expressed genes and can be used as 
standards in zebrafish and humans respectively for normalizing samples. 
In order to identify the optimal primer annealing temperature, temperature 
gradients of the human HAX1 primers (50-68 ̊C) were carried out with 
both PMN and PLB-985 cDNA. The tubes were placed in a PCR block 
and the following thermal cycling was carried out: 
 
● 1. 94 ̊C- 2 min (1 cycle) 
● 2. 94 ̊C- 30 sec 
● 3. Optimal primer annealing temperature- 1 min   
● 4. 72 ̊C- 30 sec 
● 5.Go to step 2 (29/34 X) 
● 6. 72 ̊C- 2 min 
● 7. Hold step- 4 ̊C. 
PCR products were stored at -20 ̊C. 
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2.1.16 hax1 transcript - specific primer design for Zebrafish mRNA 
Primers were designed using the NCBI Primer design tool to test whether 
chosen sequences were suitable primer sequences. It was assumed that 
the zebrafish gene would be spliced in the same way as the human gene 
and the primers were modelled using the splicing pattern described by 
Lees et al (which uses the VEGA annotation of alternatively spliced HAX1 
isoforms) and the zebrafish hax1 gene sequence (Lees et al. 2008). 
Annealing temperature gradients were carried out in order to identify the 
optimal primer annealing temperatures. The primer sequences and their 
optimal annealing temperatures are shown in Appendix 7.3.1. The 
genomic sequence of zebrafish hax1 with highlighted primer annealing 
regions is shown in Appendix 7.4. 
 
2.1.17 Amplification of zebrafish cDNA and gDNA by PCR using 
Phusion® High-Fidelity DNA Polymerase  
Unless otherwise stated, 0.5 µl of zebrafish cDNA were used in the PCR 
amplification. The following were combined in a PCR reaction, on ice: 
 
gDNA/cDNA     0.5 μl 
water      make up to 20 μl 
10 μM forward primer   0.5 μl 
10 μM reverse primer   0.5 μl 
10 mM each dNTPs (Promega)  0.4 μl 
Phusion 5 X HF Buffer (NEB)  4 μl 
Phusion® DNA Polymerase  0.2 μl 
 
The samples were mixed gently and added to a preheated thermocycler 
and cycled as follows: 
● 1. 98 ̊C- 30 sec (1 cycle) 
● 2. 98 ̊C- 10 
● 3. Optimal primer annealing temperature - 15 sec   
● 4. 72 ̊C- 5 sec 
● 5. Go to step 2 (34 X) 
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● 6. 72 ̊C- 5 min 
● 7. Hold step- 4 ̊C. 
PCR products were stored at -20 ̊C. 
 
2.1.18 PCR gel electrophoresis 
PCR products were examined on agarose (Melford Labs) gels. The 
desired % gel was made by adding a specific amount of agarose (w/v) to 
1X TAE (Tris-acetate) buffer and the melting in a microwave. 3 µl of 
ethidium bromide (BDH Electran) were added once the agarose had 
cooled and the gel was poured. After the gel had set, the comb was 
removed and the gel placed in a tank immersed in 1X TAE buffer 
(Appendix 7.5). Samples were loaded in each lane alongside the DNA 
ladder, Hyperladder I (Bioline, London, United Kingdom) to allow sizing of 
the PCR products.   
 
2.1.19 QIAquick PCR Clean-up and gel extraction 
PCR products were extracted and purified using the QIAquick gel 
extraction kit protocol (QIAGEN, Valencia, CA) according to 
manufacturer’s instructions. The DNA was eluted in in 50 µl of sterile H2O 
for injections (Braun) and samples were stored at -20 ̊C until sequencing. 
PCR clean up (with the Guanidine HCl step) was carried out according to 
the QIAquick PCR Purification Kit (QIAGEN, Valencia, CA) manual. 
Remaining PCR product was eluted into 30 µl of sterile H2O. PCR 
products were sent for sequencing to the Core Genomics Facility 
(University of Sheffield, Medical School). 
 
2.1.20 Colony PCR 
Well-separated transformant colonies were PCR amplified in order to 
screen for inserts. The following were added to a PCR tube per colony 
and mixed gently: 
9 μl water  
10 μl PCR Reddymix (Thermoscientific) 
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1 μl 10 μM each left and right primer 
 
A small amount of each colony was added to the PCR mix using a p200 
pipette tip. The tubes were then added to a preheated thermocycler and 
cycled as follows: 
 
 1: 94 °C 2min 
 2: 94 °C 20sec 
 3: initially 60 °C  (then a 0.2 °C reduction per cycle) 20 sec 
4:72 °C 45sec 
 5: go to step 2) 29 X 
 6: 72 °C 3min  
 7: 10 °C hold 
 
Each p200 pipette tip containing a colony was also used to streak out to 
give single colonies on selective plates. In order to verify the sequence, 
colonies with the correct sized PCR product were Sanger sequenced 
following ExoI-SAP treatment. On ice, 3.2 μl of ExoI-SAP mix were added 
to each PCR tube containing the PCR reactions. ExoI-SAP mix for 10 
reactions was produced by adding 1.7 μl of NEB exonuclease I and 32 μl 
of shrimp alkaline phosphatase (USB, Cleveland, OH, USA). Following 
the addition of ExoI-SAP to each PCR reaction, tubes were incubated on 
a preheated thermocycler at 37°C for 45 min and then 80 °C for 15 min.  
 
2.1.21 Whole mount in situ Hybridization (WISH) probe synthesis 
The full-length hax1 coding sequence was cloned in a pCR-BLUNT II-
TOPO plasmid vector (Appendix 7.6) according to the manufacturer’s 
instructions (Invitrogen, Carlsbad, CA). The plasmid DNA was purified by 
a high speed MIDIprep of a colony containing the vector with the gene 
according to manufacturer’s protocol (QIAGEN, Valencia, CA). The 
plasmid DNA was then eluted into 1 ml of water. In order to generate the 
anti-sense probe the plasmid was linearized with an XhoI restriction 
digest. A SpeI digest was carried out to generate the sense probe. 100 μl 
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of plasmid DNA were mixed with 11 μl of NEB Buffer 4,1.2 μl of BSA and 
3 μl of the relevant restriction enzyme. A vector containing the coding 
sequence for the positive control L-Plastin (anti-sense) was also 
linearized using 20 μg of plasmid DNA, 31 μl of water, 10 μl of NEB 
Buffer 3, 1 μl of BSA and 5 μl of NotI restriction enzyme.  
 
The digests were incubated at 37 °C for 2 h. Following the incubation the 
whole mixtures were loaded into 3 wells each an 0.8 % agarose gel 
(section 2.1.18) and the plasmids resolved by electrophoresis at 100 
Volts for 1 h and 20 min. The plasmid DNA was quantified on a 
Nanodrop™ 1000 spectrophotometer (Thermo Scientific). The purified 
linear DNA probes were in vitro transcribed using a T7 and Sp6 RNA 
digoxygenin (DIG) labelling kit (Roche) for the hax1 sense and anti-sense 
probes respectively. A T7 RNA digoxygenin (DIG) labelling kit was used 
to transcribe the L-Plastin probe. 1 μg of linear plasmid DNA was added 
to 2 μl of transcription buffer, 1 μl of RNAse inhibitor, 1 μl T7/SP6 RNA 
polymerase, 2 μl NTP-DIG-RNA and 5.6 μl of sterile water then incubated 
for 2 h at 37 °C. The plasmid DNA template was removed by digestion 
with an additional 2 μl of TURBO DNAse in a further 30 min incubation at 
37 °C. The RNA was precipitated by the addition of 4 μl of Lithium 
chloride, 1 μl EDTA (pH8), 75 μl and ethanol (100 %) at -80 °C overnight.  
The next morning, the RNA was pelleted by centrifugation at 14000 rpm 
for 30 min at 4 °C. The RNA pellet was then gently washed in 1 ml of 70 
% ethanol followed by a further 10 min centrifugation for 10 min at 4 °C, 
14000 rpm. The supernatant was removed and the pellet was air-dried 
and resuspended in 20 μl of sterile water. Presence of RNA was 
confirmed by agarose gel electrophoresis of 0.5 μl of RNA on a 0.8 % 
agarose gel. 80 μl of formamide (Sigma-Aldrich) were added to the 
resuspension and the RNA was stored at -80 °C.  
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2.1.22 Synthesis of capped zebrafish hax1 001 mRNA for 
microinjection 
The pCR-BLUNT II-TOPO hax1 001 plasmid generated in section 2.1.21 
was subjected to an EcoRI restriction digest to allow excision of the hax1 
001 insert. The restriction digest was carried out by adding 11.8 μl of 
water, 0.2 μl of 100X BSA (NEB), 2 μl of RE 10X buffer H and 1 μl of 
EcoRI (Promega, Biotec, Madison, WI) to 5 μl of the Zero Blunt TOPO 
vector containing the hax1 001 insert. The digest was incubated at 37 °C 
for 3 h. The EcoRI restriction digest products were analysed by agarose 
gel electrophoresis. The excised hax1 001 insert was gel purified as 
described in section 2.1.19. The purified insert was quantified using a 
Nanodrop™ 1000 spectrophotometer (Thermo Scientific). The insert was 
ligated O/N to EcoRI linearized pCS2+ plasmid vector by adding 50 ng of 
linearized pCS2+ to 33 ng of hax1 insert, 1 μl of 10X T4 ligase buffer and 
1 μl of T4 DNA ligase (Promega, Biotec, Madison, WI) in a final volume of 
10 μl. The ligation product was transformed into One Shot TOP10 E. coli 
competent cells (Invitrogen Life Technologies, Carlsbad, CA) according to 
manufacturer’s protocol. Transformed cells were streaked onto 
carbenicillin selective plates and grown O/N at 37 °C. Carbenicillin plates 
were made by adding carbenicillin antibiotic at 50 μg/ml to autoclaved LB 
agar.  
 
The next morning, 12 well-separated colonies were used to inoculate 5 ml 
of carbenicillin selective cultures and the cultures grown O/N at 37 °C. 
The plasmid DNA was purified using a QIAgen plasmid MINIprep kit 
according to manufacturer’s instructions (Valencia, CA). The plasmid 
DNA was screened for insertion of the hax1 001 segment by agarose gel 
electrophoresis using 1 μl of plasmid DNA loaded onto a 1 % agarose 
gel. The plasmid DNA from colonies with a shift in size from ~4000 bp to 
~5000 bp was then subjected to PCR with hax1 001 primers (Appendix 
7.3) using Reddymix (ThermoScientific) according to the manufacturer’s 
instructions. The PCR products were ExoI-SAP treated as described in 
section 2.1.20 followed by Sanger sequencing in order to determine the 
orientation of the hax1 insert in the pCS2+ plasmid vector. A clone with 
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the correct orientation was used to inoculate a 50 ml selective culture and 
the culture grown O/N at 37 °C.  The following morning, the hax1 001 
containing pCS2+ plasmid was purified from the O/N culture using a 
QIAgen plasmid MIDIprep kit (Valencia, CA) according to the 
manufacturer’s protocol. The plasmid DNA was linearized using NotI. 20 
μg of plasmid DNA were mixed with 20 μl of buffer 3 (NEB), 2 μl of 100X 
BSA, 4 μl of NotI in a total volume of 200 μl. The digest was incubated at 
37 °C for 2 h. The linearized plasmid DNA was then purified using a 
QIAgen PCR clean-up kit as described in the manufacturer’s manual. 
Purified linear plasmid DNA was transcribed into mRNA from the SP6 
promoter using an Ambion Sp6 mMessageMachine transcription kit 
(Austin, TX). The following were assembled into a PCR tube: 
 
5 μl linear pCS2+ hax1 001 (10 μg) 
10 μl NTP/CAP 
2 μl buffer 
1 μl RNAse free water 
2 μl Sp6 polymerase 
 
The contents of the tube were mixed gently and incubated at 37 °C for 2 
h. The plasmid DNA template was degraded by adding 1 μl of DNAse 
and incubating at 37 °C for 30 min. 
 
In order to purify the mRNA, synthesized mRNA was mixed 400 μl of 
Phenol Chloroform and 480 μl of RNAse free water. The mixture was 
vortexed and spun at 13000 rpm at 4 °C for 15 min. To further purify and 
concentrate the plasmid DNA, 400 μl of the upper layer were transferred 
into an Amicon ultra 0.5 ml centrifugal filter device (Millipore, Billerico, 
MA, USA) and the column inserted into a tube according to the 
manufacturer’s instructions. The tube was then centrifuged at 14000 at 
RT for 10 min. Following centrifugation, the column was transferred to a 
fresh tube and spun at 1000g at RT for 2 min. In order to quantify the 
RNA, the purified capped mRNA was then subjected to agarose gel 
electrophoresis. 1 μl of mRNA was loaded alongside Hyperladder I 
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(Bioline, London, United Kingdom) on a 1% agarose gel. The purified 
capped mRNA was diluted with RNAse free water and 50 pg (1 nl) were 
injected into each embryo as described in section 2.2.3.  
 
2.1.23 Isolation of genomic DNA from single zebrafish embryos 
Dechorionated embryos were lysed in 50 μl of embryo digestion buffer 
(10 mM Tris Hcl pH8, 1 mM EDTA, 0.3 % Tween-20, 0.3 % NP-40). 
Following a 10 min incubation at 98 °C, the embryos were transferred to 
ice and 4 μl of Proteinase K (25 mg/ml) were added. The embryos were 
then incubated for a further 3 h at 55 °C followed by a 10 min incubation 
at 98 °C. 650 μl of ammonium acetate solution were added to the lysate 
and mixed. Ammonium acetate solution for 10 samples was made up by 
adding 2.63 ml of 7.5 M ammonium acetate to 4.2 ml of water. The gDNA 
was extracted using 700 μl of chloroform and spinning at 14000 g for 1 
min at RT. The top aqueous layer (~650 μl) was then transferred to a new 
tube and 1 μl of GlycoBlue (Ambion, Austin, TX) was added to the 
sample for visualisation of pelleted nucleic acid. The gDNA was 
precipitated using 650 μl of propan-2-ol at RT and centrifugation at 
14000g for 30 min at 4 °C. The pelleted gDNA was washed with 1 ml 70 
% ethanol. Following centrifugation at 14000 g at 4 °C for 1 min, the 
supernatant was discarded and the sample pulse spun to bring down 
residual supernatant, which was then removed. The gDNA pellet was 
then air dried at RT for 1 min only followed by resuspension in 50 μl of 
water. The gDNA was stored at -20 °C.   
 
2.1.24 Isolation of genomic DNA from a pool of zebrafish embryos 
Genomic DNA (gDNA) was extracted from a pool of 10-50 embryos. 
Dechorionated embryos were lysed in 700 μl of embryo digestion buffer 
(10 mM Tris Hcl pH8, 1 mM EDTA, 0.3 % Tween-20, 0.3 % NP-40). 
Following a 10 min incubation at 98 °C, the embryos were transferred to 
ice and 30 μl of Proteinase K (25 mg/ml) were added. The embryos were 
then incubated for a further 3 h at 55 °C followed by a 10 min incubation 
at 98 °C. 700 μl of 1:1 phenol/chloroform solution were added to the 
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lysate and mixed by inversion. The tube was spun at 14000 g for 1 min at 
RT. The top aqueous layer (~450 μl) was then transferred to a new tube 
and 700 μl of chloroform were added to the solution. This was mixed by 
inversion and spun at 14000g for 1 min at RT. The gDNA was 
precipitated by transferring the aqueous layer (~450 μl) to a new tube 
containing 250 μl of 7.5 M ammonium acetate and 700 μl of propan-2-ol. 
The sample was centrifuged at 14000 g for 30 min at 4 °C. The pelleted 
gDNA was then washed in 1 ml of 70 % ethanol followed by a spin again 
at 14000 g at 4 °C for 1 min. Following the centrifugation, the supernatant 
was discarded and the sample pulse spun to bring down residual 
supernatant, which was then removed. The gDNA pellet was then air 
dried at RT for 1 min only followed by resuspension in 100 μl of water. 
The gDNA was stored at -20 °C.   
 
2.2 In-vivo techniques 
2.2.1 Whole mount in situ Hybridization (WISH)  
All WISH buffer formulas are shown in Appendix 7.7. Uninjected and 
hax1 001 mRNA injected nacre embryos at 24 hours post fertilization 
(hpf) were fixed overnight in 4 % para-formaldehyde (PFA made in 
phosphate buffered saline; PBS) at 4 °C. The embryos were then 
transferred into 100 % methanol and stored at -20 °C. Up to 20 embryos 
per eppendorf were fixed in this way. The embryos were rehydrated by 5 
min washes in 1 ml of a methanol series of 75 %, 50 % and 25 % made 
up in PBS and 100 % PBT (PBS with 0.1 % Tween-20). This was 
followed by a 15 min 1:1000 treatment in 10 μg/ml Proteinase K (Sigma-
Aldrich) in PBT then fixing for a second time in 4 % PFA for 20 min. This 
was followed by five 5 min washes in PBT and incubation in a pre-
hybridization buffer for 5 h at 70 °C. The embryos were incubated in 
probe-hybridization buffer (1:200 dilution of RNA in formamide from 
section 2.1.21 in pre-hybridization buffer) for 15 h at 70 °C. Excess RNA 
probe was removed by successive washes with 100 % brief HybWash 
and 15 min washes in 75 %, 50%, 25 % HybWash with 2X SSC at 70 °C. 
A 2X Saline-sodium citrate (SSC) wash followed by two 30 min washes 
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with 0.2X SSC at 70 °C followed. The embryos were then washed for 10 
min in a series of 0.2X SSC of 75%, 50 %, 25 % and 0% made up in PBT 
at RT. The embryos were incubated at RT in blocking solution (PBT, 2 % 
sheep serum; v/v, 2 mg/ml BSA) for several hours. This was followed by 
incubation in Blocking solution containing 1:5000 anti-DIG-AP antibody 
(Roche) overnight at 4 °C with gentle shaking. Excess primary antibody 
solution was washed of with six 15 min washes in PBT. During the last 
wash, the embryos were transferred to a 24 well plate. The embryos were 
then washed with staining wash solution three times, 5 min each time. 
This was followed by incubation in staining solution containing NBT 
(Roche) and BCIP (Roche) and the embryos were monitored with a 
dissecting microscope. Once the desired staining was achieved, the 
staining solution was removed and the reaction was stopped by adding 1 
ml of 1 mM EDTA in PBS (pH 5.5) for 5 min. The embryos were fixed in 4 
% PFA for 30 min and stored at -20 °C in methanol. Before imaging, the 
embryos were rehydrated with brief washes in 75 %, 50 % and 25 % 
methanol made up in PBS. Whole fish embryos were mounted in 80 % 
glycerol and imaged using a Nikon SMZ1500 stereomicroscope with a 
DS-Fi1 camera. Images were taken at multiple Z-planes. NIS elements 
software was used to generate the focused images.  
 
2.2.2 Morpholino phosphorodiamidate antisense oligonucleotides 
(MO) design 
Hax-1 splice blocking and translation start site blocking MOs were 
designed to target the splice acceptor of exon 3 and translation start site 
according to instructions on the http://www.gene-tools.com/Oligo_Design 
website. The MO oligonucleotides were obtained from Gene Tools, LLC 
(Corvalis, OR, USA). The sequence of the Hax-1 splice site MO was: 5’ 
AAACCTGATGGGAAGAAGCAGAACA 3’ and that of the translation start 
site MO 5’ GCTCATTTATGGACAGAATCCTGAG 3’. A p53 translational 
blocking MO was also used (5’ GCGCCATTGCTTTGCAAGAATTG 3’). 
Before injection the MOs were diluted with sterile H2O and phenol red (for 
visualization). 
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2.2.3 Zebrafish maintenance and microinjection 
Adult zebrafish were maintained at 28 °C in a 14 h light/dark cycle in 
approved Home Office facilities in the Centre for Developmental and 
Biomedical Genetics aquaria at the University of Sheffield. All zebrafish 
experiments were performed under the UK Home Office Project License 
40/3325 in accordance with Home Office legislation. Wild-type zebrafish 
(AB and EKK strains) and transgenic Tg(mpx::GFP)i114 fish (Renshaw et 
al. 2006) were set up for spawning late in the afternoon. Embryos were 
collected the next morning and grown at low density (~50 embryos per 
petri dish) in E3 media (Appendix 7.8). If embryos were required for RNA 
extraction they were then anesthetised with Tricaine methanesulfonate 
(MS222) before dechorionation and processing for genomic DNA (gDNA) 
or RNA extraction.  
 
2.2.4 Microinjection of embryos with MO and capped mRNA 
Transgenic zebrafish Tg(mpx:GFP)i114 were marbled overnight. The 
embryos were collected the following morning and ~50 embryos were 
aligned on a microinjection petri dish. The embryos were injected at the 
1-4 cell stage using 1-2 nl of diluted MO or RNA using a pulled Kwik-Filtm 
borosilicate glass capillary (World Precision Instruments) and a 
pneumatic picopump (PV830) and air compressor micromanipulator 
(World PrecisionInstruments), and a Leica S6D 100 dissecting 
microscope with a Leica L2 light source. The end of the needle was 
broken off using very fine forceps and the volume to be injected was 
quantified using a graticule. Phenol red was added to the diluted MO or 
RNA (1 µl in 10 µl final volume) for visualization of injecting under the 
microscope. After injection, embryos were placed in E3 media and 
incubated at 28.5 ̊C. Dead and unviable embryos were removed after 1 
hpf (hour post fertilization). Dead embryos were also removed after 6 and 
24 h. Embryos required for total RNA extraction were dechorionated and 
lysed in TRI reagent (Section 2.1.15). 
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2.2.5 Analysis of total zebrafish PMN counts 
Embryos were mounted in 1 % low melting point agarose containing 
MS222 in a 40 mm dish with a section of the base replaced by a 
microscopy glass coverslip. Images of embryos were captured using 
Volocity® software (Perkin Elmer, Cambridge, UK) through a Nikon 
Eclipse TE2000U inverted microscope 2x objective with 20 z planes. 
Merged z-stacks were generated using Volocity®. PMNs were counted at 
35, 48 and 72 hpf by eye from taking images of embryos on and counting 
the green fluorescent protein (GFP) labeled PMN by eye.  
 
2.2.6 Tail-fin transection of Tg(mpx:GFP)i114 embryos and analysis 
of PMN recruitment and resolution from the site of injury 
Dechorionated embryos were anesthetized by addition of MS222 to the 
E3 media at a density of 10 embryos per petri dish. In order to trigger an 
inflammatory response complete transection of the tail was performed 
midway between the terminal point of the aortic venous loop and the 
distal most part of the tail on 2-3 dpf embryos using a microsurgical knife 
(World Precision Instruments, Hertfordshire, UK) as previously described 
by Loynes et al. (Renshaw, Loynes et al. 2006). Post transection, the 
embryos were transferred to fresh E3 media and incubated at 28 °C for 
either 6 h (for analysis of recruitment of PMN to the site of injury) or 24 h 
(for analysis of PMN resolution from the site of injury) post injury (hpi). At 
the appropriate time point images of whole fish embryos were taken using 
a 2x objective on a Nikon Eclipse TE2000U inverted microscope and 
PMN at the site of injury were counted by eye. 
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Figure 2.3 Site of tail-fin transection 
An image of a 2 dpf embryo generated on a Nikon Eclipse TE2000U 
inverted microscope using a 2x objective. The red line indicates the site 
of transection. 
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2.2.7 Generation of a zebrafish hax1 targeting CoDA ZFN 
 
2.2.7.1 Adding zinc fingers to the generic backbones 
In order to insert the F1, F2 and F3 zinc fingers (Appendix 7.13.1) into the 
generic backbones, the following were assembled in a tube on ice: 
 
 
The contents of the tube were mixed gently, added to a preheated 
thermocycler and cycled as shown above. Primers for the left ZFN were 
added to the pCS2-Flag-ZFP-FokI-DD generic backbone and the right 
ZFN zinc finger primers to the pCS2-HA-ZFP-FokI-RR generic backbone.  
 
2.2.7.2 Generation of plasmid sticky ends 
The remainders of the left and right ZFN PCR products were then purified 
using a QIAquick PCR clean-up kit (with the guanidine HCl step), 
according to manufacturer’s protocol. In order to create plasmid DNA 
sticky ends and allow self-ligation of the plasmids into circular form, the 
resulting plasmid constructs (ZFN plasmids) were digested with restriction 
enzyme AgeI by adding the following components to a PCR tube, on ice: 
 
 
 
 
 
PCR reaction Components  
1ul       generic backbone amplicon 
14ul     water 
4ul       5 X Phusion HF buffer 
0.5ul   10mM each dNTPs 
0.5ul   10uM each F1+F2F3 primers 
0.4ul    Phusion HF 
PCR cycling 
parameters 
1:95 °C 2min                               
2:95 °C 20sec                            
3:50 °C 20sec                            
4:72 °C 5min 
5:go to step 2) 19x 
6:72 °C 3min 
7:10 °C hold 
Reaction components  
 44 μl of the eluted PCR product 
 34 μl of water  
 5 μl of NEB buffer I  
 1 μl of AgeI 
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The AgeI digested left and right ZFN expression vectors containing the 
F1, F2 and F3 zinc fingers were then purified using a QIAquick PCR 
clean-up kit (with the guanidine HCl step) according to manufacturer’s 
instructions and eluted in 50 μl of water.  
 
2.2.7.3 Circularisation of the ZFN backbone plasmids 
To generate a circular construct the left and right ZFN encoding plasmids 
were self-ligated by assembling the following components into a PCR 
tube: 
Reaction components  
 2 μl of the eluted AgeI digested PCR 
product  
 2.5 μl of 2X NEB quick ligase buffer 
 0.5 μl of NEB quick ligase 
This was mixed gently and incubated at room temperature (RT) for 5 min 
prior to transferring to ice. The entire reactions were then each used to 
transform 25 μl of NEB 10-beta competent E. coli (New England Biolabs, 
Ipswich MA) according to the manufacture’s instructions. Transformed 
cells (150 μl) were streaked on Ampicillin (50 μg/ml) selective LB agar 
plates and grown overnight (O/N) at 37 °C.  
 
2.2.7.4 Preparation of ZFN capped RNA for microinjection 
The two purified plasmids from section 5.1.1.3 encoding the left and right 
ZFN plasmids were linearised using NotI restriction enzyme. The 
following components were assembled in a tube, on ice: 
ZFN linearization components Reaction components  
 6 μg of each the left and right ZFN 
plasmids 
 247 μl of water  
 30 μl of NEB buffer 3 
 3 μl of 10 mg/ml BSA (NEB) 
 20 μl NotI 
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The digest was incubated at 37 °C for 1 h. The linearised plasmid DNA 
was then purified using a QIAquick PCR clean-up commercial kit as 
described in (section 2.1.19) and eluted into 30 μl of water. The plasmids 
were then used to in vitro synthesise capped RNA via Ambion’s Sp6 
mMessageMachine transcription kit (Austin, TX). The following were 
assembled into a PCR tube at RT:  
In vitro transcription components  
 3 μl 400 ng/μl Left and Right ZFN 
plasmid DNA 
 5 μl NTP CAP mix 
 1 μl 10X buffer 
 1 μl enzyme mix 
 
The contents of the tube were gently mixed and incubated at 37 °C for 2 
h. Following the in vitro RNA synthesis, the plasmid DNA template was 
degraded by adding 1 μl of DNAse turbo (Ambion, Austin, TX) to the 
sample and incubating at 37 °C for a further 20 min. The in vitro 
synthesised capped RNA was then purified using a QIAGEN RNeasy 
Minelute kit according to manufacturer’s protocol. The capped RNA was 
eluted with 18 μl of RNAse free water.  
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2.2.7.5 Preparation of zebrafish hax1 ZFN target sequence for 
Roche Titanium 454 sequencing 
 In order to allow Roche Titanium 454 sequencing of the ZFN target site, 
the hax1 target site was first amplified using LHax1ZF454 and 
RHax1ZF454 primers (Appendix 7.13.2). The following components were 
assembled into a PCR tube on ice and PCR carried out using the 
following conditions: 
 
 
 
 
 
 
 
 
 
 
 
 
PCR cycling 
parameters 
1:95 °C 30 sec                              
2:95 °C 10sec                            
3:50 °C 15sec                            
4:72 °C 5 sec 
5:go to step 2) 34 X 
6:72 °C 5min 
7:10 °C hold 
PCR reaction Components  
1 μl         20 X diluted genomic DNA 
14 μl          water 
4 μl            5X Phusion HF buffer 
0.4 μl        10 mM each dNTPs 
1 μl           10 uM each primer 
0.2 μl         Phsion HF 
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2.2.8 Generation of a zebrafish hax1 targeting TALEN 
2.2.8.1 TALEN assembly stage I 
Following identification of a suitable hax1 TALEN targeting site (described 
in Chapter 5), the first stage assembly reactions were set up on ice as 
follows: 
Left TALEN Part B 
components 
1 μl pHD1 (150 ng/μl) 
1 μl pNG2 (150 ng/μl) 
1 μl pNG3 (150 ng/μl) 
1 μl pHD4 (150 ng/μl) 
1 μl pFUS_B 
10 μl water 
2 μl T4 ligase buffer (NEB) 
2 μl T4 ligase (NEB) 
1 μl BsaI (NEB) 
Total volume: 20 μl 
Left TALEN Part A 
components 
1 μl pNI1 (150 ng/μl) 
1 μl pHD2 (150 ng/μl) 
1 μl pNI3 (150 ng/μl) 
1 μl pNN4 (150 ng/μl) 
1 μl pNN5 (150 ng/μl) 
1 μl pNN6 (150 ng/μl) 
1 μl pNI7 (150 ng/μl) 
1 μl pHD8 (150 ng/μl) 
1 μl pHD9 (150 ng/μl) 
1 μl pHD10 (150 ng/μl) 
1 μl pFUS_A (100 ng/μl) 
4 μl water 
2 μl T4 ligase buffer (NEB) 
2 μl T4 ligase (NEB) 
1 μl BsaI (NEB) 
Total volume: 20 μl 
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A list of the plasmids required for 
Golden Gate TALEN construction 
is shown in Appendix 7.17. For part 
A assembly, the first ten RVD 
modules were excised from the 
plasmids in which they were stored 
and ligated to array plasmid 
pFUS_A. For part B assembly the 
rest of the RVD modules were 
ligated to array plasmid pFUS_B. The plasmids were thawed and mixed. 
Each reaction was mixed by gentle pipetting and cycled following the 
parameters shown on the right. 
Right TALEN Part A 
components 
1 μl pHD1 (150 ng/μl) 
1 μl pNG2 (150 ng/μl) 
1 μl pNG3 (150 ng/μl) 
1 μl pHD4 (150 ng/μl) 
1 μl pNI5 (150 ng/μl) 
1 μl NG6 (150 ng/μl) 
1 μl pHD7 (150 ng/μl) 
1 μl pNI8 (150 ng/μl) 
1 μl pNG9 (150 ng/μl) 
1 μl pHD10 (150 ng/μl) 
1 μl pFUS_A (100 ng/μl) 
4 μl water 
2 μl T4 ligase buffer (NEB) 
2 μl T4 ligase (NEB) 
1 μl BsaI (NEB) 
Total volume: 20 μl 
Right TALEN Part B 
components 
1 μl pNI1 (150 ng/μl) 
1 μl pNG2 (150 ng/μl) 
1 μl pHD3 (150 ng/μl) 
1 μl pNI4 (150 ng/μl) 
1 μl pNG5 (150 ng/μl) 
1 μl HD6 (150 ng/μl) 
1 μl pFUS_B 
8 μl water 
2 μl T4 ligase buffer (NEB) 
2 μl T4 ligase (NEB) 
1 μl BsaI (NEB) 
Total volume: 20 μl 
Temperature cycling parameters 
1: 37 °C 5 min                              
2:16 °C 10 min 
3: go to step 1 9 X 
4:50 °C 5 min 
5:80 °C 5min 
7:10 °C hold 
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2.2.8.2  TALEN assembly stage I plasmid purification 
In order to remove the non-ligated linear DNA fragments, 1 μl each of 10 
mM rATP and plasmid safe nuclease (Epicentre Biotechnologies) was 
added to each of the four cloning reactions. The samples were mixed 
gently by pipetting and incubated at 37 °C for 1 h. Three μl of each 
reaction were used to transform 12.5 μl of NEB 10-beta competent E. coli 
(New England Biolabs, Ipswich MA) according to the manufacture’s 
instructions. Spectinomycin selective X-gal LB agar plates were used for 
streaking of 50 μl of transformed cells and overnight incubation at 37 °C 
followed. Three medium sized well-separated white colonies were picked 
for each transformation reaction and used to inoculate 6 ml cultures of 
Spectinomycin selective LB. The cultures were incubated O/N at 37 °C 
with shaking. Plasmid DNA was purified from overnight cultures using a 
QIAGEN MINI prep kit (with the PB buffer wash) as described in the 
manufacturer’s protocol. The purified DNA was eluted into 50 μl of water. 
In order to asses whether the RVD modules of the Part A and B of the left 
and right hax1 specific TALEN were correctly aligned, each array plasmid 
containing the RVD modules was subjected to a diagnostic digest with 
NheI and XbaI restriction enzyme (NEB). Four μl of each plasmid eluate 
were transferred to a tube containing 6 μl of restriction enzyme master 
mix of the following components: 
Assembly stage I: Diagnostic digest master 
mix  
 22 μl         water 
 5 μl           10 X NEB2 buffer 
 0.5 μl        10 mg/ml BSA 
 1 μl            NheI 
 1 μl            XbaI 
 
The digests were incubated at 37 °C for 1 h.  
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2.2.8.3 TALEN assembly stage II 
Part A and B of each subunit were combined with the following 
components in the reaction:    
 
 
 
The components of the left and right subunits were mixed by gentle 
pipetting and cycled as shown above.  
 
The resulting left and right hax1 specific pCAGT7-TALEN plasmids were 
then transformed into 25 μl of NEB 10-beta competent E. coli (New 
England Biolabs, Ipswich MA) using 2 μl of the Golden Gate reaction 
according to manufacturer’s protocol. Following streaking of 50 μl of the 
transformed cells onto carbenicillin Xgal LB agar plates and growth O/N 
at 37 °C, a well separated white colony was picked for each subunit and 
used to inoculate a 125 ml carbenicillin selective LB culture. This was 
followed by O/N incubation at 37 °C. The plasmid DNA was purified from 
each of the two O/N cultures using a Nucleobond Midi Kit (Macherey-
Nagel, Düren, Germany) according to manufacturer’s manual. During the 
second wash, the plasmid DNA was split into six 1.5 ml eppendorf tubes 
and precipitated using isopropanol. The supernatant was completely 
removed and the plasmid DNA pellet washed in 1 ml of 70 % ethanol. 
Following centrifugation, the supernatant was completely removed once 
again and the DNA pellet left to dry for 1 min. The plasmid DNA pellets in 
each of the six tubes were resuspended in 20 μl of water and pooled into 
Assembly stage II components  
5 μl         water 
4 μl         eluted Part A plasmid 
4 μl         eluted Part B plasmid 
1 μl         pLRNG (150 ng/ μl) 
1 μl         pCAG-T7-TALEN 75 ng/ μl)            
2 μl         10 X T4 DNA ligase buffer 
(NEB) 
2 μl          T4 DNA ligase (NEB) 
1 μl         Esp3I 
Temperature cycling 
parameters 
1: 37 °C 5 min                              
2:16 °C 10 min 
3: go to step 1 9 X 
4:50 °C 5 min 
5:80 °C 5min 
7:10 °C hold 
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a single tube. In order to quantify the plasmid DNA, 1 μl of each the left 
and right subunit was diluted with 99 μl of water and absorbance at 260 
nm was measured using a spectrophotometer. 
 
2.2.8.4 TALEN assembly stage II: Diagnostic digest 
In order to assess the TALEN stage II assembly, the left and right TALEN 
subunit plasmids were subjected to a BamHI and XbaI restriction digest. 
The digestion components of each reaction are shown below: 
Assembly stage II: Diagnostic digest components  
 7 μl         water 
 1.5 μl   Nucleobond purified pCAGT7-TALEN construct 
100ng/μl 
 0.1 μl      100 X BSA 
 0.5 μl      BamHI 
 0.5 μl      XbaI 
 
The contents of the digestion reaction were mixed by pipetting and 
incubated at 37 °C for 1 h.  
 
2.2.8.5 TALEN assembly stage II: Diagnostic digest 
The left and right hax1 specific TALEN encoding constructs were also 
linearised with NotI restriction enzyme to enable in vitro transcription of 
the TALEN subunit: 
The digestion reaction was 
mixed by gentle pipetting 
and incubated at 37 °C for 
1 h. Following linearization, 
the plasmid DNA was 
purified using a QIAquick 
PCR clean-up kit. The 
plasmid was run through 
two purification columns 
Construct Linearization Components 
 6 μg      Left TALEN 
construct 
 6 μg      Right TALEN 
construct 
 3 μl       10 mg/ml BSA 
 30 μl     10 X NEB buffer 3 
 30 μl      NotI (NEB) 
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and eluted with 30 μl of water. 
2.2.8.6 Preparation of hax1 exon 2 targeting TALEN RNA for 
microinjection 
In order to synthesize hax1 specific TALEN capped RNA, an Epicenter 
T7 Message Max ARCA kit was used to in vitro transcribe the NotI 
linearised TALEN encoding plasmids. The following components were 
assembled in a tube at RT: 
TALEN In vitro transcription components  
 5.5 μl     400 ng/μl linear plasmid DNA 
 2 μl        10 X buffer 
 8 μl        NTP CAP mix 
 2 μl        100 mM DTT 
 0.5 μl     Scriptguard 
 2 μl        enzyme mix 
 
The contents of the tube were mixed gently and incubated at RT for 30 
min. In order to eliminate the template plasmid DNA, 1 μl of DNAse was 
added o the sample and incubated at 37 °C for 15 min. The RNA was 
then purified using an RNeasy MinElute clean-up kit (QIAGEN, Valencia, 
CA) according to manufacturer’s protocol. The purified RNA was eluted 
with 14 μl of water.  
 
2.2.9 In vivo PMN tracking during recruitment to the site of injury 
Embryos were anesthetized with MS222 and tail fin transections were 
performed 30 min prior to commencement of tracking. Embryos were 
mounted immediately after injury using 1 % low melting point agarose 
and the tail fins were imaged using Volocity® build 5.3.2 on a Nikon 
Eclipse TE2000U inverted microscope with the 10 X NA 0.3 PlanFluor 
objective and an Orca-AG camera (Hammatsu). 5 z stacks were taken 
through the tail fin at every 2 minute intervals over a focal depth of 100 
μM over a period of 3 h. Volocity® was used to generate measurements 
such track length, average velocity (µm/sec) for the duration of the track, 
bearing (degree) and the meandering index (a ratio of displacement from 
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the origin to track length). In order to generate the final images, a 
calculated point spread function was generated followed by deconvolution 
for 30 iterations using Volocity®. 
 
2.3 Statistical Analysis  
Statistical analysis was performed using Version 5.0 GraphPad Prism 
(San Diego, CA). Data sets were analysed using either a One-Way 
ANOVA with a Bonferroni’s post test (all pairs of columns compared) or 
unpaired student’s t-tests. Significance is represented by *p≤ 0.05, **p≤ 
0.01, ***p≤ 0.001 and ****p≤ 0.0001. 
 
2.4 Bioinformatics 
Nucleotide and protein sequence searches were carried out using NCBI 
(National Centre for Biotechnology Information) Basic Local Alignment 
Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Gene 
sequence were searched and extracted from the Ensembl genome 
browser (http://www.ensembl.org/index.html). Sequencing traces were 
viewed using FinchTV (Finch TV 1.4.0, Geospiza, 
(http://www.geospiza.com/finchTV).    Nucleotide and protein alignments 
were carried out using Clustal Omega (EMBL-EBI; 
http://www.ebi.ac.uk/Tools/msa/clustalo/). The plasmid editor ApE 
(http://biologylabs.utah.edu/jorgensen/wayned/ape/) and SeqBuilder 
software (DNAstar; Lasergene, Madison, WI, USA) were used to 
generate vector constructs and restriction maps for the ZFN and TALEN 
assembly.
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3 Results- The expression, regulation and role 
of HAX1 in human myeloid cells 
3.1 Introduction 
The human HAX1 gene is found on chromosome 1 and contains seven 
exons in total (Lees et al. 2008). It has been shown to give rise to eight 
transcript variants through alternative splicing and intron retention (Lees 
et al. 2008). The gene is highly conserved across many species including 
rat and mice highlighting its essential function (Mirmohammadsadegh et 
al. 2003; Grzybowska et al. 2006; Hippe et al. 2006; Lees et al. 2008). 
The HAX1 protein is known to function to maintain mitochondrial stability 
thereby promoting cell survival (Suzuki et al. 1997; Sharp et al. 2002; 
Klein et al. 2007). A role for HAX1 in cell survival is also supported by 
reports on HAX1 overexpression in several tumours including breast 
cancer, lung cancer and melanoma (Trebinska et al. 2010). 
 
Human HAX1 deficiency leads to Kostmann disease, a severe congenital 
neutropenia (SCN) characterized by low numbers of circulating PMN and 
increased apoptosis of PMN progenitor cells in the bone marrow (Klein et 
al. 2007). It has been suggested that HAX1 plays a key role in PMN 
survival pathways but the possible mechanism is unknown (Klein et al. 
2007).  
 
To date, the expression, regulation and function of HAX1 in primary 
human PMN has not been described. The aims of this chapter were to 
study the expression of HAX1 at the mRNA and protein level in PMN and 
the myeloid cell line, PLB-985 and create HAX1 deficient cells by siRNA 
transfection of PLB-985 cells. The role of HAX1 knockdown in key 
survival assays was explored. Knockdown of HAX1 in primary human 
PMN was also attempted.  
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3.2 Results 
3.2.1 Expression of HAX1 in tissue cell lines and PMN 
In order to investigate the expression of HAX1 in a panel of human cell 
types, HAX1 isoform expression was examined using RT-PCR in three 
cell lines (Beas2B, HeLa and PLB-985), primary peripheral blood 
mononuclear cells (PBMC) and ultrapurified PMN (>97 % pure) (Fig. 3.1). 
Published HAX1 isoform primer pairs were first optimised for their 
annealing temperature in both PLB-985 and PBMC cDNA (results not 
shown) (Lees et al. 2008). cDNA for the PBMC and PMN PCRs was 
pooled from three individual donors in order to reduce donor variability. 
Primers for transcripts 004 and 007 yielded multiple bands at all of the 
annealing temperatures tested (50 - 65 °C) and therefore were omitted 
from the panel.  
 
Amplification of GAPDH was used as a loading control. Two negative 
controls consisting of PCR reactions without template at both the RT and 
PCR step were also included and no DNA was amplified for any primer 
pair. Fig. 3.1 shows that the full-length isoform HAX1 001 (151 bp) along 
with isoforms 002 (1009 bp), 003 (316 bp), 005 (165 bp) and 008 (297 
bp) are expressed in ultrapure PMN and all the other cell types tested. 
Expression of HAX1 006 is inconclusive following 35 cycles of PCR due 
to the lack of a band at the predicted size (548 bp) in the PBMC positive 
control (Lees et al. 2008). A number of additional bands were present in 
the PCRs designed to specifically amplify isoform HAX1 002 and HAX1 
008 and are detected in all cell types, labeled with an asterisk. These 
additional isoforms were also noted in the previous study by Lees et al 
(Lees et al. 2008). 
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a.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1  Multiple HAX1 transcripts are expressed in 
human cell lines and myeloid cells 
a.) Image adapted from Lees et al. indicating the human HAX1 primer 
binding sites (black arrows) used to amplify the different predicted transcript 
variants (001-008) in human cells (Lees et al. 2008). The exons (orange) 
numbered 1-7 and non-protein coding regions (grey) are also shown.  
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b.) 
 
 
 
Figure 3.1  Multiple HAX1 transcripts are expressed in 
human cell lines and myeloid cells 
b.) Total RNA was extracted from Beas2B, HeLa, PLB-985, PBMC and PMN 
followed by reverse transcription of 2 μg of total mRNA. PBMC and PMN 
RNA was extracted from three independent donors, reverse transcribed and 
the cDNA was pooled. The cDNA (4 μl) was amplified using each of the 
primer pairs, Hax-1 001-008 designed by Lees et al. (Lees, Hart et al. 2008). 
A primer pair specific for GAPDH was used as a loading control. 35 PCR 
cycles were carried out for all primer pairs shown and bands were separated 
by agarose gel electrophoresis and visualised using a UV transilluminator. A 
no template control was included in both the Reverse transcriptase (-RT) 
and PCR (-PCR) step. Also shown are the results obtained from total RNA 
extracted without the reverse transcription (RNA). Other putative isoforms 
are labeled with an asterisk.  
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HAX1 expression at the protein level was assessed using two 
commercially available antibodies (obtained from GeneTex and BD 
Biosciences) raised to two different epitopes of the HAX1 protein. Fig. 3.2 
indicates the regions of the protein that each of the antibodies recognize. 
The overall domain structure of the eight putative isoforms is also 
presented in Fig. 3.2 indicating the putative isoforms that are likely to be 
detected by the two different HAX1 antibodies. Whole cell lysates derived 
from a number of different tissue cell types were subjected to SDS-PAGE 
and identical membranes were probed with each antibody. Both 
antibodies detected a band just above the 30 kDa marker that 
corresponds to full-length HAX1 (32 kDa) (Fig. 3.3). HAX1 is highly 
expressed in tissue cell lines including PLB-985, which was used as a 
positive control for HAX1 expression from this point onwards (Tucker et 
al. 1987).  
 
HAX1 bands were clearly visible in PMN whole cell lysates derived from 
three independent donors. The existence of bands between the 20 and 
25 kDa and at 15 kDa markers should also be noted and may be of 
interest. Higher molecular weight bands (>35 kDa) were visible with both 
the GeneTex and BD Biosciences antibody however; this was less 
evident in the immunoblot incubated with the HAX1 antibody obtained 
from BD Biosciences. For bands of 30 kDa and below, some similarity of 
the pattern and intensity of banding between the PMN whole cell lysates 
and the PMN-like cell line PLB-985 is apparent in both western blots.  
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Figure 3.2  HAX1 antibody binding sites  
Image adapted from Lees et al. showing putative HAX1 isoform domain 
structure and immunogenic regions for the BD Biosciences and GeneTex 
antibodies. Each of the eight putative human HAX1 protein isoforms are 
shown and known domain structures are indicated. Amino acid length and 
weight of proteins is shown on the right. The monoclonal BD Biosciences 
Hax-1 antibody was raised against the human HAX1 amino acids 10-148, 
whereas the polyclonal GeneTex antibody was raised against a recombinant 
fragment corresponding to the region within amino acids 1 and 279 of full-
length isoform 001.  
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Figure 3.3  Detecting HAX1 at the protein level 
 
 Western blots of whole cell lysates from PMN and a number of different 
human cell lines. Lysates from the same sample were loaded in each SDS-
PAGE gel. Immunoblots were stained with the BD Biosciences antibody 
(1:400) a.) and the GeneTex antibody (1:1000) b.). The cell lines from left to 
right and number of cells loaded per lane are: HCT116 - Human colon 
carcinoma (1.5x106 cells), PLB-985- a myeloid leukemia cells (1x106 cells), 
HeLa- cervical cancer cells (5x105 cells), B2B-bronchial epithelial cell line 
(2x105 cells). Protein extracted from 2x106 PMN cells was loaded in each 
lane. Position of protein markers is shown on the left. The membranes were 
stripped and reprobed with β-actin antibody to assess the loading.
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3.2.2 Modulation of HAX1 expression during PMN lifespan 
To test whether HAX1 protein levels are regulated during PMN cell 
ageing, lysates were prepared from PMN incubated at 37 ̊C (5 % CO2) for 
0, 6 and 18 h. Since PMN contain significant amounts of proteases, which 
may cleave proteins during the lysis process and therefore affect 
detection of HAX1, lysates were prepared in the presence or absence of 
the protease inhibitor, Diisopropylfluoro-phosphate (DFP) in addition to 
the standard protease inhibitor cocktail. PMN morphological changes and 
apoptosis rates during constitutive cell death are shown in Fig. 3.4. PMN 
are seen to shrink and lose their nuclear morphology during apoptosis 
(Fig. 3.4 a.). 
 
After 18 h in culture more than two thirds of the PMN were apoptotic 
(66.67% ±11.01) (Fig. 3.4. b.).  PMN whole cell lysates at 0, 6 and 18 h in 
the presence or absence of the protease inhibitor (DFP) were prepared 
and identical samples were loaded in each of the two western blots 
shown in Fig. 3.5. Membranes were immunostained with anti-HAX1 
antibodies obtained from BD Biosciences (Fig. 3.5 a.) and GeneTex (Fig. 
3.5 b.). HAX1 protein levels decreased with aging of PMN, which was 
observed with both antibodies (Fig. 3.5). While both antibodies give rise 
to higher molecular weight bands (>35 kDa), Fig. 3.5 (b.) shows that the 
GeneTex HAX1 antibody produces a number of additional bands of high 
intensity corresponding to 15 kDa, 22 kDa and 27 kDa protein sizes 
which do not appear to be regulated during PMN cell death.  
 
The addition of DFP appeared to have no effect on full-length HAX1 
during cell lysis but it was clearly seen to have an effect on β-actin where 
a stronger β-actin signal was detected in the presence of DFP and also 
the lower molecular weight HAX1 bands (Fig. 3.5). Since the 
immunoreactivity of HAX1 was reliable for both antibodies, the BD 
Biosciences HAX1 antibody was used in all western blots shown from 
hereon. 
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Figure 3.4  Constitutive PMN apoptosis 
a.) Morphological assessment of constitutive PMN death. PMN were either 
cytospun immediately (t0) or cultured in media for 6 (t6) and 18 h (t18).  
Cytocentrifuge slide preparations were fixed and stained with Diff-quick 
solutions 1 and 2 and visualised using a light microscope with X400 
magnification. Representative micrographs of cells at different time-points 
are shown in a.). PMN underwent constitutive death displaying 
morphological changes consistent with apoptosis. Fig. b.) shows mean ± 
SEM percent apoptosis from four independent experiments (n=4), three of 
which were used to generate samples for the western blots probed with 
HAX1 antibody shown in Fig. 3.5.  Healthy and apoptotic cells were counted 
from duplicate cytospins. Data were analysed using a one-way ANOVA with 
Bonferroni's post-test:; ***p≤ 0.0001 test vs untreated; n=4. 
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Figure 3.5  HAX1 protein levels decrease during PMN 
constitutive death 
Ultrapure PMN cultured for 0, 6 or 18 h were lysed in the presence or 
absence of the protease inhibitor DFP.  Identical samples were subjected to 
two western blots. Protein from 2x106 cells was loaded in each lane.  a.) The 
membrane was immunostained with Hax-1 antibody from BD biosciences. 
Blot is representative of three independent experiments (n=3). b.) The 
membrane was immunostained with Hax-1 antibody from GeneTex. Blot is 
representative of a single experiment. Both blots were stripped and reprobed 
with antibody to β- actin in order to assess the loading. 
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The HAX1 expression levels during PMN ageing were analysed by 
densitometry. The fold changes in HAX1 levels relative to the β-actin 
loading control significantly reduced at 6 and 18 h time-points compared 
to 0 h (Fig. 3.6). The reduction in HAX1 levels with time was 
accompanied by increased apoptosis as shown in Fig. 3.6 (a.). A rapid 
fall in HAX1 levels in the first 6 h was followed by a gradual decrease 
from 6-18 h. Fig. 3.6 (b.) shows that the rapid fall in the protein level 
occurs in the first 6 h of culture and only a small number of cells are 
apoptotic at this time-point.  
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Figure 3.6  Densitometry analysis of HAX1 expression 
during constitutive cell death 
Full-length HAX1 immunoreactive band intensity from 3 independent 
experiments was quantitated by densitometry and relative expression 
compared to β-actin control was calculated. Fold change from t0 (expressed 
as 1) is shown on the y-axis and time (h) on the x-axis (a.). Data from three 
different time-points (t0, t6, and t18) were analysed. (One-way ANOVA with 
Bonferroni's post-test:; **p≤ 0.001, test vs untreated; n=3). (b.) The mean 
fold change (n=3) was plotted against % apoptosis (n=4) at 0 h (blue point), 
6 h (red point) and 18 h (green point).  
 109 
3.2.3 Regulation of HAX1 in response to inflammatory and death-
inducing stimuli 
HAX1 mRNA expression was previously shown to be upregulated in 
response to GM-CSF and LPS in a microfluidics study using human PMN 
(Kotz et al. 2010). GM-CSF is known to enhance Mcl-1 stability in PMNs 
(Klein et al. 2000; Derouet et al. 2004). GM-CSF, the potent pan-caspase 
inhibitor qVD-OPh and heat killed bacteria are known to prolong PMN 
survival (Brach et al. 1992; Caserta et al. 2003; Baran et al. 1996). 
Conversely, the bacterial endotoxin pyocyanin and the protein 
biosynthesis inhibitor cyclohexamide (CHX) have been shown to induce 
PMN apoptosis (Usher et al. 2002; Gong et al. 1993). To investigate 
whether HAX1 is regulated at the protein level by these factors that 
modulate apoptosis, PMN were incubated with inflammatory and death-
inducing stimuli and HAX1 expression was explored by western blotting 
(Fig. 3.7). Ultrapure PMN were cultured in the absence and presence of 
GM-CSF, pyocyanin, heat killed (HK) E. coli, HK S. aureus, qVD-OPh 
and CHX for 6 and 18 h. Cytocentrifuge slides and protein lysates were 
prepared at the appropriate time-point. HAX1 expression increased 
relative to the untreated PMN control in response to all of the 
inflammatory stimuli (GM-CSF, qVD-OPh, HK E. coli and HK S. aureus). 
It remained unchanged in response to pyocyanin and CHX. The 
combined CHX and qVD-OPh treatment of PMN also resulted in 
increased HAX1 levels.  
 
Densitometric analysis from three independent experiments did not reveal 
statistically significant changes. This is shown in Fig. 3.8 (a.) and (b.) 
after 6 h and Fig. 3.8 (c.) and (d.) after 18 h time-points. Changes in 
HAX1 expression were accompanied by changes in PMN apoptosis rates 
as assessed by counts on cytocentrifuge slide preparation (Fig. 3.9). The 
inflammatory stimuli, GM-CSF, qVD-OPh, HK E. coli and S. aureus, 
resulted in decreased apoptosis of PMN. On the other hand, CHX lead to 
significantly increased apoptosis at both 6 and 18 h. Interestingly, cells  
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Figure 3.7  Full length HAX1 expression in PMN after 
treatment with inflammatory stimuli and death inducing agents   
Cells were cultured with GM-CSF 50 units / ml, Q-VD.OPh (1 μM), CHX 
(100 μM), pyocyanin (50 μM), heat killed E. coli (MOI = 10) or heat killed S. 
aureus (MOI = 10) for 6 and 18 h. At the relevant time-point, cells were lysed 
and lysates were subsequently subjected to western blotting. 2 x 106 lysed 
cells were loaded per lane. The western blots were immunostained with 
HAX1 antibody and stripped and re-immunostained with β-actin antibody to 
assess the loading. Immunoblots are representative of 3 independent 
experiments.
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Figure 3.8  Mean fold change in HAX1 expression from 
untreated control in response to inflammatory and death inducing 
stimuli 
PMN were treated as indicated for 6 h (a. & b.) or 18 h (c. & d.) and whole 
cell lysates prepared as described in section 2.1.10. Samples from three 
independent experiments were subjected to western blotting for the 
detection of HAX1 and β-actin loading control. Full-length HAX1 
immunoreactive band intensity from 3 independent experiments was 
quantitated by densitometry and relative expression normalized to the 
untreated control sample was calculated and is shown on the y- axis in 
response to each stimulus as well as in the untreated control PMN. Relative 
densitometry data were analysed using a one-way ANOVA with Bonferroni's 
post-test, n=3 (ns indicates not significant).  
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Figure 3.9  Regulation of Apoptosis in response to 
inflammatory and death inducing stimuli 
PMN were treated as indicated for 6 (a. & b.) or 18 h (c. & d.) and 
cytocentrifuge slides were prepared. Slides were fixed and stained with Diff-
quick solutions 1 and 2 and visualized using a light microscope with X1000 
magnification.  Apoptosis rates were scored from duplicate slides and % 
apoptotic cells are shown for each condition.  (One-way ANOVA with 
Bonferroni's post-test; overall ANOVA for a. and c. * p≤ 0.05, Bonferroni's 
post-test ns, a. n=4, c. n=3; b. and d.) One-way ANOVA with Bonferroni's 
post-test; ****p≤ 0.0001, test vs untreated, n=4). 
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with the combined treatment of CHX and qVD-OPh were significantly less 
apoptotic at 18 h with qVD-OPh preventing the CHX induced death. 
 
3.2.4 Regulation of HAX1 expression in PLB-985 cells by death 
inducing agents 
In order to establish whether PLB-985 cells have a similar HAX1 
expression and regulation profile to PMN, PLB-985 cells were incubated 
with the death inducing agents CHX and staurosporine (STSP, a protein 
kinase inhibitor) for 3 h in the presence and absence of qVD-OPh. 
Cytocentrifuge slides and whole cell lysates were prepared as described 
in sections 2.1.4 and 2.1.10 respectively. Changes in HAX1 expression 
were explored by western blotting. In contrast to the media control, 
incubation with 100 µM CHX and STSP resulted in the appearance of 
additional HAX1 specific bands indicated by the red arrows in Fig. 3.10 
(a.). When cells were co-incubated with the pan-caspase inhibitor qVD- 
OPh these bands disappeared. Percent apoptosis of control and treated 
cells from 3 independent experiments is shown in Fig. 3.10 (b.). 
Interestingly, the loss of the HAX1 specific lower molecular weight bands 
in cells with the combined CXH or STSP and qVD-OPh treatment was 
accompanied by abrogation of the CHX-induced apoptosis. PLB-985 cells 
treated with STSP were significantly more apoptotic than the control. The 
accelerated apoptosis was inhibited by qVD-OPh. The morphology of 
these cells is shown in Fig. 3.10 (c.).  
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Figure 3.10 HAX-1 is regulated in response to CHX and STSP in 
PLB-985 cells 
PLB-985 cells were incubated with CHX and STSP for three hours with or 
without a 30 min pre-incubation with qVD-OPh.  Protein from 1x106 cells 
was loaded in each lane and subjected to western blotting (a.). The blot 
was immunostained with HAX1 antibody followed by stripping and re-
immunostaining with β-actin in order to assess protein loading. 
Percentage apoptosis scored from cytocentrifuge slide preparations from 
the same experiments is shown (bars represent mean ± SEM) in Fig. b. 
(bars represent mean ± SEM). Data were analysed using a one way 
ANOVA with Bonferroni's post-test:; **p≤ 0.0012 test vs untreated and 
STSP vs STSP & qVD-OPh; n=3 with qVD-OPh and n=4 without qVD-
OPh). c. Light micrographs of control, STSP, and combined STSP & 
qVD-OPh treated PLB-985 cells. An apoptotic PLB-985 cell is indicated 
by the red arrow. 
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3.2.5 HAX1 protein levels decrease during PLB-985 differentiation 
Healthy cells were treated with various differentiation stimuli over five 
days; a cell count was carried out on each day followed by preparation of 
duplicate cytocentrifuge slides. The effectiveness of the differentiation 
media was assessed by analysis of morphological changes and was 
compared to primary human PMN. Fig. 3.11 shows images of PLB-985 
cells taken on day 4. The arrows indicate the appearance of 
promyelocytes, metamyelocytes and band cells at different stages of 
differentiation.  
 
The various stimuli had similar effects on the PLB-985 differentiation 
state. All stimuli yielded band cells and cells with nuclear indentations in 
comparison to the round nucleated undifferentiated promyelocytes. 
Differentiation by combined RA and DMSO treatment of cells generated 
most PMN-like cells on day 5 (data not shown) however, the combination 
was toxic to the cells and would not yield high enough numbers of cells to 
lyse for protein. PLB-985 differentiation was achieved using 1 μM RA in 
the following experiments. 
 
PLB-985 cells differentiated for 5 days were lysed to generate whole cell 
protein lysates as described in section 2.1.10. Two cytocentrifuge slides 
were also prepared to assess the morphological changes. The lysates 
were subjected to western blotting for the detection of HAX1 protein. Full-
length HAX1 levels were downregulated with increased differentiation 
(Fig. 3.12 a.). Densitometry data analyses of two independent PLB-985 
differentiation experiments up to day 3 is shown in Fig. 3.12 (b.) and 
demonstrates the same trend. Interestingly, as the level of full-length 
HAX1 protein (~30 kDa) decreased, a second lower molecular weight 
band (~ 28 kDa) was observed.  
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Figure 3.11 Induction of morphological changes during PLB-985 
differentiation into PMN-like cells by different stimuli 
Undifferentiated PLB-985 cells were cultured in media (a.), 0.5 μM RA (b.), 
0.75 μM (c.), 1 μM RA (d.), 1 μM RA & 0.5 % DMF (e.), 1 μM RA & 1.25 % 
DMSO (f.) or 1.25 % DMSO (g.) for four days. A primary PMN image is also 
shown for comparison. Duplicate cytocentrifuge slides were prepared for 
each of the conditions and cell morphology assessed by light microscopy. 
Images were taken at X400 magnification, (black arrow- promyelocyte, cyan 
arrow- band cell, red arrow- metamyelocyte). Images shown are 
representative of n=3. 
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Figure 3.12 HAX1 protein levels are downregulated during PLB-985 
differentiation 
PLB-985 cells were differentiated over 5 days using 1 μM RA. At the 
appropriate time-point two cytocentrifuge slides were prepared in order to 
assess the differentiation and the rest of the cells were lysed for protein. The 
lysates were subjected to western blotting and blots immunostained with 
HAX1 antibody (a.). Protein levels were quantitated using Image J as fold 
change from t0 (undiff., expressed as 1) relative to the β-actin control and 
densitometric data showing HAX1 degradation with over 3 days is shown in 
(b.). 
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3.2.6 Transient knock-down of gene expression in PLB985 cells 
In order to test the hypothesis that HAX1 is important in myeloid cell 
survival and homeostasis, HAX1 specific siRNA (short interfering RNA) 
strategies to knockdown HAX1 in PLB-985 cells were followed. siRNAs 
work by targeting the specific mRNA for degradation via the RNAi (RNA 
interference) pathway thus preventing gene expression (Martinez et al. 
2002). Dharmacon ON – TARGETplus SMART pool siRNA was used 
which comprised 4 different siRNAs targeting six of the published 
isoforms, isoforms 001 – 006 (Lees et al. 2008).  PLB-985 cells were 
transfected using the Amaxa nucleofection system™. 
 
3.2.7 Transient Cyclophilin B knock-down in PLB-985 cells 
The Amaxa nucleofection system™ had previously been used in PLB-985 
cells by others but only for the purpose of delivering plasmid DNA into the 
cells (Chen et al. 2007). To test the ability of the Amaxa nucleofection 
system™ to knockdown genes in PLB-985, Amaxa mediated siRNA gene 
knockdown of the housekeeping gene Cyclophilin B (Cyc B) was 
optimised. Fig. 3.13 shows successful Cyc B knockdown in PLB-985 
cells. Cyc B siRNA transfected cells showed a reduction in Cyc B 
expression when compared with untransfected and mock-transfected 
cells (cells that underwent electroporation in the presence of 
nucleofection solution V without any siRNA) relative to GAPDH levels. 
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Figure 3.13 Cyclophilin B knockdown in PLB-985 cells 
PLB-985 cells (3 x 106) were transfected with Cyc B siRNA or nucleofection 
solution V only (Mock control) and cultured for 24 h following transfection. 
Total RNA was then extracted from control untrasfected, mock transfected 
and CYCB siRNA transfected cells. Following reverse transcription the 
cDNA was amplified using primers specific for either Cyc B or GAPDH 
loading control and samples were subjected to agarose gel electrophoresis. 
A no template control was included in both the reverse transcription (-RT) 
and PCR (-PCR) step. 
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3.2.8 Transient HAX1 knock-down in PLB-985 cells and its effect on 
apoptosis and mitochondrial membrane stability (Δψm) 
Since we determined that Cyc B gene expression could be disrupted 
using siRNA transfected via the Amaxa nucleofection system™, we went 
on to investigate the effects of HAX1 knockdown in PLB-985 cells. HAX1 
ON–TARGETplus SMART pool siRNA was transfected into PLB-985 cells 
and knockdown was analysed at the mRNA level by RT-PCR and protein 
level by western blotting. The siRNA was designed to target four different 
regions of the mRNA spanning all of the isoforms published by Lees et al. 
(Lees et al. 2008). HAX1 levels were visibly reduced at 10 h and 24 h 
following transfection in response to HAX1 siRNA when compared to the 
untransfected and scrambled siRNA controls (Fig. 3.14 a.). HAX1 
knockdown had no effect on apoptosis rates at 24 h post transfection 
(n=6) (Fig. 3.14 b.). In addition, the knockdown was without effect on 
mitochondrial membrane permeability (Δψm), an early marker for 
commitment of PMN to apoptosis, when compared to the untransfected 
and mock-transfected controls assessed by JC-1 staining (Fig. 3.15). The 
potassium ionophore valinomycin (Val) is known for its role in inducing 
apoptosis through its actions on decreasing Δψm (Janeway Jr. & 
Medzhitov 2002). Val treated cells underwent a large dissipation of Δψm 
as shown by the profound increase in FL-1 signal in all conditions. The 
HAX1 siRNA transfection did not enhance the loss of Δψm in these 
experiments.  
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Figure 3.14 Transient HAX1 knockdown in PLB-985 cells does not 
induce apoptosis 
PLB-985 cells (3 x 106) were transfected with scrambled, HAX1 siRNA or 
nucleofector solution V only (mock) using Amaxa. RNA and protein were 
extracted at 10 and 24 h (n=6) and knockdown was assessed by RT-PCR 
(a.) and western blotting (n=2) (b.). Percent apoptosis was quantified by light 
microscopy at 24 h post-transfection (c.). Apoptosis counts from six 
independent experiments are shown and were analysed using a one way 
ANOVA with Bonferroni's post test; n=6). ns indicates not significant. 
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Figure 3.15 The effect of HAX1 knockdown in PLB-985 cells on 
mitochondrial transmembrane potential (Δψm) 
PLB-985 cells were transfected with scrambled control siRNA, HAX1 siRNA 
or nucleofector solution V only (mock). Loss of Δψm was detected using the 
cationic dye JC-1 in control and knockdown cells at 24 h post-transfection in 
cells with and without a 3 h treatment with 5 μM valinomycin (Val). Gain of 
green fluorescence (FL-1) indicative of loss of Δψm was measured in intact 
cells identified by forward (FSC) and side scatter (SSC) characteristics using 
flow cytometry. Representative histograms are shown in Fig. a.. Basal 
changes in control and HAX1 knockdown cells are shown in Fig. b. and 
changes induced by Val are shown in Fig. c.; bars represent mean % ±SEM, 
(one way ANOVA with Bonferroni's post-test, p≤ 0.05, n=3). 
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3.2.9 The effect of HAX1 siRNA encapsulated polymerosomes on 
HAX1 levels in human PMN 
A recent study has shown that polymerosomes (nanometre-sized 
vesicles) can be utilised as nanovectors for the delivery of active proteins 
into cells and targeting of intracellular mechanisms (Canton et al. 2013). 
Polymerosomes are non-cytotoxic and have also been used for rapid and 
efficient intracellular delivery of nucleic acids (Lomas et al. 2008).  During 
my studies, a member of Dr Steve Renshaw’s lab (James Robertson) has 
generated unpublished evidence that knockdown of Mcl-1 accelerates 
PMN apoptosis in vitro using polymerosome encapsulated siRNA. PLB-
985 cells are undifferentiated myeloid progenitors and therefore differ 
from PMN in many ways and therefore in order to investigate whether 
HAX1 knockdown has an effect on PMN apoptosis, we attempted to 
knockdown the gene in primary human PMN using polymerosome 
encapsulated HAX1 siRNA. These experiments were carried out in 
collaboration with James Robertson, who had previously optimized the 
technique. Cells were treated with GM-CSF in order to prolong survival, 
allowing enough time for efficient delivery of the siRNA and gene 
knockdown. Untreated and PBS treated controls were included. Cells 
were incubated with polymerosomes containing 20 μM HAX1 siRNA 
(prepared in PBS). Following 30 h of culture, the cells were harvested for 
protein and mRNA. Since Mcl-1 is known to play a role in PMN apoptosis, 
encapsulated Mcl-1 siRNA was also used as a positive control. Samples 
were subjected to RT-PCR and western blotting. Fig. 3.16 shows that the 
HAX1 and Mcl-1 siRNA encapsulated polymerosomes were unsuccessful 
in knocking down the respective genes in PMN tested at the transcript 
and protein level for HAX1 and only protein level for Mcl-1. 
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Figure 3.16 Effects of polymerosome encapsulated HAX1 siRNA on 
PMN HAX1 protein levels 
Ultrapurified cells were cultured with 20 μM polymerosome encapsulated 
siRNA and 50 u of GM-CSF for 30 h. Since the encapsulation efficiencies 
were different for the HAX1 and Mcl-1 siRNAs, two different doses of empty 
polymerosome were applied to control for the number of polymerosomes 
added to the cells (Empty 1 and Empty 2). A PBS control in the presence 
and absence of GM-CSF was also included. At the appropriate time point 
the cells were lysed for RNA (0.5 x 106) and protein (2 x 106) and analysed 
by RT-PCR and western blotting.  Once probed with HAX1 the western blot 
was then stripped and re-immunostained with MCL1 antibody. This was 
followed by a second stripping and reprobing with β-actin to assess the 
loading. Images are representative of 3 independent experiments (n=3). 
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3.3 Summary 
The aim of this chapter was to investigate the expression, regulation and 
function of HAX1 in PMN and PLB-985 cells. Expression was analysed at 
both the transcript and protein level. siRNA technology was applied in 
order to test the effects of HAX1 knockdown on cell survival and 
mitochondrial membrane potential.  
 
I found that human PMN and PLB-985 cells express multiple HAX1 
isoforms at the mRNA level including the full-length isoform 001. HAX1 
expression in human PMN and PLB-985 cells at the protein level was 
also confirmed. Although HAX1 protein levels were shown to increase in 
response to anti-apoptotic factors, GM-CSF and qVD-OPH as well as 
heat killed bacteria, the increase in HAX1 expression is likely to reflect 
the apoptosis rates. In PLB-985 cells, incubation with death inducing 
stimuli generated lower molecular weight HAX1 specific bands. 
Interestingly, HAX1 levels decreased as PLB-985 cells gained a more 
PMN-like morphology during differentiation. Furthermore, I found that 
transient knockdown of HAX1 in PLB-985 did not affect basal apoptosis 
rates or mitochondrial membrane stability.  
 
3.4 Discussion 
3.4.1 HAX1 expression in human myeloid cells 
3.4.1.1 HAX1 isoforms 
Lees et al. first reported the existence of multiple HAX1 isoforms in a 
panel of different cell types (Lees et al. 2008). This study found that at 
least six isoforms are transcribed in any one particular tissue. There was 
no specific expression pattern associated with the cell types. In the same 
study, it was demonstrated that at least two out of three PBMC samples 
expressed all of the isoforms. Therefore, the PBMC sample used for this 
thesis functioned as a positive control for the expression of the different 
HAX1 transcript variants. In agreement with Lees et al. findings, the 
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transcript expression in this chapter shows numerous isoforms exist in 
PMN and PLB-985 cells.  
 
I have shown that PMN express the full-length HAX1 (001 - 31.6 kDa) 
variant at both the transcriptional and protein level. This is the most 
abundant isoform in many different cell types (Lees et al. 2008). Isoforms 
002, 003, 005 and 008 were also detected in PMN, PLB-985, HeLa and 
Beas2B cells at the mRNA level. The lack of 006 expression 
demonstrated in this chapter is in agreement with Lees et al. who 
revealed a restricted distribution of this isoform in their panel of 19 human 
cell lines (Lees et al. 2008). Isoform 006 detection was limited to cell lines 
VB6 (squamous cell carcinoma,), BT20, T47D, ZR75 (all of which are 
breast carcinomas), SW620 (colon adenocarcinoma) and A375M 
(melanoma) (Lees et al. 2008).  
 
Isoform 005 (32.4 KDa) is also a common isoform with a very similar 
protein size to 001 (31.6 KDa). Therefore, if this isoform were also to be 
expressed in PMN we would be unable to distinguish between the two 
isoforms on a conventional western blot and it is possible to mistake one 
isoform for the other. Our transcript expression data demonstrate that 
HAX1 005 is not very highly expressed in PMN and that the HAX1 
immunoreactive band present at 30 kDa is most likely to represent 
isoform 001. Further experiments such as antigen competition or protein 
sequencing of the immunoreactive product would be required to be 
certain of the exact protein species. Bands <30 kDa in size are also 
visualised in the panel of cells by western blotting. We can speculate as 
to the potential isoform identity of the remaining bands based on previous 
work by Lees et al. (Lees et al. 2008).  
 
Although our transcript data does not identify any myeloid cell lineage 
specific isoforms, HAX1 specific bands are visible in PMN as well as 
PLB-985 cells in the western blots (Fig. 3.3). Both HAX1 antibodies 
bound to bands lower than 30 kDa in size. On analysis of the sizes of the 
putative HAX1 protein variants generated by Lees et al. through in silico 
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translation, it becomes apparent that the 15 kDa band seen in both PLB-
985 and PMN cells may correspond to isoform 003 while the 23 kDa band 
only visible in the PMN samples could correspond to isoform 006. All 
three isoforms (001, 003 and 006) contain exon 2, which is mutated in 
Kostmann syndrome patients (Klein et al. 2007; Lees et al. 2008), 
suggesting that exon 2 is critical for PMN function. These three bands 
appear to be specific to the PLB-985 and PMN cells at the protein level 
and could play myeloid specific roles. 
 
Using the BD Biosciences HAX1 antibody, Germeshausen et al showed 
that in HL-60 cells HAX1 runs as a doublet at ~35 kDa with the upper 
band being described as isoform 001 and the lower band described as 
isoform 004 (Germeshausen et al. 2008). Although bands are detected 
around the 30-35 kDa size in our western blots the high expression of full-
length HAX1 in the PLB-985 cells combined with the low resolution of the 
western blots does not allow us to verify the expression of isoform 004. 
However, this is visible in Fig. 3.12 (a.) showing the expression of HAX1 
during PLB-985 differentiation where lower numbers of lysed cells were 
used. The possibility that these bands are phosphorylated forms of the 
same isoform was ruled out in a study carried out by Lees et al. who saw 
no modulation of the bands after treatment with serine, threonine and 
tyrosine phosphatase inhibitors prior to lysing cells for western blot 
analysis (Lees et al. 2008).  
 
Higher molecular weight >50 kDa HAX1 forms have also been implicated 
in the regulation of apoptosis (Yap et al. 2011). Bands larger than 50 kDa 
in size are visible in our western blots when immunostaining with BD and 
GeneTex HAX1 antibodies. Yap et al found that ~65 kDa, ~50 kDa and 
25 ~ kDa protein bands showed restricted expression to normal breast 
epithelium and were absent from tumorigenic breast epithelium (Yap et 
al. 2011). This led them to propose that these forms may promote cell 
death. Control of apoptosis in this fashion is seen with Mcl-1 (Bae et al. 
2000). Although Mcl-1 is a pro-survival protein, a truncated transcript 
variant of Mcl-1 known as Mcl-1s possesses only the pro-apoptotic BH3 
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domain and its expression results in apoptosis. If this were the case with 
HAX1 then levels of these HAX1 isoforms would be expected to increase 
during apoptotic cell death. Our results indicate that the additional HAX1 
bands described by Yap et al. do not appear to be upregulated during 
PMN cell death (Fig. 3.5).   
 
3.4.2 Mechanisms of HAX1 regulation in myeloid cells 
3.4.2.1 Regulation of PMN apoptosis 
Our data generated by western blotting suggest that HAX1 protein levels 
decrease with the increasing age and apoptosis of PMN (Fig. 3.6). Since 
the HAX1 reduction occurs in conjunction with increased apoptosis rates, 
it raises the question whether HAX1 protein is simply being degraded by 
caspase activity during the late stages of apoptotic cell death or whether 
the reduction in HAX1 levels is upstream of the caspase activation and 
would therefore play a causative role in mediating cell death. HAX1 
protein has previously been identified as a substrate of caspase 3 and is 
cleaved at Asp127 during apoptosis (Lee et al. 2008). This study 
suggests that a loss of hax1 may reflect an event that occurs once the 
apoptotic process has been engaged rather than being upstream of 
apoptosis.  
 
The decrease in HAX1 protein level in Fig. 3.6 (b.) is time dependent and 
appears to precede apoptosis in the sense that the percentage of 
apoptotic cells at the 6 h time-point is very low, however HAX1 levels are 
reduced by more than half. This may suggest that HAX1 plays a role in 
PMN survival and that HAX1 protein degradation may occur upstream of 
the activation of the apoptotic pathway. Since morphological changes 
only appear after the onset of apoptosis further work would be required to 
investigate this. 
 
 
 129 
3.4.2.2 HAX1 expression during PLB-985 differentiation 
In agreement with previous transcript data, HAX1 protein levels 
decreased as PLB-985 differentiated from less prolific to more terminally 
differentiated and PMN-like cells (Theilgaard-Mönch et al. 2005). In 
support of this, a paper published during this PhD also reported the 
decrease in HAX1 protein expression as PLB-985 cells differentiated 
(Cavnar et al. 2011). This suggests that HAX1 may play more important 
roles in undifferentiated myeloid cells. The high expression in the myeloid 
progenitors may protect the cells from apoptosis and loss of HAX1 with 
time as cells become terminally differentiated could allow PMN to rapidly 
undergo apoptosis. A recent study showed myeloid cells derived from 
congenital neutropenia patients with HAX1 deficiency were arrested at 
the myeloid progenitor cell stage with increased predisposition to 
apoptosis, supporting a role for HAX1 in the differentiation pathway of 
myeloid cells (Morishima et al. 2013).  
 
3.4.2.3 Effects of HAX1 knockdown on PLB-985 Apoptosis and 
Mitochondrial stability 
If HAX1 is functionally more important in progenitor myeloid cells then 
HAX1 knockdown in PLB-985 cells would provide a good system for 
investigating HAX1 function. However, PLB-985 cells are a cell line and 
caution should be taken when interpreting data obtained from cell lines, 
particularly in models of cell death.  
 
The function of HAX1 in myeloid cells was investigated by transiently 
knocking down HAX1 in PLB-985 cells using siRNA. Percentage 
apoptotic death of the PLB-985 cells that had been transfected with HAX1 
siRNA was compared to that of cells transfected with non-specific 
scrambled siRNA or mock-transfected controls. Interestingly, these 
studies showed that HAX1 had no effect on PLB-985 and mitochondrial 
membrane stability (a common component of cell death) or apoptosis 
assessed by morphological analysis of cytospin preparations. Due to the 
lack of expression of phosphotidyl-serine in undifferentiated PLB-985 
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cells we were unable to confirm this finding by Annexin V binding by flow 
cytometry (Huynh et al. 2002). It is important to note that Fig. 3.14 shows 
that although most of HAX1 is knocked down at both the transcript and 
protein level, a very small amount of protein remains and may be 
sufficient to inhibit any phenotype. 
 
Published studies on HAX1 knockdown in cell lines provide contradictory 
data. Contrary to our findings, HAX1 targeting by siRNA in a study carried 
out by Li et al. resulted in increased apoptosis of melanoma cells (Li et al. 
2009). Further support for a role of HAX1 in apoptosis is provided by Sun 
et al. demonstrating that HAX1 knockdown inhibited the malignant 
phenotypes of EC9706 cells while overexpression of the gene promoted 
cell proliferation against cisplatin in the same cell line (Sun et al. 2012). 
During the course of my studies, a study was published containing work 
carried out on PLB-985 cells. In agreement with our knockdown data, it 
was found that HAX1 knockdown by lentiviral shRNA technology in PLB-
985 cells showed no decrease in the basal level of apoptosis and only a 
mild increase in apoptosis in response to H2O2 (Cavnar et al. 2011). 
HAX1 was shown to instead be involved in regulating PMN adhesion and 
chemotaxis through GTP-ase RhoA (Cavnar et al. 2011).  
 
Analysis of cell death in the Hax1 -/- mouse however, suggests that HAX1 
does have a role in PMN apoptosis since the lack of HAX1 was reported 
to have an effect on PMN apoptosis (Chao et al. 2008). Although the 
authors of the study focused on the effect of the Hax1 knockout in 
lymphocytes and studies in granulocytes were limited, they presented a 
single piece of evidence where they demonstrated that G-CSF deprived 
PMN from the Hax1 null mice were more apoptotic than PMN from wild 
type mice. 
 
Controversial data suggests that the mitochondrion plays a central role in 
PMN apoptosis (Maianski et al. 2004). Klein et al. have previously 
generated strong support for an essential role of HAX1 in maintaining 
mitochondrial membrane stability (Klein et al. 2007). They showed that 
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circulating CD34+ cells isolated from SCN patients underwent accelerated 
apoptosis due to loss of Δψm, which was prevented by transduction with 
a HAX1 encoding retrovirus. Further support for an anti-apoptotic function 
of HAX1 comes from mammalian studies investigating HAX1 protein-
protein interactions in the mitochondria. It has been proposed that in 
human cardiac myocytes HAX1 directly interacts with caspase 9 in the 
mitochondria and inhibits its activation (Han et al. 2006). The protein has 
also been shown to present Omi (high-temperature regulate A2) to 
mitochondrial PARL (pre-senilin associated, rhomboid-like) and facilitate 
its processing into an active protease which in turn prevents the 
accumulation of the pro-apoptotic protein Bax (Chao et al. 2008).  
 
It has previously been shown that HAX1 deficiency is associated with 
defective expression of the mitochondrial protein Bcl-2 and constitutive 
release of cytochrome c from the mitochondria (Carlsson et al. 2004). In 
viral models, the HIV Vpr protein was shown to interact with HAX1 and 
cause it to dislocate from its normal residence in the mitochondrial 
membrane to the cytosol (Yedavalli et al. 2005). This would imply that 
perhaps a global decrease in HAX1 levels and therefore its dislocation 
from the mitochondria causes mitochondrial instability in myeloid cells 
and results in the onset of apoptosis. This does not appear to be the case 
in PLB-985 cells in our studies as transient HAX1 knockdown did not 
affect basal changes in the mitochondrial membrane potential when 
analysed by JC-1 staining in HAX1 knockdown and control transfected 
cells.  
 
3.5 Conclusion 
I have provided evidence for HAX1 expression at both the transcript 
variant and protein level in primary human PMN and a number of cell 
lines including the myeloid leukaemia cell line, PLB-985. I have shown 
that HAX1 protein levels decrease as PMN undergo constitutive 
apoptosis. Using the caspase inhibitor qVD-OPh and a number of 
inflammatory stimuli, I have demonstrated that HAX1 protein levels are 
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higher in response to these stimuli when compared to control untreated 
cells and that this is accompanied by reduced apoptosis rates. This 
suggests that the increased HAX1 levels in response to the PMN survival 
stimuli are likely to reflect the apoptosis rates and result directly from 
caspase inhibition by qVD-OPh. Furthermore, I have determined that 
HAX1 protein levels are regulated during PLB-985 differentiation and 
apoptosis. Finally, I have provided evidence that HAX1 knockdown in 
PLB-985 cells does not affect basal PMN apoptosis and mitochondrial 
membrane stability. The high complexity generated by the appearance of 
a multiple HAX1 banding pattern in western blotting and PCR techniques, 
in addition to the lack of tools for the genetic manipulation of human 
primary PMN and the limitations of using the cell line PLB-985 highlight a 
need for a new model for the study of HAX1 function in PMN survival. 
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4 Results- hax1 expression and transient 
knockdown in Danio rerio 
 In the previous chapter, I discussed the limitations of the studies of HAX1 
function in the human and the lack of evidence for HAX1 function from 
patient data. In the model organism, the mouse, a Hax1-/- null mutation 
resulted in postnatal lethality (Chao et al. 2008). Therefore, the in vivo 
role of HAX1 in PMN remains unknown and there is need for new tools to 
discover its immediate molecular, cellular, and developmental functions.  
 
The zebrafish have emerged as a powerful research model for the study 
of vertebrate development and haematopoiesis. Following fertilisation, 
zebrafish embryos survive with only the innate immune system for 4-6 
weeks (Lam et al. 2004). This temporal separation provides an excellent 
opportunity for the study of innate immunity in isolation in vivo. Many of 
the components of zebrafish innate immunity have remarkable similarities 
to their mammalian counterparts (Lieschke 2001). The transparent larval 
model also allows visualisation of the PMN through the use of the 
Tg(mpx:GFP)i114 transgenic line (Renshaw et al. 2006). These properties 
together with the availability of a large range of tools for the study of 
genetic factors drove us to utilise the zebrafish for the in vivo study of 
hax1 gene function. 
 
To date there have been no studies examining zebrafish hax1 variant 
expression or function. The exon/intron organization of the zebrafish hax1 
gene is the same as that of the human, comprising 7 exons. Based on 
this, I hypothesized that the splicing of the zebrafish hax1 gene is similar 
to that reported for the human HAX1 gene with multiple variants arising 
from alternative splicing and intron inclusion. The aim of this chapter was 
to investigate the expression of hax1 mRNA in the zebrafish embryos and 
to validate the use of morpholinos as a suitable tool for studying hax1 
function in vertebrate embryos.  
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4.1 RNA extraction from zebrafish embryos 
To assess whether total RNA extracted from zebrafish embryos using the 
TRI reagent protocol (Section 2.1.15) is of good quality and therefore can 
subsequently be used for RT-PCR, RNA was extracted from EKK and AB 
embryos at 1-4 days post fertilization (d.p.f). Total RNA was then 
resolved on a 1% denaturing agarose gel. Fig. 4.1 shows that all of the 
RNA samples have two sharp bands which correspond to 28S and 18S 
rRNA (ribosomal RNA). In most lanes the 28S rRNA band is more intense 
than the 18S rRNA with no visible smearing under the 18 S rRNA band 
indicating that the RNA is intact and of good quality. This showed that 
RNA extraction from zebrafish embryos using TRI reagent yields good 
quality RNA that can be used in downstream processing reactions such 
as RT-PCR.  
 
4.2 Multiple hax1 transcript variants are expressed in the 
zebrafish  
In order to study Hax1 function in the zebrafish it was first necessary to 
explore the hax1 transcript expression. Due to the same exon-intron 
structure (Figure 4.2 a.), I hypothesized that the splicing of the zebrafish 
hax1 gene is similar to that seen in the human and designed isoform 
specific primers based on this hypothesis. hax1 primers were designed to 
selectively amplify the following transcript variants: 001 (964 bp), 002 
(1150 bp), 003 (1625 bp), 005 (130 bp), 007 (907 bp) and 008 (592 bp). 
Two extra sets of primers were also designed. The first pair was intended 
to amplify additional variants that may have arisen from splicing occurring 
between exon 1 and 7 of the gene (variant x- 818 bp). The second primer 
pair was designed to amplify multiple transcript variants; this set of 
primers is denoted simply as hax1 (984 bp) and is likely to amplify 
variants 001, 002 and 003. The primer annealing temperatures for each 
primer pair were optimised on a gradient of 55- 65 °C using cDNA from 
embryos at 1 and 2 dpf. Primer sequences and binding sites are shown in 
Appendix 7.3.   
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Figure 4.1  Assessment of RNA qualities extracted from 
zebrafish embryos at various stages of development  
Total RNA was extracted from embryos of EKK and AB strains at 1-4 dpf 
using TRI reagent. The quality of the RNA was assessed by denaturing 
agarose gel electrophoresis. RNA bands were visualised using a UV 
transilluminator. The 18S and 28S rRNA bands are shown. 
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Figure 4.2  Zebrafish express the putative hax1 full length 
transcript at different stages of development 
a.) Exon-intron structure of the human and zebrafish hax1 genes. Exons are 
shown in blue (human) and orange (zebrafish). b.) RNA was extracted from 
Tg(mpx:GFP)i114 embryos at different stages of development (1-5 dpf) 
using TRI reagent. This was followed by RT-PCR using primers for 
amplification of hax1 001 (full length) with Phusion High-Fidelity DNA 
Polymerase. The results obtained from total RNA extracted from 2 dpf 
embryos without the reverse transcription (RNA) and a no template control 
for the RT (-RT) and PCR (-PCR) steps are also included. c.) RNA was 
extracted from zebrafish embryos at the single cell stage (single cell) and 
RT-PCR was carried out using hax1 001 and ef-1 α loading control primers. 
d.) cDNA from adult Tg(mpx:GFP)i114 zebrafish FACS sorted GFP +ve 
(PMN) cells was amplified by PCR using hax1 specific primers (isoform x 
primers). Also shown is a negative PCR control lacking the template cDNA (-
PCR) and the results from PCR with the ef-1 α loading control. PCR bands 
were resolved by agarose gel electrophoresis and visualised using a UV 
transilluminator.
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To examine the expression of hax1 full-length transcript 001 in zebrafish 
embryos at different stages of development. RNA extracted from embryos 
at 1-5 dpf was subjected to RT-PCR. The PCR products were resolved by 
agarose gel electrophoresis. Fig. 4.2 (b.) shows that a band 
corresponding to hax1 001 was visible in embryos at all of the 
developmental stages tested, 1-5 dpf. Lower molecular weight bands are 
also visible but at a much lower intensity. Amplification of ef-1α was used 
as a loading control and also produced an amplicon at the expected size 
in all of the samples tested. The two additional negative controls 
consisting of reactions without template at the RT and PCR step were 
clear for both the hax1 001 and ef-1α primer pairs.  
 
It has previously been shown that some mRNAs are maternally 
transferred to fertilised zebrafish eggs playing essential roles in the early 
stages of embryonic development (Dosch et al. 2004). The onset of gene 
activation in the zebrafish is delayed until the midblastula transition at 
which stage the embryo consists of around 1000 cells (Kane & Kimmel 
1993). To investigate whether hax1 001 mRNA is maternally transferred, 
RNA was extracted from embryos at the single cell stage. This was 
followed by RT-PCR for the detection of hax1 001. PCR analysis shows 
that hax1 001 is present in the single cell embryo mRNA (Fig. 4.2 c.). A 
band of the expected size was also visible in the RT-PCR reaction carried 
out using the ef-1α loading control primers while the negative RT-PCR 
controls remained clear.  
 
In order to determine the presence of the hax1 001 transcript in the adult 
zebrafish PMN, the cDNA of PMN was subjected to 35 cycles of PCR 
with hax1 001 and ef-1α primers. To visualise the bands PCR products 
were separated by agarose gel electrophoresis and imaged using a UV 
transilluminator. Emily Hogget, a former BMedSci student in Dr 
Renshaw’s lab, prepared the cDNA. Briefly, RNA was extracted from 
PMN of Tg(mpx:GFP)i114 zebrafish adult tissue sorted by FACS 
(fluorescence activated cell sorting), gated on the green fluorescence-
positive events. It was then reverse transcribed to generate cDNA. Due to 
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limited sample availability I was only able to carry out the PCR on the 
PMN sample once. PCR analysis shows that a band of the expected size 
for the transcript was detected in the PMN sample (Fig. 4.2. d.). Variant 
001 from zebrafish embryos was cloned into a TOPO blunt vector and 
sequenced to confirm expected splicing pattern. As in the human, 
zebrafish hax1 001 is comprised of all seven exons of the gene. Blast 
analysis of the sequencing output is shown in Fig. 4.3. 
  
Having established that the full-length hax1 001 transcript is expressed in 
zebrafish embryos, I next investigated whether other putative transcript 
variants resulting from alternative splicing and/or intron inclusion are also 
expressed. The same RNA extracted from embryos at 2 dpf and used in 
the RT-PCR analysis of variant 001 (Fig. 4.2) was subjected to RT-PCR 
using primers specific for the different hax1 isoforms. PCR products of 
the expected sizes were detected for putative transcript variants 002, 007 
and 008 (Fig. 4.4). I was unable to reliably detect variants 003 and 005 in 
zebrafish embryos.  Multiple PCR bands were visible in the reactions with 
primers specific for isoform 003 & 005 and 007. Some of these bands 
were also detected in the sample not subjected to reverse transcription (-
RNA) confirming that these were generated from the amplification of 
contaminating genomic DNA and not cDNA. Primers for isoform 007 did 
not always produce the same pattern of banding as highlighted by Fig. 
4.4 (b.). Primers amplifying isoform x (labelled as x) also produced a 
strong band at ~ 800 bp. Fig. 4.4 also shows the PCR products for the 
positive PCR primers, ef-1α with relatively high levels found in the 
samples indicating that the samples were likely to have good quality 
cDNA for amplification with hax1 primers. The existence of additional 
species visible with all of the primer pairs except that amplifying hax1 
variant 008 should be noted. 
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Figure 4.3 hax1 001 expression in zebrafish embryos 
The DNA fragment amplified using primers for hax1 001 was TOPO cloned 
into a Zero BLUNT® TOPO® plasmid vector and Sanger sequenced using 
M13 forward and reverse primers. The output sequences from the M13F (a.) 
and M13R (b.) were then subjected to a nucleotide Blast search. The hax1 
specific fragment contained only hax1 exonic regions. The hax1 exon 
structure was deduced from the Ensembl sequencing data. 
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Figure 4.4  Zebrafish embryos express multiple putative 
hax1 transcript variants 
a. Detection of hax1 isoforms using RT-PCR (35 cycles) with Phusion High-
Fidelity DNA Polymerase in RNA extracted from Tg(mpx:GFP)i114 embryos 
at 2 dpf. 2  μl of template cDNA were used for each PCR reaction. 2 PCR 
products were analysed by agarose gel electrophoresis. A no template 
control was included in both the Reverse transcriptase (-RT) and PCR (-
PCR) step. Also shown are the results obtained from total RNA extracted 
from 2 dpf embryos without the reverse transcription (RNA) and the ef-1 α 
loading control. b. Detection of hax1 007 in a second sample of cDNA from 
day 2 embryos. 
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Fig. 4.5 is a schematic illustrating the human and zebrafish hax1 genetic 
organisation and the putative hax1 isoforms detected in embryos at 2 dpf  
(Figures 4.3 and 4.4). The green coloured arrows indicate primer-binding 
sites of the putative variants expressed in embryos at 2 dpf (Fig. 4.5). 
Transcript variants 008 and x were gel extracted, purified and sequenced. 
Sequencing confirmed expected splicing pattern at the 3’ end of variant 
008 with intron 5-6 being retained at the mRNA level. Blast analysis of the 
sequence extracted from the strong band produced by hax1 isoform x 
primers revealed that variant x is full-length hax1 variant 001 since the 
primers anneal to the first and last exon of the transcript and the Sanger 
sequence shows that the transcript contains exons 2-6. Blast analyses 
output data for transcript variant x (001) sequence with the isoform x 
primers and variant 008 is shown in Appendices 7.9 and 7.10 
respectively.  
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Figure 4.5  The structure of the Danio rerio hax1 gene and putative mRNA variants 
hax1 gene structure showing exonic (orange/blue, ex 1-7) and intronic (grey) regions. The human and zebrafish genes are shown. 
Putative zebrafish hax1 transcript variants detected by RT-PCR are listed with primer binding sites indicated by the arrows (green). 
Numbers above the exons and in the intronic regions denote size in basepairs (bp). Red arrows indicate binding of hax1 specific primers 
to identify additional isoforms arising from alternative splicing and intron inclusion between exons 1 and 7 (isoform x). Blue arrows 
indicate binding sites for primers used to amplify multiple isoforms of hax1. PCR products obtained from these primers will be labelled 
simply as hax1. Please note diagram is not to scale. 
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4.3 HAX1 putative protein sequence analysis 
4.3.1 HAX1 protein sequences are conserved across many different 
species 
In order to investigate the sequence similarities between human (Homo 
sapiens), zebrafish (Danio rerio), macaque (Macaca mulatta), rat (Rattus 
norvegicus) and mouse (Mus musculus) Hax1 protein, sequences were 
extracted from the Ensembl Genome browser and aligned using 
ClustalW2 (Fig. 4.6). Previously identified regulatory regions are 
highlighted (Han et al. 2006; Fadeel & Grzybowska 2009; Li et al. 2012).  
Although the zebrafish Hax1 sequence is the most divergent, a single 
alignment of zebrafish Hax1 001 protein and human full length HAX1 
(data not shown) shows that there is still 40 % identity and 70% similarity. 
Fig. 4.6 shows that an acid box, a region consisting mainly of acidic 
residues has been conserved through evolution in all of the species 
included in the alignment. The zebrafish sequence also differs to the rest 
in that it shown reduced similarity at the putative PEST sequence and 
transmembrane domain regions in comparison to the other species. A 
search for PEST signals using ePESTfind 
(http://emboss.bioinformatics.nl/cgi-bin/emboss/epestfind) in the zebrafish 
Hax1 protein could only generate weak PEST sites.  
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Figure 4.6 Bioinformatic 
analysis of HAX1 protein 
sequences from different 
species
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Figure 4.6  Bioinformatic analysis of HAX1 protein sequences from different species 
A comparison of HAX1 protein sequences from five different species (Homo sapiens- human: ENSP00000329002, Macaca mulatta- 
macaque: ENSMMUP00000014178, Rattus norvegicus- rat: ENSRNOP00000064877, Mus musculus- mouse: 
ENSMUSP00000078661, and Danio rerio- zebrafish:ENSDARP00000053379) using a CLUSTALW2 multiple sequence alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). The protein sequences were taken from the Ensembl Genome Browser website  
(http://www.ensembl.org/index.html). Putative regulatory regions were identified through literature searches and are highlighted (Fadeel 
and Grzybowska 2009; Li, Hu et al. 2012).  
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4.3.2 Sequence analysis of zebrafish putative Hax1 protein 
isoforms  
Cloning and sequencing of variant 001, RT-PCR of bands at the expected 
sizes for isoforms 002, 005, 007 and 008 and sequencing of the 008 PCR 
band allowed me to predict the splicing pattern of each variant and 
perform in silico translation. The intron exon boundaries for isoforms 001, 
002, 007 and 008 were identified using Ensembl Genome Browser.  A 
splice site predictor was used to identify a splice site with the highest 
score in the 3’ region of intron 2-3 of transcript 005 which would result in 
the inclusion of 452 bases of this intron. Open reading frames were found 
for all of the isoforms. The open reading frames of isoforms 005 and 008 
were quite short and may represent incomplete coding sequences. An 
alignment of the isoform sequences is presented in Fig. 4.7. All three 
isoforms 001, 002 and 003 contained the acid box. Variations from the 
Hax1 001 are described in the following paragraph. 
 
  The putative Hax1 002 isoform lacks a short region of the N-terminal as 
a result of the absence of exon 1 and uses an alternative splice site found 
in exon 2 in frame with the Hax1 001 stop codon. Inclusion of exon 1 in 
the 002 mRNA sequence did not make a difference in the protein 
sequence generated. Putative isoform 005 is likely to be a truncated 
version of Hax1 001. It contains an identical N-terminal sequence to 
isoform 001 with the exception of the last six amino acids at the 3’ end of 
the protein. Both potential isoforms 007 and 008, however, lack the N-
terminal of isoform 001. These isoforms are almost identical to the C-
terminus of Hax1 001.These two isoforms use a splice site in exon 3. 
Inclusion of intron 4-5 in isoform 007 generates an isoform specific region 
comprising 26 amino acids, which is in frame with the Hax1 001 stop 
codon and reverts back to the Hax1 001 reading frame. In the putative 
isoform 008 inclusion of intron 5-6 would also results in a 008 specific 3’ 
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Figure 4.7  Sequence alignment of the zebrafish Hax1 001 
isoform and predicted  isoforms 002, 005, 007 and 008 
Using the predicted mRNA variant data from Fig. 4.5, the transcript 
sequences were in silico translated using the Expasy translate tool 
(http://web.expasy.org/translate/). The longest open reading frames were 
then aligned using Clustal Ω. The exon intron boundaries used were those 
found on the Ensembl Genome Browser (http://www.ensembl.org/index 
.html).  A hax1 005 internal splice site at the 3' of intron 2-3 was identified 
using a splice site predictor (Reese, Eeckman et al. 1997). Black boxes 
indicate isoform specific sequence. Numbers at the end of each sequence 
represent length of the protein sequence. 
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end and early termination of the protein sequence. It should be noted that 
transcript variants 005, 007 and 008 are only hypothetical. Cloning and 
sequencing would be required to confirm the complete splicing pattern. 
4.4 Microinjection of high hax1 splice site morpholino 
oligonucleotide (MO) doses results in the death of 
Tg(mpx:GFP)i114 embryos 
Many studies investigating the role of HAX1 have shown that it is a 
multifunctional protein and so the disruption of its expression in the 
zebrafish was likely to affect many different pathways. To investigate the 
role of Hax1 in the zebrafish in vivo model, hax1 knockdown by 
morpholino (MO) was carried out in one cell stage embryos. An exon 3 
splice acceptor targeting MO was designed to prevent correct splicing of 
the gene. At least three hax1 transcript variants express exon 3 (variants 
001, 002 and 005) and therefore this MO is likely to affect multiple hax1 
variants. The dose of MO for injecting was optimized on the basis of 
using a dose which would lead to </= 40 % death after injection. Embryos 
were injected with varying doses of hax1 MO as indicated in Fig. 4.8. 
High doses, 2nl of 2mM - 1 nl of 0.5 mM, resulted in highly dysmorphic 
embryos (data not shown) and reduced viability of embryos (>79 % 
death) at 24 hours post fertilization (hpf). After numerous injections with 
different doses of the hax1 splice MO, the optimized dose chosen was 1 
nl of 0.25 mM MO which generated a death rate of ~33% at 24 hpf. Most 
of the embryos injected with this dose showed varying degrees of 
dysmorphology.   
 
4.4.1 RT-PCR analysis of hax1 MO injected zebrafish embryos at 12 
hpf 
In order to establish whether the hax1 MO targeting exon 3 splicing has 
any effect on hax1 mRNA levels, one cell stage Tg(mpx:GFP)i114 
embryos were injected with 1 nl of 0.25 mM MO. hax1 splice MO injected 
embryos were grouped based on their morphology: healthy-looking 
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Figure 4.8  Optimisation of hax1 splice MO concentration  
Tg(mpx::gfp)i114 embryos at the 1-4 cell stage were injected with varying 
amounts of hax1 MO on three different occasions. Embryos were then 
incubated at 28 °C for 24 h. Non-viable embryos were removed 1 h after 
injection and remaining healthy embryos were counted. At 24 hpf, the 
number of healthy embryos was counted once again and % number of dead 
embryos (% death) was calculated (excluding non-viable embryo counts 1 h 
following injection). 
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(normal), mildly dysmorphic (mild) and severely dysmorphic (severe) in 
order to investigate whether this would be linked to the extent of 
knockdown in the hax1 mRNA level (Fig. 4.9). When compared to 
uninjected and standard control MO injected embryos, hax1 splice MO 
injected embryos did not appear to have the expected reduced levels of 
isoform 001 mRNA tested by the two different sets of primers. However, 
the hax1 splice MO injection appears to induce the expression of a very 
high molecular weight species (>2500 bp) indicated by the red arrows in 
Fig. 4.9.  Lowering the PCR cycle number from 30 to 25 cycles showed 
that hax1 mRNA levels were reduced but not abolished in severely 
dysmorphic embryos when compared to the uninjected control (Fig. 4.9 
b.). The 2500 bp band was still visible and is indicated by the red arrow. It 
was thought that splicing into an alternative cryptic splice site found only 
a few bases into the 5’ end of exon 3 may have been used instead of the 
targeted splice site, which would yield an amplicon of a similar size to the 
full-length hax1 transcript and therefore undistinguishable by standard 
RT-PCR. As a result, the PCR product was sequenced and blast analysis 
of the data carried out. Comparison to the normally splice full-length hax1 
sequence showed no evidence of alternative splicing into the cryptic 
splice site. 
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Figure 4.9  Analysis of hax1 splice MO injected zebrafish 
embryos at 12 hpf 
a.) Tg(mpx:GFP)i114 embryos at the 1-4 cell stage were injected with 1 nl of 
0.25 mM standard control (Control MO) and hax1 splice MO and grouped 
into 3 categories: embryos with a normal morphological phenotype (hax1 
MO normal), embryos that were mildly dysmorphic (hax1 MO mild) and 
embryos that were severely dysmorphic (hax1 MO severe). Total RNA was 
extracted from embryos at 12 hpf. 2 µg of RNA were used for each RT 
reaction. Negative RT (- RT) and PCR (- PCR) controls containing water 
instead of RNA and cDNA respectively are also shown. hax1 was amplified 
using two sets of primers.  PCR products after 30 cycles were analysed by 
agarose gel electrophoresis. Red arrows indicate the appearance of an 
additional band in the hax1 MO injected embryos. Note not all Hyperladder 
marker sizes are shown. b.) Repetition of PCR using uninjected and hax1 
splice MO injected embryo cDNA with a reduced number of PCR cycles (25) 
and hax1 primers. 
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4.4.2 Disruption of hax1 gene expression results in abnormal 
development and lower total PMN counts 
To test whether a longer time-point after MO microinjection results in a 
further decrease in hax1 mRNA levels, embryos were injected with either 
standard control or hax1 splice MO and incubated for 24 h. RNA 
extracted from the embryos using TRI reagent was subjected to RT-PCR 
with hax1 primers. Microinjection of hax1 splice MO resulted in either a 
decrease in hax1 mRNA level (Fig. 4.10 a.) or the appearance of a high 
molecular weight band ~2500 bp (Fig. 4.10 b.). This band was not seen in 
the standard control MO injected sample and was also used as an 
indicator of disruption of hax1 transcription. After each experiment, 
embryos were collected at 24 hpf, RNA extracted and knockdown 
(decrease in hax1 mRNA level, appearance of ~2500 bp band or 
combination of both) was determined by RT-PCR analysis; any 
experiments not showing knockdown were discarded. RT-PCR analysis 
results representative of 6 independent experiments are shown in Fig. 
4.10 a. and b.. The mRNA was also amplified with positive control ef-1α 
primers that show constant levels of the transcript in all samples.  
 
The effect of hax1 knockdown on whole embryo PMN numbers of 
zebrafish was assessed using Volocity® software. Uninjected, standard 
control MO and hax1 splice MO injected Tg(mpx:GFP)i114 embryos 
(morphants) were incubated at 28 °C for 35 and 48 h. At the relevant time 
point, embryos were mounted in 1% low melting point agarose and 
imaged under a 2x objective on a Nikon Eclipse TE2000U inverted 
microscope. GFP labelled PMN were counted from at least six embryos 
in each experiment. At 35 hpf, hax1 MO knockdown significantly reduced 
total PMN number compared to uninjected and standard control 
morpholino injected embryos (Fig. 4.10 c.). There was no significant 
difference between uninjected and standard control injected embryos 
(Fig. 4.10 c.). In half of the experiments (3 out of six), hax1 MO injected 
embryos failed to survive to 48 h. Total PMN counts were carried out in 
the three experiments where injected embryos did survive past 48 hpf 
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Figure 4.10 hax1 RT-PCR analysis and PMN whole embryo counts 
of Tg(mpx:GFP)i114  embryos following injection with hax1 splice 
MO 
RT-PCR analysis of total RNA from uninjected, standard control and hax1 
morpholino injected (1 nl of 0.25 mM- splice MO) Tg(mpx:GFP)i114 
zebrafish embryos at 24 h post injection. cDNA was amplified using hax1 
and positive control ef-1 α  primers. DNA bands after 30 cycles of PCR were 
separated by agarose gel electrophoresis and visualised using a UV 
transilluminator. A no template control was included in both the Reverse 
transcriptase (-RT) and PCR (-PCR) step. PCR results shown in a. and b. 
are representative of 6 independent experiments. Red arrow indicates 
presence of additional band in hax1MO injected cDNA. Whole embryo PMN 
counts were carried out at 40 hpf (c.) (uninjected n=3, control and hax1 MO 
n=4) and 48 hpf ( d.) (n=3) from at least 6 embryos per condition on each 
independent experiment. Total PMN numbers at 40 hpf from three 
independent experiments were analysed using a one way ANOVA with 
Bonferroni's post test; ****p≤ 0.0001. Total PMN counts at 48 hpf were 
analysed using an unpaired t-test, ****p≤ 0.0001. 
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 (Fig. 4.10 d). PMN counts in hax1 morphants remained low (mean±SEM: 
34.54 ± 3.939) compared to the uninjected control (mean±SEM: 98.62 ± 
5.826) (Fig. 4.10 d.).  
 
On morphological analysis, most of the hax1 splice MO embryos were 
developmentally delayed compared to the healthy control uninjected (Fig. 
4.11 a.) and standard control MO injected embryos (Fig. 4.11 b.).The 
hax1 MO injected embryos at 48 hpf were classified into four groups 
based on gross morphology and developmental delay. Micrographs taken 
using the brightfield and GFP channels are shown in Fig. 4.11 a-e. The 
groups were: healthy embryos which resembled the morphology of the 
uninjected and control MO injected embryos, curly tailed embryos (curly, 
Fig. 4.11 c.), embryos with a curly tail and brain swelling (brain swelling, 
Fig. 4.11 d.) and severely dysmorphic embryos (severe, Fig. 4.11 e.). The 
reduced number of PMN in the hax1 morphants is also apparent from the 
micrographs taken using the GFP channel. Embryos were sorted into the 
four different morphological groups and RNA extracted. RT-PCR analysis 
revealed that although there was no difference in the hax1 mRNA levels 
between the controls (uninjected, standard control MO) and the hax1 
splice MO injected morphants (curly, brain swelling, severe) (Fig. 4.11 f.); 
the ~2500 bp band (red arrow) was still visible at a very low intensity in 
the hax1 PCRs of the curly, brain swelling and severely dysmorphic 
groups.  
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Figure 4.11 RT-PCR and morphological analysis 48 hpf following 
injection with hax1 splice site MO 
a-e.) Representative micrographs showing uninjected, standard control MO 
injected and hax1 MO injected embryos with brain swelling (red arrow) and 
curly tail (cyan arrow) at 48 hpf.  f.) RT-PCR analysis of total RNA from 
standard control and hax1 morpholino injected Tg(mpx:GFP)i114 zebrafish 
embryos 48 h following injection. RT-PCR was carried out using hax1 and 
positive control ef-1α primers. PCR bands were separated by agarose gel 
electrophoresis. A no template control was included in both the Reverse 
transcriptase (-RT) and PCR (-PCR) step. hax1 MO injected embryos fell 
into four categories: normal morphology, curly tail (curly), brain swelling & 
curly tail (brain swelling), and severely dysmorphic (severe) embryos. Red 
arrow indicates additional 2500 bp hax1 specific band. Note not all 
Hyperladder marker sizes are shown.  
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4.4.3 RT-PCR and morphological analysis of embryos co-injected 
with hax1 and p53 MO 
A study evaluating the off-target effects of sequence-specific gene 
knockdowns demonstrated that p53 activation is a side effect of 
morpholino injection and siRNA silencing (Robu et al. 2007). In order to 
assess whether the developmental delay in hax1 morphants was 
mediated by p53 activation, a p53 MO (0.4mM) was co-injected with the 
hax1 splice MO. Amplification of mRNA with hax1 primers shows the 
appearance of the ~2500 bp band in the hax1 and combined hax1 p53 
morphants (Fig. 4.12 a.). Negative reverse transcription controls were 
carried out for each sample of RNA and were all clear. RT-PCR analyses 
using the ef-1α loading control primers shows ef-1α levels were uniform 
in all PCR samples.  
 
While the hax1 morphants failed to survive to 48 hpf, the co-injection with 
p53 MO prevented the death of the embryos. However, most of the co-
injected embryos remained highly dysmorphic even with the p53 co-
injection. The morphologies of uninjected, standard control MO and hax1 
p53 MO co-injected embryos at 48 hpf are displayed in Fig. 4.12 b. Total 
numbers of PMN from embryos of the same experiment were counted at 
40 hpf (Fig. 4.12 c.). Total PMN numbers were considerably lower in hax1 
and co-injected morphants when compared to sibling controls (uninjected 
and control MO injected). The difference appeared to persist at 48 hpf 
(Fig. 4.12 d.). 
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Figure 4.12 Analysis of i114 embryos co-injected with 
hax1 and p53 MO 
a.) Tg(mpx:GFP)i114 embryos at the 1-4 cell stage were injected with 
standard control MO, hax1 MO or co-injected with 1nl hax1 and p53 MOs 
(n=1). Total RNA was extracted 24 h following injection and RT-PCR was 
carried out using hax1 and loading control primers ef-1α. The PCR products 
were separated by agarose gel electrophoresis and bands were detected 
using a UV transilluminator. b.) Micrographs of uninjected and injected 
embryos at 48 h post injection. Total PMN counts were carried out on 
images taken using the GFP channel from 6 embryos at 40 h (n=6 
performed as a single experiment) (c.) and 10 embryos at 48 h  (n=10 
performed as a single experiment) (d.) following injection. Total PMN counts 
were analysed using a one way ANOVA with Bonferroni's post 
test;p<0.0001. Bars represent mean values ±SEM. 
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4.5 hax1 splice site MO induces aberrant splicing of the 
gene in zebrafish embryos 
To explore whether the hax1 specific ~2500 bp visible only in the RT-
PCRs using hax1 morphant mRNA is a result of altered pre-mRNA 
splicing of the gene, the band was cloned into a pCR-BLUNT II-TOPO 
vector and sequenced using M13 primers. PCR bands were excised from 
the gel and purified from pooling lanes 1-4 (Fig. 4.13 a.). The purification 
was assessed by agarose gel electrophoresis. Fig. 4.13 b. shows that a 
sufficient amount of the large DNA band was purified from the gel extract to 
allow subsequent cloning. Once the ~2500 bp PCR product was inserted 
into pCR-BLUNT II-TOPO and transformed into Amp resistant TOP10 
comptetent E. coli, colony PCR was carried out with M13 primers to confirm 
insertion of the ~2500 fragment into the pCR-BLUNT II-TOPO. PCR analysis 
of colony 1 containing the ~2500 bp insert is shown in Fig. 4.13 c. 
Sequencing of the plasmid vector from a mini-preparation from colony 1 
revealed that the ~2500 band seen in the hax1 morphants is due to aberrant 
splicing of the hax1 gene (Fig. 4.13 d.). Blast analysis of the sequencing 
output showed that the band amplified using the hax1 primers generated a 
2599 bp product consisting of exon 2, intron 2-3, exon 3, intron 3-4, exon 4, 
exon 5, exon 6 and exon 7. The exon/intron organization of the zebrafish 
gene, the normal splicing of variant 001 and 002 in the region amplified by 
hax1 primers (green arrows) and the abnormal splicing as a result of the 
hax1 MO injection are shown in Fig. 4.13 d. In silico translation of the mRNA 
species generated as a result of the MO injection reveals premature 
truncation of the protein sequence due to intron 2-3 being maintained in the 
transcript (Fig. 4.14). 
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Figure 4.13 Cloning of alternatively spliced 2500 bp band observed 
in response to hax1 splice MO injection 
a.) cDNA from hax1 morphants at 24 hpf was amplified using hax1 001 
primers with a 2 min PCR cycle extension step. Following 35 cycles of PCR, 
the DNA bands  (lanes 1-4) were resolved on an agarose gel and visualised 
using a UV transilluminator. A no template control at the RT and PCR step is 
included. Note not all ladder sizes are shown. The 2.5 kb band was gel 
extracted and PCR purified. Purification of the band was confirmed by 
agarose gel electrophoresis (b.). The 2.5 kb band was inserted into a pCR-
BLUNT II-TOPO vector. The TOPO cloning reaction was transformed into 
competent TOP 10 E. coli that were streaked on Amp selective media. c.) 
Colony PCR using M13 primers was carried out to confirm cloning of 2.5 kb 
hax1 specific insert into the plasmid. Colony 1 was used to inoculate a 5 ml 
culture and incubated O/N at 37 °C. d.) Plasmid DNA was purified and 
sequenced. Normal and aberrant splicing induced by the MO injection is 
shown alongside the gene containing the numbered exons. Green arrows 
indicate site of hax1 001 primer binding and the black arrow indicates 
binding of the hax1 MO intron 3-4 primer binding site. 
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Figure 4.14 The hax1 splice MO introduces a premature STOP 
codon 
The hax1 001 mRNA sequence was obtained from cloning and sequencing 
of hax1 transcript variant 001 (Uninjected) whereas the sequence of the 
~2500 bp band from the hax1 MO injected embryos (MO) was determined 
by cloning and sequencing of the band. In silico translation of the mRNA 
sequences was carried out using the Expasy translate tool 
(http://web.expasy.org/translate/). A CLUSTALW2 alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) reveals premature truncation of 
the hax1 001 mRNA in the hax1 splice MO injected embryos. 
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4.6 Transient knockdown of hax1 using a translation 
start site targeting MO and co-injection with the hax1 
splice MO 
In order to investigate whether a hax1 translation start site targeting MO 
(ATG MO) would replicate the phenotypic changes and reduction in total 
PMN number seen with the hax1 splice MO  (section 4.5), a hax1 ATG 
MO was designed and three different concentrations of the MO were 
injected into Tg(mpx:GFP)i114 one cell stage embryos. ATG MOs work by 
inducing post-transcriptional interference of gene expression. Since the 
ATG MO does not affect mRNA levels the MO efficiency is not 
quantifiable by RT-PCR and to date, there are no commercially available 
zebrafish hax1 antibodies to allow validation of the knockdown at the 
protein level. Uninjected, control MO and hax1 ATG injected embryos 
were cultured for 48 h after which they were visualized under a Leica 
MZ10F fluorescent microscope with the GFP+ filter. Total PMN number 
from 12 embryos per condition was counted by eye. The number of PMN 
decreased slightly as the concentration of the ATG MO was increased 
when compared to the uninjected and standard control MO injected 
groups (Fig. 4.15). The hax1 ATG MO resulted in very few or no no-viable 
embryos at 24 hpf and only a slight delay in development even with the 
highest dose tested (1nl 0.5 mM).  
 
In a second experiment, the dose of the hax1 ATG MO was increased to 
1 mM to test the tolerance of this concentration with respect to embryonic 
development. The ATG MO was co-injected with 0.2 mM hax1 splice MO. 
Note the concentration of the hax1 splice MO is not the same as the 
previously optimized dose (section 4.4). The dose of the hax1 splice MO 
was lowered in the co-injection with the ATG MO in order to try and 
reduce off-target effects that may result from p53 activation. In addition, 
since the hax1 splice MO alone caused severe embryonic development it 
was anticipated that any additional hax1 knockdown by the ATG MO 
could result in death therefore lowering the splice MO dose could prevent 
this.
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Figure 4.15 Optimisation of hax1 ATG MO 
Tg(mpx:GFP)i114 embryos at the one cell stage were injected with 1nl of 
standard control MO and varying doses of hax1 ATG MO as indicated. 
Micrographs were taken using the GFP channel at 48 hpf. Whole embryo 
PMN numbers, n=12 performed as a single experiment were analysed using 
a one way ANOVA with Bonferroni's post test;****p≤ 0.0001. Bars represent 
mean ±SEM. 
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Morphological analysis of the embryos shows that in comparison to the 
healthy uninjected and standard control injected embryos, the hax1 ATG 
MO injected alone had a slight delay in development indicated by the 
curling of the tail in Fig. 4.16. The severity of the tail curling increased in 
the co-injected morphants particularly with the higher dose of the MOs (1 
mM ATG and 0.2 mM splice) however, this delay in development was not 
as marked as that seen with the 1 nl 0.25 mM hax1 splice MO injection 
alone. Analyses of PMN counts at 48 hpf show that total PMN levels were 
lower in the hax1 ATG MO injected and hax1 splice MO & ATG MO co-
injected embryos (both doses) when compared to the uninjected and 
standard control MO injected embryos (Fig. 4.17 a.). This is clearly visible 
from the micrographs taken using the GFP channel (Fig. 4.16). The ATG 
injected and MO co-injected embryos survived past 54 hpf and so PMN 
numbers were also counted at this time point (Fig. 4.17 b.). The PMN 
numbers in the 1 mM hax1 ATG MO injected and hax1 splice MO ATG 
MO co-injected embryos remained low at 54 hpf .The 1 nl 1 mM ATG and 
0.2 mM splice hax1 MOs co-injection dose generated embryos with the 
lowest PMN numbers. 
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Figure 4.16 Morphological analysis of zebrafish embryos co-
injected with hax1 splice and ATG MO 
Tg(mpx:GFP)i114 embryos were injected at the 1- 4 cell stage with standard 
control MO, hax1 ATG MO or co-injected with hax1 ATG and splice MO as 
indicated. Micrographs using the brightfield and GFP channel were taken at 
48 hpf using a 2x objective on a Nikon Eclipse TE2000U inverted 
microscope. Images are representative of 12 embryos from a single 
experiment.
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Figure 4.17 The effects of co-injection of hax1 start MO and hax1 
splice MO on whole body PMN counts  
Tg(mpx:GFP)i114 embryos at the one cell stage were injected with 1nl of 1 
mM hax1 ATG MO and co-injected with varying doses of hax1 splice and 
ATG MOs as indicated. Micrographs of uninjected and injected embryos 
were taken at 48 h (a.) and 54 h (b.) following injection. Total PMN numbers 
were counted by eye from 12 embryos per condition. Total PMN counts 
(n=12 performed as single experiments) were analysed using a one way 
ANOVA with Bonferroni's post test;p<0.0001. Bars represent mean ±SEM. 
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4.7 Generation of hax1 RNA probes for use in whole-
mount in situ hybridization (WISH) in zebrafish embryos 
WISH is an efficient method used to allow the detection of spatial gene 
expression patterns in zebrafish embryos. To detect the sites of hax1 
expression in the zebrafish embryo, a full-length hax 1 antisense and a 
sense control RNA probe were generated. The region consisting of the 
full coding sequence of hax1 (001) was PCR amplified and used as a 
template for the synthesis of an antisense and sense (negative control) 
probe (Fig. 4.18). The hax1 001 coding sequence containing vector was 
transformed into TOP10 competent E. coli as described in section 2.1.21. 
This was followed by purification from a midi scale DNA preparation. Purified 
plasmid vector was subjected to PCR with hax1 001 primers in order to 
confirm insertion of the template into the plasmid. Agarose gel 
electrophoresis of the PCR band and visualization using a UV 
transilluminator confirmed the successful insertion of the hax1 001 template 
into the plasmid vector (Fig. 4.18 c.). The plasmid DNA was also sequenced 
to ensure the sequence of the template was intact and to determine the 
orientation of the insert. Blast analysis of the sequencing output is shown in 
Appendix 7.12. SpeI and XhoI restriction digests were then used to linearize 
the circular plasmid DNA (Fig. 4.18 d.). 
 
 Linear DNA was subjected to agarose gel electrophoresis (Fig. 4.18 e.) to 
allow quantification of each of the plasmids containing the hax1 001 
antisense, hax1 001 sense negative control and the positive L-plastin control 
(a kind gift from Catherine Loynes, University of Sheffield) probes. Each 
linearized plasmid was used for the synthesis of the RNA probes labeled 
with digoxigenin-linked nucleotides. The quality of the RNA probe was 
assessed by agarose gel electrophoresis and is shown in Fig. 4.18 e. A 
single RNA band was visible for the L-plastin and the hax1 001 sense 
probes. The hax1 001 antisense probe consisted of two bands likely to result 
from differing secondary structures of the RNA species.  
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Figure 4.18 Generation of whole mount in situ hybridisation hax1 
sense and anti-sense probes 
a.) The full length hax1 cds was cloned into a pCR-BLUNT II-TOPO plasmid 
vector. b.) The TOPO cloning reaction was transformed into competent cells. 
A single colony was used to inoculate a 50 ml culture and incubated at 37 
C for 12 h. c.) The plasmid DNA was then purified and the insert amplified 
by PCR with hax1 001 primers. d.) Plasmid DNA containing the insert was 
linearised using SpeI (hax1 sense probe) and XhoI (hax1 anti-sense probe) 
for generation of mRNA using the Sp6 and T7 promoter, respectively. e.) 0.1 
(lane 1), 0.5 (lane 2) and 1 (lane 3) μl of linearised L-plastin, hax1 sense and 
anti-sense plasmid DNA were resolved on an agarose gel to allow 
quantification using the Hyperladder I band DNA quantities. f.) Linearised 
DNA was in vitro transcribed using DIG-labelled NTPs. RNA clean-up was 
carried out and the RNA was resolved on an agarose gel alongside 
Hyperladder I and visualised by a UV transilluminator. 
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4.8 Overexpression of hax1 001 in zebrafish embryos 
4.8.1 Cloning of hax1 001 into the multifunctional expression vector 
pCS2+ 
The pCS2+ vector has been shown to permit very effective in vitro 
expression fusing an artificial 3’ UTR with a polyadenylation (poly A) signal 
to the gene of interest (Turner & Weintraub 1994). This provides increased 
stability of the mRNA. Since the hax1 001 full cds containing pCR-BLUNT II-
TOPO plasmid vector did not contain a polyadenylation signal, the hax1 001 
insert was excised from the pCR-BLUNT II-TOPO plasmid using EcoRI 
digestion and cloned into the multifunctional expression vector pCS2+ (Fig. 
4.19). A colony containing the hax1 insert (colony 2- Fig. 4.19 b.) was used 
for the preparation of the plasmid. Sequencing of the plasmid DNA with the 
M13 reverse primer revealed that the insert was in the correct orientation 
with the 3’ region of the gene adjacent to the SV40 poly (A) signal. 
Linearization of the plasmid with the NotI restriction enzyme resulted in 
migration of the plasmid according to its true size (Fig. 4.19 c. and d.). In 
vitro mRNA synthesis using an SP6 transcription kit (Roche Applied 
Science) generated capped mRNA for injection into single cell embryos (Fig. 
4.19 e.). 
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Figure 4.19 Cloning and in vitro transcription of zebrafish full length 
hax1 into pCS2+ 
a.) The full length hax1 cds was excised from pCR-BLUNT II-TOPO by 
EcoRI digestion and ligated to EcoRI linearised pCS2+ plasmid vector 
containing SV40 polyA tail. The ligation reaction was transformed into 
competent E. coli, which were subsequently plated on Amp selective media. 
Single colonies were used to inoculate a 50 ml culture which was incubated 
O/N at 37 °C. b.) The plasmid DNA was then purified and resolved on an 
agarose gel. Colony 2 contained the hax1 insert. Plasmid DNA from colony 
2 was linearised by digestion with the restriction enzyme NotI. d.) 
Undigested and NotI digested plasmid DNA was resolved on an agarose 
gel. The linearised plasmid DNA was then in vitro transcribed using an SP6 
RNA polymerase. hax1 mRNA was loaded onto an agarose gel and 
resolved by electrophoresis (e.). The mRNA band was visualised using a UV 
transilluminator. 
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4.8.2 Whole-mount in situ hybridization analysis of uninjected and 
hax1 001 mRNA injected embryos 
In situ hybridization using the hax1 001 antisense RNA probe (section 
4.8.1) shows that hax1 001 mRNA is ubiquitously distributed in zebrafish 
embryos at 24 hpf (Fig. 4.20 a.) with high expression around the brain 
region. Some non-specific staining is visible in the WISH with the 
negative control hax1 001 sense probe. WISH with the L-plastin 
antisense probe produced the expected staining pattern with staining in 
the anterior yolk region and posterior intermediate cell mass (ICM). The 
overexpression of hax1 001 was also verified by the in-situ hybridization. 
Injection of hax1 001 mRNA resulted in increased staining with the hax1 
antisense probe (Fig. 4.20 b.) when compared to the uninjected control 
embryos. As expected, there was no such increase in staining with the 
sense probe. 
 
4.8.3 RT-PCR analysis of hax1 001 mRNA injected and hax1 001 
mRNA splice MO co-injected embryos 
In order to assess whether hax1 001 overexpression could prevent the hax1 
splice MO induced phenotypic changes of the embryos and concomitant 
decrease in the PMN number, embryos were injected with hax1 001 mRNA, 
hax1 splice MO or co-injected with hax1 001 mRNA and hax1 splice MO. 
Following a 24 h incubation period, the embryos were anaesthetized and 
RNA extracted using TRI reagent. RT-PCR with hax1 primers was used to 
confirm the overexpression. RT-PCR analysis showed that hax1 splice MO 
injection resulted in decreased hax1 levels, whereas the hax1 001 mRNA 
and hax1 001 and splice MO co-injection led to elevated hax1 levels (Fig. 
4.21).  
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Figure 4.20 hax1 is ubiquitously expressed in zebrafish embryos 
NACRE embryos at the 1 cell stage were injected with 1 nl of hax1 mRNA at 50 ng/ μl. Uninjected (a.) and hax1 mRNA injected embryos 
(b.) were then subjected to WISH at 24 hpf. An L-plastin anti-sense probe was used as a positive control.  A hax1 sense probe was also 
included for detection of non-specific binding. Images are representative of at least 15 embryos per condition from a single experiment. 
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Figure 4.21 RT-PCR analysis of hax1 001 overexpression in 
zebrafish embryos at 24 hpf 
Tg(mpx:GFP)i114 embryos were injected at the one cell stage with control 
mCherry mRNA (1 nl of 50 ng/μl), hax1 mRNA (1 nl of 50 ng/μl), hax1 splice 
MO and combined hax1 mRNA and splice MO. Following injection (24 hpf), 
total RNA was extracted from the embryos and RT-PCR using hax1 001 
primers carried out. Results for PCR carried out using ef-1α loading control 
primers are also shown. Negative RT (- RT) and PCR (- PCR) controls 
containing water instead of RNA and cDNA respectively are also shown. 
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4.8.4 Effects of hax1 001 overexpression on embryonic morphology 
and total PMN number 
Having demonstrated both by in situ hybridization and RT-PCR that hax1 
001 mRNA injection into single cell embryos results in increased embryonic  
mRNA levels at 24 hpf, I next examined the effects of hax1 001 
overexpression on embryo morphology and total PMN number. It has 
previously been shown that injection of mCherry mRNA into embryos 
results in red fluorescing embryos. In experiments where the mCherry 
mRNA was used as a control, embryos were visualized under a Leica 
MZ10F fluorescent microscope using the red filter at 24 hpf in order to 
validate the overexpression. In each case, all of the embryos expressed 
the fluorescent protein indicating efficient injection and translation (data 
not shown). Control mCherry mRNA, hax1 001 mRNA, hax1 splice MO 
injected and hax1 001 mRNA hax1 MO co-injected embryos were cultured 
for 48 h and imaged using a Nikon Eclipse TE2000U inverted microscope 
with the 2x objective. Representative images are shown in Fig. 4.22 a. 
The hax1 001 overexpression did not affect the overall appearance of the 
embryos.  Both the mCherry and hax1 001 mRNA injected embryos 
remained healthy throughout the course of the experiment. The hax1 
splice MO however, resulted in the characteristic delayed development 
and dysmorphic phenotype. Co-injection of the hax1 mRNA with the hax1 
splice MO had no effect on the morphology of the embryos. The co-
injected morphants remained developmentally delayed and dysmorphic 
with similar morphology to the hax1 splice MO only injected group (Fig. 
4.22 a).  
 
Total PMN counts of uninjected, mCherry control, hax1 mRNA, hax1 
splice MO injected and hax1 mRNA MO co-injected embryos were 
carried out at 48 hpf (Fig. 4.22 b.). PMN were counted from at least six 
embryos per condition. The hax1 001 overexpression had no effect on 
total PMN numbers when compared to the uninjected and mCherry 
control groups. As shown earlier in the chapter, the hax1 splice MO 
resulted in reduced total PMN number. Co-injection with hax1 001 mRNA 
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Figure 4.22 Effects of hax1 001 overexpression in zebrafish embryos 
Tg(mpx:GFP)i114 embryos were injected at the one cell stage with control 
mCherry mRNA (1 nl of 50 ng/ μl, hax1 mRNA (1 nl of 50 ng/ μl), hax1 splice 
MO and combined hax1 mRNA and splice MO. Following injection (24 hpf), 
total RNA was extracted from the embryos and RT-PCR using hax1 001 
primers carried out. a. ) Bright field micrograph of embryos were taken 48 
following fertilization. Total PMN numbers were counted from at least 6 
embryos from each independent experiment at 48 hpf (uninjected and hax1 
mRNA, n=3; mCherry, hax1 splice MO, combined hax1 MO and mRNA, 
n=2) ( b.)  and 54 hpf. (n=3). Uninjected and hax1 mRNA injected total PMN 
counts at 48 hpf were analysed using an unpaired student's t-test, p<0.05. 
Total PMN counts at 54 hpf were analysed using a one way ANOVA with 
Bonferroni's post test. 
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did not affect this reduction. Interestingly, MO injected and the hax1 001 
mRNA hax1 splice MO co-injected embryos failed to survive to 48 hpf in 
the third experiment. Very few or none survived to 54 hpf in any of the 
three independent experiments carried out.  
 
In order to test whether the hax1 001 overexpression affected PMN 
number at 3dpf, total PMN counts of uninjected, mCherry mRNA and 
hax1 001 mRNA injected embryos were also counted at 54 hpf. Statistical 
analysis shows that there was no difference in the total PMN number 
between the control  (uninjected, mCherry mRNA) and hax1 001 mRNA 
injected embryos from three independent experiments. 
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4.9 Summary 
The aims of this chapter were to assess hax1 mRNA expression in 
zebrafish embryos and study the effects of hax1 knockdown on total PMN 
number in zebrafish. Novel evidence for the multiple hax1 transcript 
variant expression in the zebrafish embryo is presented through the use 
of hax1 isoform specific primers. The full-length hax1 transcript is 
expressed throughout embryonic development and in the adult PMN. Via 
cloning of the (full-length) hax1 001 cds, the ubiquitous expression of 
hax1 001 was determined using in situ hybridization of zebrafish embryo 
at 24 hpf. This observation shows that as in humans, hax1 001 
expression is not restricted to any cell type. Attempts to knockdown hax1 
by injection of a splice MOs were unsuccessful since it is demonstrated 
that it resulted in developmental delay, which did not correlate with the 
degree of knockdown. I have shown that these morphants also exhibit a 
reduction in total PMN numbers and this is likely to be due to the 
concomitant developmental delay observed. Furthermore, I found that 
hax1 001 overexpression did not prevent the splice MO induced 
developmental delay and reduction in PMN number.  
 
4.10 Discussion 
4.10.1 hax1 transcript expression in D. rerio  
In this chapter, for the first time I have shown that zebrafish express at 
least five different hax1 mRNA variants. This is in accordance with a 
study carried out by Lees et al (Lees et al. 2008), which describes the 
existence of eight HAX1 alternative splice variants in human cell types. 
Transcript variants 001, 002, 005, 007 and 008 were all expressed in 
embryos at 2 dpf. The RT-PCR data indicate that the hax1 001 transcript 
is the most abundantly expressed. The hax1 001 mRNA was detected in 
embryos at different stages of development (single cell embryo, 1-5 d.p.f) 
and in adult zebrafish PMN. These findings support a possible role for 
hax1 in the zebrafish embryo development and PMN. The ubiquitous 
expression of the full-length hax1 mRNA suggest that hax1 plays an 
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important global role in the cells of the zebrafish embryo. The RT-PCR 
evidence in this thesis for hax1 maternal mRNA transfer to the fertilized 
zebrafish egg further supports this notion.  Maternal factors have been 
shown to regulate development prior to the activation of the embryonic 
genome and our data suggest that hax1 may be involved in this process 
(Kane & Kimmel 1993).     
 
To date, HAX1 alternative splicing has been analysed in the genomes of 
three different species: the rat, mouse and human. Despite the high 
sequence similarity between the mouse and human HAX1 cDNAs, the 
mouse variants identified so far appear to be distinct (Hippe et al. 2006; 
Lees et al. 2008). The rat and human variants are similar and are 
generated mainly from intron retention and the use of internal splice sites 
in exon 2 (Grzybowska et al. 2006; Lees et al. 2008). Human and 
zebrafish Hax1 protein share 60 % sequence similarity and 60 % identity 
at the cDNA level suggesting a similar functional importance. The data 
generated in this chapter suggests that the splicing pattern of zebrafish 
hax1 is also in part analogous to that of the human HAX1 gene (Lees et 
al. 2008). PCR bands of the expected sizes were generated for primers 
specific for transcript variants 001, 002, 005, 007 and 008 indicating that 
these variants are likely to be spliced in the same manner as the human 
variants. Cloning and sequencing of the full-length transcript (001) 
confirmed the expected splicing pattern for this variant. Sequencing of the 
PCR band generated for transcript 008 also verified the expected splicing 
pattern at the 3’ end of the transcript. Additional bands were visible in 
PCRs with most of the primers indicating that other hax1 zebrafish 
isoforms are likely to exist. These data provide further support for a 
regulatory role of the alternative splicing in assigning variability in Hax1 
function.  
 
 It is worth noting that in order to fully verify the splicing patterns in 
isoforms 002, 005, 007 and 008, each transcript should be cloned from 
the start to stop codon and correct splicing pattern determined by 
sequencing analysis. A detected PCR band that has the expected size 
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might not necessarily have the expected splicing pattern. The protein 
sequences for each isoform discussed below are generated from the 
predicted splicing pattern of variants 002, 005, 007 and 008. The putative 
open reading frames of the zebrafish Hax1 isoforms 005 and 008 are 
quite short and may represent incomplete coding sequences. 
 
 The predicted proteins encoded by the zebrafish hax1 variants show 
variability at the C- and N-termini. Alternative splicing at the 5’ region of 
the hax1 mRNA generates three different protein start sites. Hax1 
isoforms 001 and 002 appear to have an identical splicing pattern to that 
described in the human gene with isoform 002 missing a short protein 
region of the N- terminus of 001 (Lees et al. 2008). In silico translation 
analysis shows that even if exon 1 inclusion occurred in the zebrafish 
isoform 002, it is still likely to generate the same protein open reading 
frame.  
 
Whereas the putative human isoform 005 is almost identical to isoform 
001 and differs only by 8 amino acids, the zebrafish isoform 005 is a 
truncated version of the full-length isoform 001 and differs only by 6 
amino acids at its C-terminus. The zebrafish isoforms 007 and 008 are 
also truncated version of isoform 001 and unlike their human 
counterparts, which show no resemblance to human isoform 001, these 
two isoforms are almost identical to the C-terminus of zebrafish Hax1 
001.  
 
Suzuki et al revealed some sequence similarity of the human HAX1 N-
terminus to the Bcl-2 family homology (BH) domain regions of the Bcl-2 
family (Suzuki et al. 1997). In the rat, the N-terminal region of the protein 
is thought to contain a localization sequence in two rat-specific transcripts 
(Grzybowska et al. 2006). Many other groups have reported the C-
terminus of the protein to be responsible for protein-protein interactions. 
For example, interactions with caspase 9 (Han et al. 2006), Omi (Chao et 
al. 2008), and viral proteins Vpr (Yedavalli et al. 2005), human 
herpesvirus 8 K15 and HIV-1 REV (Modem & Reddy 2008) are all 
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reported to occur at the C-terminus of the protein. The alternative splicing 
at the N-terminus of zebrafish hax1 may result in changes in the 
localization, stability or function of the protein. On the other hand, isoform 
specific regions found in the C-termini of the isoforms could determine the 
protein-binding partners thus enhancing the control of hax1 expression in 
different cell types. The regulation of Hax1 isoform expression and or 
tissue specific isoform expression may in turn modulate the role of Hax1 
in apoptosis signalling.  
 
4.10.2 Zebrafish as a model for studying hax1 function 
In the last twenty years, the zebrafish has become a widely used model 
for the study of gene function and disease pathogenesis during 
embryonic development (Lieschke & Currie 2007). One of the many 
advantages of using the vertebrate model is the unique opportunity for 
the in vivo analysis of genes required for a normally functioning innate 
immune system. The optical transparency of the embryos allows 
excellent visualisation of fluorescent proteins in many different cellular 
processes (Renshaw et al. 2006; Ellett et al. 2011). This property has 
permitted the identification of numerous blood cell lineages through the 
generation of many transgenic lines in which GFP expression is driven by 
cell specific promoters. Embryonic zebrafish myelopoiesis has been 
shown to generate several cell types including the zebrafish PMN 
(sometimes termed heterophil), which closely resembles the human 
PMN. Embryonic PMN are fully functional by 48 hpf further facilitating the 
study of myelopoiesis in this model (Lieschke et al. 2001).  
 
Though the components interacting with pathogens are more divergent, 
many of the factors acting downstream of the receptors in zebrafish 
innate immunity have remarkable similarities to the mammalian 
counterparts (Lieschke 2001; Stein et al. 2007). Caspases and many of 
the mammalian Bcl-2 protein family members involved in the control of 
the intrinsic apoptotic pathway have structural and functional counterparts 
in the zebrafish (Kratz et al. 2006). This is important because HAX1 has 
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been shown to bind to numerous factors involved in the intrinsic apoptotic 
pathway and disruption of the gene in the zebrafish is more likely to 
reproduce the human phenotype if these factors are conserved through 
evolution in the zebrafish.  
 
Previous studies have highlighted that there is a striking similarity between 
zebrafish mutant phenotypes and human disease emphasizing its efficacy 
as a model system for elucidating pathophysiological mechanisms (Lieschke 
& Currie 2007). The utility of the zebrafish model therefore becomes 
particularly valuable in instances where mouse models fail to accurately 
recapitulate the human disease phenotype. Several studies have shown that 
mouse models for sever congenital neutropenia (SCN) are not necessarily 
neutropenic (Belaaouaj et al. 1998; Grenda et al. 2002). Although a single 
experiment carried out on the Hax1 knockout mouse indicated a role for 
Hax1 in suppressing granulocyte apoptosis, the mouse phenotype did not 
accurately model the phenotype of HAX1 deficient patients, since the mouse 
phenotype is not limited to neutropenia.  
 
The relevance of the zebrafish as a model for the study of hax1 function is 
further emphasized by the high similarity of the zebrafish Hax1 to the human 
HAX1 protein sequence. Interestingly, both the extreme N-terminal region 
and that containing the acid box identified by Lees et al have been 
maintained through evolution across species and may underline key roles 
for these protein regions (Lees et al. 2008).  Grzybowska et al utilised 
PSORT prediction software to suggest that the rat Hax1 amino acid residues 
1-26 may function in mitochondrial localization (Grzybowska et al. 2006). 
This particular region corresponds to the N-terminal region with a very high 
sequence identity found in human, rat, mouse, macaque and zebrafish 
species.  
 
The function of the N-terminus in mitochondrial localization has been verified 
by Yap et al. who demonstrated that deletion of 59 amino acid residues 
within the N-terminus of human HAX1 results in the abolishment of its 
mitochondrial targeting and reduced anti-apoptotic capacity (Yap et al. 
 183 
2010). Interestingly, mutations in the human in this region of the gene are 
implicated in the neutropenic phenotype associated with these mutations. 
Germeshausen et al have shown that mutations affecting isoform 001 
exclusively result in congenital neutropenia without the neurological 
phenotype (Germeshausen et al. 2008). This implies that it is this region, 
which has a functional importance in the PMN. Perhaps mutations in this 
region prevent the localization of HAX1 to the mitochondria and this in turn is 
detrimental to its normal function. The high similarity in this region of the 
zebrafish full-length Hax1 protein to human HAX1 suggests that this region 
is likely to have a similar function in the zebrafish and we have used this 
logic to design knockdown tools targeted to this region in order to 
recapitulate the SCN phenotype in the zebrafish. 
 
4.10.3 The use of MOs to inhibit hax1 expression in the zebrafish  
MOs are a powerful approach to loss of function analysis in the zebrafish 
(Nasevicius & Ekker 2000). A splice site MO and an ATG MO targeting 
hax1 splicing and translation respectively were used in this chapter in 
order to knockdown hax1 mRNA levels and study the effects on PMN 
number. In humans HAX1 mutations result in SCN as well as severe 
neurodevelopmental delay (Matsubara et al. 2007; Germeshausen et al. 
2008). I have shown that disruption of hax1 expression in the zebrafish 
embryo through MOs leads to a reduced PMN number and delay of 
generalised development. Although it is tempting to speculate that this 
phenotype is hax1 specific, due to insufficient knockdown and factors 
discussed below, it is likely that the developmental delay and reduced 
PMN number are MO off-target effects. 
 
Detection of hax1 by RT-PCR analysis of RNA extracted from hax1 splice 
site MO injected embryos yielded variable results. In some experiments 
gene knockdown was visible however, on others knockdown was poor 
and instead an additional ~2500 bp band was visible. Cloning and 
sequencing of the additional high molecular weight band identified a hax1 
specific amplicon resulting from a splicing abnormality (Fig. 4.13 d.).  
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The RT-PCR detection of the maternal hax1 001 mRNA may explain the 
variable and poor gene knockdown in these studies. There is evidence for 
maternal pre-mRNA in eggs demonstrating that they cannot be blocked 
by splice MOs (Bennett et al. 2007). Some maternal mRNAs can persist 
in the embryo for up to three days (Alexa et al. 2009).  Since the highly 
abundant hax1 001 transcript expresses exon 3 and it has been shown in 
this chapter to be maternally transferred, this demonstrates that the 
splice-blocking MO cannot fully inhibit the hax1 001 expression. Yet, the 
partial disruption of the hax1 mRNA transcript expression leads to 
multiple defects in embryonic development indicating an essential 
embryonic role for the gene. In addition, it also caused a reduction in total 
PMN number. This raised the question as to whether this phenotype is 
hax1 MO specific or a result of off-target effects?  
 
4.10.4 Limitations of using MOs 
Despite the large success rate, there are known limitations of utilising MO 
based gene targeting. One of the main problems with using MOs is that 
they may have off-target effects. This can occur by MO binding and 
disruption of a non-related gene. Although this is not likely, a published 
example of such effects in the zebrafish does exist (Ekker & Larson 
2001). A second source of off-target effects is p53 activation (Robu et al. 
2007). The induction of the p53-dependent cell death pathway leads to 
widespread apoptosis (Robu et al. 2007), neural degeneration 
(Nasevicius & Ekker 2000) and defects in epiboly (Imai & Talbot 2001). 
Some of these effects were visible with the hax1 splice MO. Co-injection 
of MOs with a p53 ATG MO has been shown to rescue the p53-
dependent apoptosis phenotype revealing the true effects of MOs (Robu 
et al. 2007). However, though the co-injection of a p53 ATG MO extended 
the survival of the embryos it did not appear to alleviate the severe 
developmental delay. It also did not have an effect on the reduced total 
PMN number. Although the data are representative of a single 
experiment and so it is not possible to draw any conclusion from the 
results, this may suggest that the hax1 splice MO phenotype specifically 
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inhibits hax1 pre-mRNA splicing and that the neurodevelopmental delay 
and PMN phenotype is specific to hax1 knockdown. In support of this, 
MO targeted to cytochrome c oxidase led to neuronal cell death, which 
was not inhibited by co-injection with a p53 MO (Baden et al. 2007).  
 
The recapitulation of the hax1 phenotype although less marked using the 
ATG MO provides further support for the specificity of the hax1 MO. The 
hax1 ATG MO is likely to inhibit the translation of any maternal mRNA as 
well as zygotic hax1 transcripts. However, the transcript variant 
expression data presented earlier in this chapter shows that alternative 
splicing generates hax1 transcripts with at least three different ATG start 
sites hence only transcripts with the same start site as the full-length hax1 
are likely to be affected by the hax1 ATG MO. This could justify the milder 
effects of the hax1 ATG MO on the developmental delay and reduction in 
PMN number compared to the hax1 splice MO. The lack of a zebrafish 
Hax1 antibody means that it is not possible to assess whether the ATG 
MO has successfully targeted hax1 however, even if it was available it 
would not address whether the noted effects are caused solely by the 
hax1 knockdown. 
 
The most reliable control for a MO is rescue of the phenotype by co-
injection of in vitro transcribed mRNA of the targeted gene (Eisen & Smith 
2008). Contrary to the above findings, attempts to rescue the hax1 splice 
MO induced phenotype by co-injection with hax1 001 mRNA were 
unsuccessful. Co-injection did not prevent the characteristic 
developmental delay or the reduction in the total PMN number. This 
raises a concern about the specificity of the MO. however, due to the 
complex organization of the zebrafish hax1 gene it cannot be ruled out 
that the phenotypic changes in response to the hax1 splice MO injection 
are mediated by the inhibition of transcript variants other than hax1 001. 
On the other hand, this could suggest that full-length zebrafish hax1 
isoform may not play a role in embryonic development or PMN survival 
and homeostasis. A third explanation may be that the capped hax1 001 
mRNA was not functionally active in the injected embryos. In order to test 
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whether hax1 001 mRNA overexpression had an effect in PMN apoptosis 
and in turn demonstrate that the mRNA was functional, uninjected and 
hax1 001 injected Tg(mpx:GFP)i114 embryos at 30 h were treated with 50 
μM pyocyanin in the media for 6 h. Dual staining for the PMN specific Mpx 
(tyramide signal amplification-TSA) and an apoptotic marker (terminal 
deoxynucleotidyl transferase dUTP nick end labelling-TUNEL) revealed 
that the pyocyanin did not have an effect on PMN apoptosis in the 
embryos (data not shown) and therefore it was not possible to determine 
whether the hax1 001 mRNA injection was in fact functional.  
 
Further extensive analysis and characterization of the hax1 mRNA 
variants is required in order to establish the exact isoform specificity of 
the MOs to determine the functional redundancy of the different isoforms. 
Future work could involve further characterization of the hax1 transcript 
expression profile using qPCR. The expression of each isoform could 
also then be tested for maternal transfer. Following this, isoform specific 
MOs could be designed and injected to test their effects on total PMN 
number and embryonic morphology. Attempts to rescue the phenotype 
with mRNA from each isoform could be carried out to test for redundancy 
and isoform specific functions.   
 
4.11 Conclusion 
This work provides novel evidence for the expression of multiple hax1 
transcript variants in the zebrafish embryo with a similar splicing pattern 
to that found in the human. I have shown that full-length hax1 isoform 001 
is ubiquitously expressed supporting a multifunctional role for the gene in 
the zebrafish. Furthermore, I have explored the effects of inhibition of the 
hax1 gene in vivo and shown that this results in decreased total PMN 
number with concomitant developmental delay. I have shown that 
overexpression of hax1 001 did not rescue any of the MO induced 
effects. In conclusion, due to the insufficient hax1 knockdown using the 
splice MO and lack of phenotypic rescue by co-injection with 001 mRNA, 
the reduced total PMN number is likely to be a secondary effect of the 
 187 
delayed development and not a direct effect of the MO. Further work 
utilizing stable knockout zebrafish lines was required to validate these 
findings. The generation of stable hax1 knockout lines and effect on total 
PMN number is described in Chapter 5.  
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5 Results- Creation of hax1 mutant zebrafish 
lines 
The aim of this chapter was to generate zebrafish hax1 knockout lines in 
order to analyse the effect on total PMN number and function and to 
validate the morpholino data presented in Chapter 4. Zinc finger 
nucleases (ZFNs) and transcription activator-like effector nucleases 
(TALENs) are genetically engineered chimeric nucleases designed to 
specifically bind to DNA sequences (Cathomen & Joung 2008; Sander et 
al. 2011; Cermak et al. 2011). These proteins comprise a powerful class 
of tools enabling targeted genetic modification across many different 
species by induction of double stranded DNA breaks, which are repaired 
by the error-prone non-homologous end joining (NHEJ) mechanism 
(Bibikova et al. 2002) (Fig. 5.1). NHEJ generates many different indel 
mutations including frame-shift mutations resulting in inactivation of the 
target gene (Muhlrad & Parker 1994).  
 
ZFNs and TALENs are hybrids of a non-specific DNA cleavage domain 
and a targeting DNA binding domain (Fig. 5.1 b and c.). This chapter 
describes the detailed protocols for generating a hax1 targeting nuclease 
construct, initially by ZFN and subsequently by the newer TALEN 
approach. In both the ZFN and TALEN approach, the hax1 binding 
domains were engineered into generic backbones encoding the FokI 
nuclease domains.  
 
5.1 hax1 targeted mutagenesis using the ZFN context 
dependent assembly (CoDA) approach 
The ZFN CoDA approach was first described by Sander et al. (Sander et 
al. 2011) and is a publicly available platform of reagents and software for 
creating ZFNs. ZFNs function as dimers with each monomer composed 
of an engineered zinc finger (ZF) array (ZF domain) fused to a non-
specific FokI nuclease domain (Kim et al. 1996). ZFN CoDa 
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Figure 5.1 Schematic overview of genomic editing using ZFN and 
TALEN mutagenesis  
a.) Outcome of gene targeting using engineered nucleases (ZFN and 
TALEN). Binding to the target site induces a double stranded mutation. A 
non-homologous error-prone joining mechanism then repairs the DNA break 
introducing indel mutations resulting in gene inactivation (Bibikova et al. 
2002). The structure of a ZFN nuclease (b.) and TALEN (c.). Two 
monomeric molecules are required to bind the target DNA to enable Fok I to 
dimerise and cleave the DNA. Each monomer is composed of a DNA 
binding domain and an FokI nuclease domain. (Cermak et al. 2011; Sander 
et al. 2011). The lengths of the recognition sites and spacer regions are 
shown (nt-nucleotides). 
 190 
entails assembly of three-finger arrays using N and C terminal fingers 
previously identified in other arrays containing a common middle finger 
(F2 unit) (Sander et al. 2011). With each ZF unit specifically binding to 3 
base pairs, a 3-finger array ZFN monomer recognizes 9 base pairs. 
Sander et al. demonstrated that a large archive of N-terminal fingers (F1 
units) and C-terminal fingers (F3 units) positioned adjacent to fixed F2 
units could be utilised to create functionally active ZFNs (Sander et al. 
2011). CoDA increases the probability of engineered ZFN activity by 
taking into consideration the context-dependent effects between adjacent 
fingers (Isalan et al. 1997; Isalan et al. 1998). This approach was used to 
generate a hax1 specific ZFN expression vector and the product was 
then injected into single cell zebrafish embryos in order to create hax1 
mutant zebrafish lines. The ZF units were added as 5’ extensions on 
primers used to amplify generic backbones (pCS2-Flag-ZFP-FokI-DD and 
pCS2-HA-ZFP-FokI-RR) containing the endonuclease FokI.   
 
5.1.1 Generation of a zebrafish hax1 targeting CoDA ZFN 
5.1.1.1 Identification of a CoDA ZFN site in the zebrafish hax1 gene 
The zebrafish hax1 gene sequence, deduced from the Ensembl website, 
was entered into the ZiFiT Targeter sequence window 
(http://zifit.partners.org/ZiFiT/ChoiceMenu.aspx) with exonic regions in 
uppercase and intronic regions in lowercase. The targeter generated five 
CoDA ZFN sites for the hax1 gene, one found at the 5’ of intron 1-2 and 
four target sites located on exon 3. It is necessary to use a CoDA target 
site that is most likely to disrupt the coding region of the genomic 
sequence of the target gene as intronic regions are likely to be spliced out 
and modifications of these regions would have no effect on the mRNA 
stability, protein structure and function. Since the first hax1 CoDA ZFN 
site (ZFN-CHROMOSOME:zv8:19:7484201:7490708:1-SP-5-1) targeted 
intronic sequence of the gene this was not considered a suitable target 
site. The CoDA target site furthest from the 5’ region of exon 3 was 
chosen (Fig. 5.2 a.). Figure 5.2 b. shows the hax1 exon 3 target region 
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with the ZFN binding sites and spacer highlighted. The ZiFiT targeter also 
generated FASTA sequences of the left and right ZF domains. These 
were used to design F1 and F2F3 primers (Fig. 5.3) in order to allow 
addition of the ZF domains to the generic backbones. Two primers were 
generated for each subunit (Appendix 7.13.1). The 3’ end of each primer 
contained 20 complementary bases to the generic backbone to ensure 
annealing and amplification by PCR. An F1 primer contained the F1 unit 
as the 5’ extension whereas an F2F3 primer comprised units F2 and F3 
of the ZF domain at the 5’ end. Both the F1 and F2F3 primers were 
designed with an AgeI restriction site in order to allow digestion with AgeI 
following the PCR. This would then enable self-ligation of the AgeI 
digested plasmids into circular form with ZF units in the correct order. In 
addition the primers also contained 5’ extensions (red) beyond the AgeI 
site (blue) to facilitate the AgeI restriction digest.  
 
5.1.1.2 Preparation of the ZFN generic backbones 
The left and right ZFN backbones (pCS2-Flag-ZFP-FokI-DD and pCS2-
HA- ZFP-FokI-RR) (Meng et al. 2008) were kindly provided by Dr Stone 
Elworthy (Dept. of Biomedical Science, University of Sheffield). Briefly, Dr 
Elworthy prepared the plasmids by linearization with AgeI and PCR 
amplified the linear plasmids using primers LCS2 and goodRCS2 
(Appendix 7.13) excluding the AgeI site from the amplified plasmid 
sequence. A 1 h restriction digest with DpnI followed in order to remove 
the starting plasmid. The plasmids were then gel purified and could be 
used as generic templates for generating CoDA ZFNs using PCR 
amplification with primers containing the specific F1, F2 and F3 zinc 
fingers, generated in section 5.1.1.1. An overview of the hax1 targeting 
ZFN pair assembly is shown in Fig. 5.4.  
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Figure 5.2  Identification of potential CoDA ZFN target sites 
in the zebrafish hax1 gene 
a.) hax1 CoDA targeting output from ZiFiT version 3. The hax1 gene 
sequence was entered into the ZiFiT sequence window following the 
instructions from the website (http://zifit.partners.org/ZiFiT/ChoiceMenu. 
aspx). The chosen ZFN target is indicated by the red box. The ZiFiT Targeter 
software summary of the CoDA zinc finger units shows the 3 bp targets of 
the hax1 specific ZFN pair. b.) A diagram of the left and right zinc finger 
nuclease subunits and the target site in exon 3 of the hax1 gene. Each 
nuclease consists of three zinc fingers (F1-F3) linked to the DNA-cleavage 
domain of FokI. Each finger binds to three consecutive basepairs of the 
DNA. Left and right ZFN subunit binding to this site generates a 5 bp spacer 
region.
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Figure 5.3  Annotation of the ZiFiT FASTA sequence output 
for the left and right ZFN subunits and ZFN primer design 
The ZiFiT targeter sequence output for the Left (a.) and Right (b.) ZF 
domains.  The red arrows indicate the sequence used to generate the ZFN 
F1 and F2F3 primers. The F1 and F2F3 units of each ZF domain are 5' 
extensions of the primers used to anneal and amplify the generic backbone 
plasmids pCS2-Flag-ZFP-FokI-DD (left ZFN subunit) and pCS2-HA-ZFP-
FokI-RR (right ZFN subunit). The ZiFiT Targeter sequence output also 
contains an AgeI restriction site between the F1 and F2F3 fingers 
(overlapping region of the red arrows- ACCGGT). The F1, F2 and F3 units 
are annotated in colours correspond to those used in Fig. 5.2. Yellow arrows 
indicate primer annealing regions on the generic backbones.  
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Figure 5.4  An overview of the assembly of a ZFN pair 
targeting the hax1 gene 
AgeI linearised left (pCS2-Flag-ZFP-FokI-DD) and right (pCS2-HA-ZFP-
FokI-RR) ZFN generic backbones were amplified using the zinc finger units 
(ZFs) as primers. The F1 and F2F3 primers contained an AgeI restriction 
site (light blue) and a 5' extension beyond the AgeI site. Following 
amplification by PCR, the plasmids were subjected to an AgeI restriction 
digest and then allowed to self-ligate. The circular plasmids were 
transformed into competent cells. Purified plasmid preparations were then 
pooled and linearised using the unique restriction site for NotI. The NotI 
linearised plasmids were in vitro transcribed and the ZFN RNA injected into 
singe-cell embryos. The single-cell embryo image was adapted from the 
ZFIN website (http://zfin.org/zf_info/zfbook/stages/figs/fig3.html).     
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5.1.1.3 Addition of zinc fingers to the generic backbones 
In order to verify the amplification of the ZFN generic backbones with the 
F1,F2 and F3 zinc fingers, the PCR products generated from the 
reactions assembled in section 2.2.7.1 (expected size: 5069 base pairs-
bp) were subjected to agarose gel electrophoresis (Fig. 5.5 a.). A band of 
the expected size (~5 kb) was visible in both lanes with the PCR reaction 
amplifying the left ZFN producing a lower intensity band than PCR of the 
right ZFN construct. In order to assess the purification of the ZFN left and 
right plasmid following the generation of sticky ends by an AgeI, 
restriction digest (Section 2.2.7.2), the linearised plasmids were subjected 
to agarose gel electrophoresis. A band of the expected size (~5 kb) was 
visible for each the left and right ZFN encoding plasmids (Fig. 5.5 b.). 
 
Following ZFN plasmid self-ligation and transformation into competent 
cells (Section 2.2.7.3), screening for zinc finger inserts was carried out by 
colony PCR of several well-separated, transformant colonies (Colony 
PCR- Section 2.1.20) using LseqCS2 and RseqCS2 primers (Appendix 
7.13). A band of the expected ~600 bp size was visible in PCR reactions 
from colonies expressing both the left (L1, L8, L9, L10, L12, L14, L16) 
and right ZFN (R1, R3-8) subunits (Fig. 5.6). Colony PCR reactions 
displaying the expected PCR band size (~600 bp) were subjected to 
ExoI-SAP (exonuclease I- shrimp alkaline phosphatase) treatment 
followed by Sanger sequencing using LseqCS2 and RseqCS2 primers. 
Sequencing and bioinformatics analysis was carried out in order to 
examine whether the ZF units had inserted in the predicted order and 
verify the sequence. Blast analysis of the sequencing output of colony 
L12 and R3, which were used for in vitro transcription of the ZFN 
subunits, is shown in Appendix 7.14 (7.14.1 and 7.14.2).   
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Figure 5.5  Addition of zinc fingers to the generic backbone 
a.) The generic backbones were PCR amplified with the F1 and F2F3 
primers. Following purification using a QIAquick PCR clean-up kit and 
elution into 44 μl of water , 2 μl of each PCR product was resolved on a 0.8 
% SeaKem agarose gel and PCR bands were visualised using a UV 
transilluminator. b.) Following a 1 h incubation of the AgeI restriction digest, 
the left and right ZFN encoding plasmids were purified using a QIAquick 
PCR clean-up kit. Purified plasmid DNA was then subjected to agarose gel 
electrophoresis using a 0.8 % SeaKem agarose gel and 10 μl of the eluted 
DNA.
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Figure 5.6  Verification of left and right ZFN subunit ZF 
domains by colony PCR and Sanger sequencing   
a.) Left and right ZFN plasmid transformant colonies were PCR amplified 
using the LseqCS2 and RseqCS2 primers (red arrows). These primers flank 
the region containing the ZF inserts. The sequence shown is of the left ZFN 
subunit analysed using DNASTAR version 10.0 (Lasergene, Germany). b.) 
5 μl of each PCR reaction was resolved on a 1.5 % SeaKem agarose gel 
and PCR bands were visualised using a UV transilluminator. 
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In order to ensure that the FokI DD (left ZFN) and FokI RR (right ZFN) 
nuclease domains also contain the intended sequence, clones with the 
verified zinc finger sequences were further examined by colony PCR and 
Sanger sequencing using LseqFok and RseqFok primers (Appendix 7.13) 
(Fig. 5.7). The PCR products were resolved by agarose gel 
electrophoresis. In order to validate the sequence, the colony PCR 
products of the correct size were Sanger sequenced using the LseqFok 
and RseqFok primers following ExoI-SAP treatment. Blast analysis of the 
FokI domain region from colonies L12 and R3, which were used for in 
vitro transcription of the ZFN subunits, is shown in Appendix 7.14 (7.14.3 
and 7.14.4).   
 
Once it was established that clone L12 (left ZFN subunit) and clone R3 
(right ZFN subunit) contained verified sequences of the zinc finger and 
nuclease domains, a colony of each was used to inoculate a 50 ml 
carbenicillin (50 μg/ml) selective culture and grown O/N at 37 °C with 
shaking. The plasmid DNA was purified using a MIDI prep kit according to 
manufacturer’s protocol (QIAGEN, Valencia, CA). The purified plasmid 
was quantified using a spectrophotometer. The left and right ZFN purified 
plasmids were linearised using NotI restriction enzyme as described in 
section 2.2.7.4. The left and right ZFN linear constructs were resolved by 
agarose gel electrophoresis alongside the circular plasmids (Fig. 5.8). 
The quoted DNA ladder bands were used as a comparator for 
quantitation
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Figure 5.7  Verification of left and right hax1 ZFN subunit ZF 
domains by colony PCR and Sanger sequencing   
a.) Following verification of the ZF domain sequence of left ZFN expressing 
colony L16 and right ZFN expressing colony R3, colony PCR using the 
LseqFok and RseqFok primers was carried out. The L and RseqFok primers 
(brown arrows) flank the region of the ZFN plasmid containing the nuclease 
domain. The sequence shown is of the right ZFN subunit annotated using 
DNASTAR version 10.0 (Lasergene, Germany). b.) The PCR products 
(expected size: 705 bp) were resolved on a 1.5 % SeaKem agarose gel 
electrophoresis using 5 μl of the PCR reaction. PCR products were 
visualised using a UV transilluminator. 
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Figure 5.8  Preparation of hax1 targeting ZFN RNA   
a.) ZFN plasmids from 50 ml carbenicillin cultures were purified using a 
QIAGEN plasmid MIDI kit. 6 μg of each plasmid were pooled and subjected 
to a NotI restriction digest. Following NotI linearisation and purification of the 
plasmids using a QIAquick PCR clean-up kit, 0.5 μl of the left and right ZFN 
plasmid eluates were added to 9.5 μl of loading dye. 1 μl, 3 μl and 6 μl of 
this mixture were loaded alongside NEB 1 kb ladder (volumes from left 1μl, 
2 μl and 5 μl) and left and right ZFN circular constructs on a 0.8 % SeaKem 
agarose gel. 
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5.1.2 Preparation of ZFN capped RNA for microinjection 
In order to assess the quality and purity of the ZFN plasmid RNA 
generated in Section 2.2.7.4, the RNA was subjected to agarose gel 
electrophoresis.  Figure 5.9 shows that a single RNA band was visible in 
the lane loaded with ZFN RNA. 
Fig. 5.9  In vitro transcription of hax1 
targeting ZFN expression vector 
Following in vitro transcription and 
purification, 0.5 μl of the capped RNA was 
resolved on a 0.8 % agarose gel.  
 
 
 
5.1.3 Microinjection of embryos with in vitro transcribed hax1 
targeting ZFN mRNA 
The toxicity of different ZFN RNAs varies greatly (Cornu & Cathomen 
2010) and hence a range of ZFN mRNA doses were injected in order to 
optimize the dose in AB embryos. Single cell embryos were injected with 
various doses of capped RNA. Injected embryos were grown at low 
density (<50 per petri dish) and unfertilized or damaged embryos were 
removed. At 24 hpf, the embryos were inspected to determine the dose of 
mRNA resulting in the vast majority of embryos to be free of toxic effects. 
Embryos injected with ~40 pg (quantified on an agarose gel) of the 
capped RNA generated from section 2.2.7.4 resulted in an appropriate 
30 % rate of deformity 24 hpf (data not shown). 
 
5.1.4 hax1 gene sequence analysis of zebrafish embryos injected 
with ZFN-encoding RNA 
In order to analyse the zebrafish hax1 gene sequence for somatic 
mutations PCR was carried out on pooled genomic DNA (gDNA) 
encompassing the CoDa ZFN target site. The annealing sites of the 
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LHax1ZFN and RHax1ZFN primers (Appendix 7.13) used for the PCR 
along with the ZFN binding site and spacer region are shown in Fig. 5.10 
a. A restriction enzyme site for HpyAV was also identified in the spacer 
region in order to subsequently allow screening of mutants by restriction 
enzyme digest (Fig. 5.10 a.). The PCR product was then either subjected 
to Roche Titanium 454 sequencing or was TOPO cloned and Sanger 
sequenced. Analysis of the ZFN target site through TOPO cloning and 
colony PCR would only determine whether the mutation rate at the ZFN 
target site was more than ~2%.  
 
5.1.4.1 Analysis of zebrafish hax1 ZFN target sequence by TOPO 
cloning and colony PCR 
Genomic DNA from 50 embryos injected with the hax1 targeting CoDA 
ZFN was extracted at 24 hpf as described in section 2.1.24. A single 
microliter of gDNA template and Phusion HF DNA polymerase (section 
2.1.17) were used in a PCR reaction amplifying the hax1 gene region 
containing the exon 3 ZFN target site. In order to assess the amplification 
the PCR product was resolved by agarose gel electrophoresis (Fig. 5.10 
b). A single ~300 bp band was visible in the PCR reaction carried out 
using the gDNA of ZFN injected embryos and the negative PCR control 
was clear. TOPO cloning was carried out using 4 μl of the PCR reaction 
and a Zero Blunt TOPO PCR cloning kit according to manufacturer’s 
protocol. The cloning reaction (2 μl) was then used to transform a vial of 
competent One Shot TOP10 E. coli cells (Invitrogen Life Technologies, 
Carlsbad, CA) according to manufacturer’s instructions. Transformed 
cells were streaked onto ampicillin (50 μg/ml) selective LB agar plates 
and grown overnight (O/N) at 37 °C. On the following morning, 96 well-
separated colonies were picked from the plates and colony PCR (2.1.20) 
was carried out using LHax1ZFN and RHax1ZFN and a 96 well PCR 
plate.
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Figure 5.10 LHax1ZFN and RHax1ZFN primer binding sites  
a.) The LHax1ZFN and RHax1ZFN primers (blue) were designed to span a region of 305 bp with the ZFN target spacer region (yellow) 
in the centre of the sequence. The left and right ZFN subunit binding sites found on exon 3 of the gene (orange) are also shown. The red 
box indicates the recognition site for the restriction enzyme HpyAV. b.) gDNA was extracted from 50 healthy hax1 ZFN injected embryos 
and PCR carried out using the Hax1ZFN primers. PCR product was resolved by agarose gel electrophoresis and visualised using a UV 
transilluminator. A no template control  for the PCR reaction (- PCR) was also included. 
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In order to assess the amplification, PCR products from numerous 
random colonies were resolved by agarose gel electrophoresis. All tested 
colonies contained a PCR band of the expected ~300 bp size (Fig. 5.11 
a.). Following Exo-SAP treatment of the remainders of the PCR reactions, 
each PCR product was Sanger sequenced using LHax1ZFN and 
RHax1ZFN primers. The sequences of the hax1 targeting ZFN injected 
embryos were then compared to the wild type (WT) reference sequence. 
Ape software was used to align 20 sequences at a time. An example of 
the output for the sequences generated from the left (b.) and right (c.) 
ZFN primers are shown in Fig. 5.11. The Sanger sequence analysis using 
both primers revealed that there were no changes detected in the site of 
the ZFN target or the regions flanking the site.  
 
5.1.4.2 Analysis of zebrafish hax1 ZFN target sequence by Roche 
Titanium 454 sequencing 
 In order to analyse the hax1 ZFN target site by Roche Titanium 454 
sequencing and detect mutations at a frequency lower than 2%, gDNA 
was PCR amplified using LHax1ZF454 and RHax1ZF454 primers 
(Appendix 7.13.2), which bind on the same region as those shown in Fig. 
5.9 a but contain a 5’ extension to allow Roche 454 sequencing.  
The remaining PCR product was purified using a QIAquick PCR clean-up 
kit and the purified DNA subjected to PCR amplification using 1 μl of the 
eluted PCR product and the a titanium and b titanium primers (Appendix 
7.13). The component and PCR cycling used were as shown above. This 
was again followed by purification using a QIAquick PCR clean-up kit. 
Following the PCR product purification, amplification of the PCR reactions 
each with the LHax1ZF454 and RHax1ZF454 primers (Fig. 5.12 a.) and 
the a titanium and b titanium primers (Fig. 5.12 b.) was assessed by 
agarose gel electrophoresis using a 2% 1:1 metaphor and SeaKem 
agarose gel. PCR analysis shows that a band of the expected ~400 bp 
size was clearly visible in both Fig. 5.12 a. and Fig. 5.12 b. The resulting 
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Figure 5.11 Analysis of hax1 gDNA from embryos injected with 
hax1 encoding zebrafish RNA by colony PCR and Sanger 
sequencing 
a.) Colonies of competent cells transformed with the hax1 fragment 
generated using the Hax1ZFN primers were selected and colony PCR 
carried out. 96 colonies were picked in total. 5 μl of PCR product from 18 
randomly chosen colonies were resolved by agarose gel electrophoresis. 
Bands were visualised using a UV transilluminator.  Following ExoI-SAP 
treatment, the PCR products were Sanger sequenced with LHax1ZFN (b.) 
and RHax1ZFN (c.) primers. Sequencing traces were analysed using Ape 
software. Sanger sequencing did not reveal any changes in the hax1 ZFN 
target region. The top sequence in b. and c. represents the WT reference 
sequence. The spacer region is highlighted in yellow (b.) and green (c.). 
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Figure 5.12 Preparation of the hax1 ZFN target sequence and 
analysis by Roche Titanium 454 sequencing   
a.) Genomic DNA extracted from 50 healthy hax1 ZFN injected embryos 
was PCR amplified with L and RHax1ZF454 primers (gDNA). 5 μl of the 
PCR product were resolved on a 2% 1:1 metaphor and SeaKem agarose 
gel and visualised using a UV transilluminator. b.) The remainder of the PCR 
product was purified using a QIAquick PCR clean-up kit (with the guanidine 
HCl step) and eluted with 300 μl of water. Following PCR amplification using 
atitanium and btitanium primers, the PCR product was once again subjected 
to purification using a QIAquick PCR clean-up kit (with the guanidine HCl 
step) and elution into 30 μl of water. The purified PCR product (gDNA) was 
then subjected to agarose gel electrophoresis. c.) Frequencies and 
sequences of changes in the hax1 ZFN target site of ZFN RNA 
microinjected embryos. The wild type reference sequence (orange) with the 
spacer region highlighted in green is also included. 
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amplicon from PCR using the a titanium and b titanium primers was 
subsequently subjected to Roche Titanium 454 sequencing. Analysis of 
the Roche Titanium 454 sequencing showed that out of 4938 reads 
received, 208 contained differences in the target sequence (Fig. 5.12 c.) 
resulting in a mutation frequency of 4.2%. Most of these differences were 
found in the region encompassing the spacer and ZF binding region. The 
sequence modifications were mostly single base changes and included 
insertion of a single A or T nucleotide and substitution of a T with C 
nucleotide. There were no large multiple base deletions or insertions 
detected by the Roche 454 sequencing. The full Roche 454 amplicon 
analysis is shown in Appendix 7.15. Since only a few of these mutations 
could be detected by Roche 454 sequencing, this method was unlikely to 
successfully generate knockout mutants and therefore, an alternative 
method using targeted transcription activator-like effector nucleases 
(TALENs) was utilised.  
 
5.2 hax1 targeted mutagenesis using a transcription 
activator-like effector nuclease (TALEN) 
Transcription activator-like effector nucleases are a relatively new class of 
specific DNA binding proteins formed by a fusion between TALEN 
activator-like TAL effectors of the plant pathogenic bacteria of the genus 
Xanthomonas spp. to the FokI nuclease (Christian et al. 2010). The 
native function of TAL effectors is to directly modulate host gene 
expression (Bogdanove et al. 2010; Christian et al. 2010). TALEN 
specificity is determined by a central domain comprising 12-27 tandem 
repeats of 33-35 amino acids (aa) followed by a single truncated repeat of 
20 amino acids (Boch & Bonas 2010). The amino acid positions 12 and 
13 in each repeat known as the repeat variable di-residue (RVD) specify 
the target nucleotide. The Cermak et al. TALEN design is based on the 
use of four common RVDs HD, NI, NG and NN, which most frequently 
associate with nucleotides Cytosine, Adenine, Thymine and Guanine 
respectively (Cermak et al. 2011).  
 208 
Multiple design scaffolds for TALEN assembly have been described 
differing in parameters including the spacer length, repeat array length 
and the base preference preceding the target site on the 5’ end (Cermak 
et al. 2011; Miller et al. 2011; Li et al. 2011). TALEN assembly techniques 
also differ in the N and C terminus of the TALEN protein (Miller et al. 
2011). The Golden Gate method described by Cermak et al. (Cermak et 
al. 2011) was used for the assembly of a hax1 targeting TALE nuclease. 
Golden gate cloning utilises Type IIS restriction endonucleases, which 
cleave DNA at a defined distance from their recognition site to create 
unique 4 bp overhangs. This allows digestion and ligation of multiple 
constructs in the same reaction (Engler et al. 2009).  
 
The set of Golden Gate TALEN assembly plasmids required for the 
construction of the TAL array is publicly available from the Addgene 
website (https://www.addgene.org). MIDI preparations of the plasmids at 
the desired working concentration were kindly provided by Dr Freek Van 
Eeden (Dept. of Biomedical Sciences). Each tandem repeat (module) 
containing a specific RVD is encoded by a single plasmid (Cermak et al. 
2011). Cermak et al. utilised the TypeIIS restriction enzyme BsaI to 
initially excise from the plasmids and ligate to one another the first ten 
modules containing the RVD sequences. In the same reaction the RVD 
modules were cloned into an array plasmid pFUS_A (Cermak et al. 
2011). Remaining modules are cloned in the same way into other 
specified array plasmids depending on the number of RVD repeats. This 
is carried out for both the left and right TALEN subunits. Esp3I digestion 
of the array plasmids, a plasmid containing the last repeat and the 
destination vector in a second reaction allows ligation of the RVD and 
assemble in the correct order (Cermak et al. 2011). 
 
 The following sections describe the design and construction 
methodology of a hax1 targeting TALE nuclease using the pCAG-T7-
TALEN(Sangamo) destination vector . To date, there are no published 
data describing the use of this generic TALEN backbone in successful 
TALEN mutagenesis approaches. Sequence analysis of the induced 
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mutations and preliminary results on the effects of the mutations are also 
included. 
 
5.2.1 Construction of a hax1 targeting TALE nuclease  
5.2.1.1 Identification of a TALEN site in the zebrafish hax1 gene 
It has previously been shown that HAX1 human mutations affecting the 5’ 
region of exon 2 result exclusively in a neutropenic phenotype whereas 
individuals harbouring mutations in the 3’ region of the exon in addition to 
neutropenia also exhibit neurological symptoms (Germeshausen et al. 
2008). Due to the TALEN technique offering more flexibility with the target 
site than the CoDA ZFN approach, it was possible to design a TALE 
nuclease targeting the 5’ region of exon 2 of the zebrafish hax1 gene. In 
order to allow quick and easy screening of TALEN induced mutations, the 
sequence of the hax1 gene was initially deduced from the Ensembl 
website and inserted into the NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2/) for enzyme restriction analysis. A 
restriction site for BspHI in the 5’ region of exon 2 was identified. The 
sequence containing the BspHI site and fifty bases upstream and 
downstream (Appendix 7.16) of the site was entered into the on-line tool 
TALEN targeter 2.0 (https://tale-nt.cac.cornell.edu/node/add/talen-old), 
which scanned for TALEN sites based on the TALEN design guidelines. 
The BspHI site is found a few bases downstream of the conserved 
putative acid box identified in Chapter 4, which may play a functional role.  
Firstly, the spacer region length was set from a minimum 16 bp to a 
maximum of 21 bp. Secondly, the minimum repeat array length setting 
was set to 15 bp and the maximum to 21 bp. Screenshots of the TALEN 
Targeter tool and the output for the chosen hax1 specific TALEN pair are 
shown in Fig. 5.13. All of the boxes shown in Fig. 5.13 a. were un-ticked 
except the last box stating that a T was required at position N. The site 
shown in Fig 5.13 b. was used for the TALEN design described in this 
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Figure 5.13 Identification of hax1 TALEN site using TALEN Targeter 
2.0 
a.) A screenshot showing the TALEN target DNA sequence input window 
and the design parameters available. b.) A small section of the targeter 
output for the human hax1 exon 2 showing the target site. The 
corresponding Repeat Variable Di-residues (RVDs) and the restriction sites 
found in the target region are also included. 
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chapter. The hax1 specific TALEN pair comprises a left subunit binding to 
15 base pairs and a right subunit recognising 17 base pairs. Binding of 
the TALEN pair to the target site produces a spacer region of 19 base 
pairs. The left and right RVD sequences and the recognition site of the 
hax1 exon2 specific TALEN are shown in Appendix 7.16.  Figure 5.13 b. 
shows the TALEN target site containing the BspHI within the spacer 
region. PCR primers were designed to amplify a sequence encompassing 
the spacer region, ensuring that the overlapping BspHI restriction site 
was unique in the amplicon (Fig. 5.14).  
 
the TALEN pair to the target site produces a spacer region of 19 base 
pairs. The left and right RVD sequences and the recognition site of the 
hax1 exon2 specific TALEN are shown in Appendix 7.16.  Figure 5.13 b. 
shows the TALEN target site containing the BspHI within the spacer 
region. PCR primers were designed to amplify a sequence encompassing 
the spacer region, ensuring that the overlapping BspHI restriction site 
was unique in the amplicon (Fig. 5.14).  
 
5.2.1.2 hax1 exon 2 specific Golden Gate TALEN assembly stage I 
In the first Golden Gate reaction, the left and right hax1 TALEN subunits 
were each initially compiled into two halves (left TALEN part A and B, and 
right TALEN part A and B). The reaction components are shown in 
section 2.2.8.2. An outline of the whole assembly process is shown in Fig. 
5.15. Following the assembly of the two parts of each TALEN, the 
resulting plasmids were subjected to a double restriction digest using 
NheI and XbaI. The digestion products of each of the four reactions 
carried out in section 2.2.8.2 were resolved by agarose gel 
electrophoresis (Fig. 5.16). The expected band sizes 266 bp, 2132 bp 
and 500 bp-1100 bp depending on the RVD module number were visible 
in all four lanes. The sizes of the left and right part B plasmids are 
consistent with the number of RVD modules cloned into the array plasmid 
(left Part B- 4 RVDs and right Part B- 6 RVDs). This indicated that the 
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Figure 5.14 LHax1TalRE and RHax1TalRE primer binding sites  
a.) The LHax1TalRE and RHax1TalRE primers (blue) were designed to span a region of 534 bp with the TALEN target spacer region in 
the centre of the sequence. The left (green) and right (yellow) TALEN subunit binding sites on exon 2 of the gene and the amplicon 
unique BspHI restriction site overlapping the spacer region are also shown. Non-highlighted region represents intronic sequence. 
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Figure 5.15 hax1 exon 2 specific Golden Gate TALEN assembly 
a.) Assembly process of the left hax1 specific TALEN. The RVD modules (HD- orange, NI-green, NG-red, NN-yellow) required to 
generate the left TAL domain were initially cloned into an array plasmid using BsaI digestion and self ligation of the RVD sequences to 
one another and the array plasmid. The first 10 modules were inserted into pFUS_A (Part A) and the remaining 4 into pFUS_B (Part B). 
In the second assembly reaction, the two array plasmids and a final plasmid containing the last half repeat (LRNG) were cloned into the 
generic backbone pCAG-T7-TALEN (Sangamo). The generic backbone contains a nuclear localisation signal (NLS) and the FokI 
nuclease domain downstream of the RVD sequence (not shown). The N and C terminal of the subunit are also shown. 
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Figure 5.15 hax1 exon 2 specific Golden Gate TALEN assembly 
 
b.) Assembly process of the right hax1 specific TALEN. The RVD modules (HD- orange, NI-green, NG-red, NN-yellow) required to 
generate the left TAL domain were initially cloned into an array plasmid using BsaI digestion and self ligation of the RVD sequences to 
one another and the array plasmid. The first 10 modules were inserted into pFUS_A (Part  A) and the remaining 6 into pFUS_B (Part B). 
In the second assembly reaction, the two array plasmids and a final plasmid containing the last half repeat (LRNG) were cloned into the 
generic backbone pCAG-T7-TALEN (Sangamo). The generic backbone contains a nuclear localisation signal (NLS) and the FokI 
nuclease domain downstream of the RVD sequence (not shown). The N and C terminal of the subunit are also shown. 
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Figure 5.16 Assembly stage I: Analysis of diagnostic digests of 
hax1 specific TALEN constructs 
Part A and B purified plasmid DNA was subjected to an XbaI and NheI 
double digest. Following incubation at 37 °C, the digestion products were 
resolved on a 1.1 % SeaKem agarose gel and bands were visualised using 
a UV transilluminator. The sizes of the digestion products are indicated on 
the right. Note not all ladder band sizes are shown. 
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plasmids were very likely to have assembled correctly and therefore, 
were used in the next Golden Gate reaction. 
 
5.2.1.2 hax1 exon 2 specific Golden Gate TALEN assembly stage II 
In order to assemble the RVD modules contained in part A and B of each 
subunit into a single plasmid containing the FokI nuclease domain, the 
purified array plasmids pFUS_A and pFUS_B consisting of the RVD 
modules were subjected to a second Golden Gate reaction. A map of the 
generic backbone (pCAGT7-TALEN Sangamo) is shown in Appendix 
7.18. 
 
In order to assess the second stage assembly, the hax1 specific left and 
right TALEN encoding plasmids generated in section 2.2.8.3 were 
subjected to a diagnostic digest with BamHI and XbaI restriction 
enzymes. The digestion components are shown in Section 2.2.8.4. In 
order to assess the ligation from the second golden gate reaction and the 
linearization (Section 2.2.8.5), the BamHI XbaI diagnostic and purified 
NotI digests were subjected to agarose gel electrophoresis (Fig 5.17). 
Bam HI and XbaI digestion was expected to produce two bands of size 
5322 bp and 2207 bp for the left TALEN subunit encoding construct and 
5322 and 2411 for the right TALEN subunit encoding plasmid. The 
agarose gel in Fig 5.17 a. shows that the BamHI XbaI digestion reaction 
yielded the predicted band sizes for both subunit-encoding plasmids.  
Agarose gel resolution of the Not I linearization products also shows a 
band corresponding to the expected size (~8 kb) (Fig. 5.17 b.). The exact 
sizes of the plasmids containing the left and right TALEN subunits were 
7529 and 7733 bp respectively. The relative ladder band intensities were 
used to quantify the ~8 kb plasmid DNA. 
 
In order to analyse the sequence of the purified plasmid DNA, 20 μl of 
100 ng/μl of each subunit encoding plasmid from the MIDI preparations 
was sent for Sanger sequencing by TAL_R2 and SeqTALEN_5.1 primers 
(Appendix 7.19). The sequence was analysed by SeqBuilder (Lasergene 
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Figure 5.17 Assembly stage II: Analysis of diagnostic digests and 
linearisation of hax1 specific TALEN plasmids 
a.) The purified left (L) and right (R) hax1 specific TALEN constructs were 
subjected to an XbaI BamHI double digest and the reaction products were 
resolved on a 0.7 SeaKem agarose gel alongside a Generuler 1 kb DNA 
ladder. Note not all ladder band sizes are shown. b.) The left and right 
TALEN subunit encoding plasmids were pooled into a linearization reaction 
using NotI restriction enzyme. The products were subjected to agarose gel 
electrophoresis using a 0.7 % agarose gel. A single μl of the reaction was 
added to 9 μl of loading dye. 1 μl, 3 μl and 6 μl (lanes 4-6) were then loaded 
onto the gel alongside 5,2 and 1 μl (lanes 1-3) of Hyperladder I. Plasmid 
bands were visualised using a UV transilluminator.  
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10, DNA Star). The Find function was used to examine whether the 
Sanger sequence matched the expected plasmid sequence. The TAL_R2 
and SeqTALEN_5.1 primer annealing sites on the left and right hax1 
specific TALEN encoding vectors, annotated in SeqBuilder, are shown in 
Appendix 7.20.  Sanger sequencing confirmed that the RVD repeats for 
the left and right subunits had assembled in the correct order and 
validated the sequence at these sites. 
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5.2.2 Preparation of hax1 exon 2 targeting TALEN RNA for 
microinjection 
In order to assess the transcription and purification processes described 
in Section 2.2.8.6, the RNA was subjected to agarose gel electrophoresis.   
 
Fig. 5.18 In vitro transcription of hax1 targeting 
left and right TALEN subunit expression vectors 
Following in vitro transcription and purification, 0.5 μl 
of the capped RNA was resolved on a 0.7 % agarose 
gel. Note not all ladder band sizes are shown.  
 
5.2.3 Microinjection of Tg(mpx:GFP)i114 embryos with TALEN 
encoding RNA 
On the morning of injection fresh injection solution was prepared by 
adding 3.5 μl TALEN RNA to 0.5 μl of 0.5 % phenol red. Two doses of the 
solution were injected at the single cell stage 0.5 nl or 1 nl per embryo in 
order to test the effect of the dose of the TALEN RNA on toxicity. Injected 
embryos were grown at low density (<50 per petri dish) and unfertilized, 
non-viable or damaged embryos were removed. At 24 hpf, uninjected and 
TALEN RNA injected embryos were inspected for toxic effects induces by 
the TALEN encoding RNA. At both doses, very few of the TALEN RNA 
injected embryos exhibited morphological defects at 24 hpf (data not 
shown).  
 
5.2.4 Detection of somatic mutations in hax1 specific TALEN mRNA 
microinjected Tg(mpx:GFP)i114 embryos 
In order to determine whether the hax1 specific TALEN generated in 
section 5.2.1 was functionally active and thus was likely to generate indel 
mutations resulting in the inactivation of the zebrafish hax1 gene, the 
region spanning the hax1 TALEN target was amplified using the L and R 
Hax1TalRE primers (Appendix 7.19) and a BspHI restriction digest 
carried out on the PCR product. As described in section 5.2.1.1 the BspHI 
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unique restriction site in the amplicon was used to screen for any TALEN 
induced indel mutations as the restriction site for the enzyme overlaps the 
hax1 specific TALEN spacer region. Amplicons from non-mutated 
embryos would contain an intact BspHI restriction site and would undergo 
complete digestion with the BspHI enzyme (Fig. 19 a.). TALEN induced 
mutation in the spacer region would result in the loss of the BspHI 
restriction site and therefore lead to resistance to BspHI cleavage. In 
order to ensure complete digestion of the hax1 PCR products, all BspHI 
restriction digests were incubated at 37 °C for 6 h. 
 
Genomic DNA was extracted from four individual control uninjected 
embryos, four individual hax1 specific TALEN injected embryos (section 
2.1.23), a pool of 20 uninjected and 20 TALEN injected embryos (section 
2.1.24). The gDNA was subjected to PCR amplification using the L and R 
Hax1TalRE primers and Phusion DNA polymerase (2.1.17). BspHI 
digestion was carried out by adding 1 μl of BspHI enzyme to the PCR 
reaction. Figure 5.19 a. illustrates the expected outcome of the digest 
from non-mutated and mutated hax1 target region. Pre- and post- BspHI 
cleavage products were subjected to agarose gel electrophoresis and 
visualised using a UV transilluminator (Fig. 5.19 b.). In order to test 
whether the TALEN mutation resulted in embryonic dysmorphism, gDNA 
was also extracted from three individual dysmorphic embryos and 
subjected to PCR analysis followed by the BspHI digest (Fig. 5.19 c.). 
Though the control uninjected embryo PCR products were completely 
cleaved by the BspHI enzyme, BspHI digestion of all TALEN injected 
embryos resulted in incomplete cleavage.  
 
5.2.5 Identification of founder mutants harbouring hax1 germline 
transmitted mutations  
Once it was established that the hax1 specific TALEN had successfully 
cleaved the hax1 zebrafish gene, about 120 TALEN injected embryos 
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Figure 5.19 Identification of somatic mutations in Tg(mpx:GFP)i114 
embryos injected with hax1 specific TALEN RNA 
a.) Restriction digest analysis of the zebrafish hax1 gene. The PCR product 
amplified using L and R Hax1TalRE primers yields an amplicon harbouring a 
unique BspHI restriction site. BspHI digestion of non-mutated hax1 leads to 
complete digestion of the PCR product with the BspHI enzyme. Mutated 
hax1 loses its BspHI restriction site resulting in reduced or no cleavage by 
the BspHI enzyme. b.) gDNA was extracted from four (lane 1-4) individual 
uninjected, four (1-4) hax1 TALEN RNA injected embryos, a pool of 20 
uninjected embryos (uninj pool) and a pool of 20 TALEN injected embryos 
(TALEN pool). PCR was carried out using L and R Hax1TalRE primers. 5 μl 
of the PCR reaction were subjected to agarose gel electrophoresis. The 
remaining PCR product was then subjected to a BspHI restriction digest. c.) 
gDNA was also extracted from three dysmorphic TALEN RNA injected 
embryos and subjected to PCR analysis with L and R Hax1TalRE primers 
followed by a BspHI digest. 
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were raised to adulthood. A schematic outline for generating hax1 
homozygous mutants is shown in Fig. 5.20. In order to screen for 
germline-transmitted mutations, potential adult hax1 TALEN founders 
were out-crossed individually to WT nacre zebrafish. The resulting F1 
progeny embryos from each individual pair were then subjected to gDNA 
extraction at 48-72 hpf. Following PCR using the L and R Hax1TalRE 
primers and Phusion DNA polymerase, 1 μl of BspHI enzyme was added 
to each PCR reaction. From each potential founder, gDNA was extracted 
from eight pools of 3 embryos. gDNA extraction was carried out in a 96 
well PCR plate and 50 μl of embryos digestion buffer (10 mM Tris Hcl 
pH8, 1 mM EDTA, 0.3 % Tween-20, 0.3 % NP-40) added to each pool of 
3 embryos. Following a 10 min incubation at 98 °C, the embryos were 
transferred to ice and 4 μl of Proteinase K (25 mg/ml) were added. The 
embryos were then incubated for a further 3 h at 55 °C followed by a 10 
min incubation at 98 °C. The gDNA was diluted with 100 μl of water and 
cell debris was pelleted by centrifugation at 14000 g at 4 °C for 30 min.  
A Phusion DNA polymerase master mix was generated as described in 
section 2.1.17 and PCR carried out using 1.5 μl of the gDNA and L and R 
Hax1TalRE primers. Following incubation with 0.5 μl of BspHI restriction 
enzyme, digestion products were resolved by agarose gel 
electrophoresis. Representative gel images taken using a UV 
transilluminator are shown in Fig. 5.21. BspHI digested hax1 PCR 
products from fish with no mutations or somatic mutations underwent 
complete digestion (Fig. 5.21a.) whereas BspHI restriction analysis of 
gDNA from fish with germline-transmitted mutations showed partially 
resistance to BspHI cleavage (Fig. 5.21 b-d). The higher the number of 
pools with partially digested PCR product indicated a better mutation 
transmission rate (e.g. Fig. 5.21 d.).    
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Figure 5.20 Schematic outline of zebrafish hax1 specific TALEN 
mutagenesis 
TALEN RNA was injected into Tg(mpx:GFP)i114 single cell embryos. The 
injected embryos were raised to adulthood. The TALEN injected fish were 
then out-crossed with wild type nacre fish to generate heterozygous F1 
germline mutants. In-crossing of heterozygous siblings from the F1 
generation resulted in homozygosity in the F2 generation. Mating of the F2 
generation would lead to an F3 generation of mutants deprived of any 
maternal hax1 mRNA (maternal mutants). 
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Figure 5.21 Identification of germline mutants (founders) by 
restriction digest analysis 
Adult TALEN fish were out-crossed to the wild type nacre strain. Following a 
72 h incubation of the offspring, gDNA was extracted from 8 pools of three 
embryos (lanes 1-8) from each potential founder. The gDNA was then 
subjected to PCR using L and R Hax1TalRE primers. The PCR product was 
digested using BspHI restriction enzyme and digestion products were 
resolved on a 1.8 % agarose gel. Representative digests from progeny of 
TALEN injected fish with (a.) no germline mutation and three founders (b-d) 
are shown. Also shown are lanes containing NEB 100 DNA ladder. 
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5.2.6  Screening for F1 mutants by PCR and BspHI analysis 
Once numerous F0 fish that transmitted hax1 mutations through the 
germline were identified, their 30-60 embryos from their F1 progeny 
(section5.2.4) were raised to adulthood. In order to identify F1 
heterozygous mutants and determine the exact sequence of the 
mutations, anaesthetised F1 fish were screened by isolating gDNA from 
caudal fin clippings at 2-3 months post fertilisation (Fig. 5.22 a.). A fin clip 
from each individual F1 fish was placed in a 96 well PCR plate and 
residual liquid removed using a closed Pasteur pipette. gDNA was 
extracted by addition of 50 μl of embryos digestion buffer (10 mM Tris Hcl 
pH8, 1 mM EDTA, 0.3 % Tween-20, 0.3 % NP-40) followed by a 10 min 
incubation at 98 °C. The plate was then transferred to ice and 4 μl of 
Proteinase K (25 mg/ml) were added to fin clip. This was followed by 
incubation for a further 3 h at 55 °C followed by a 10 min incubation at 98 
°C. The gDNA was diluted with 100 μl of water and cell debris was 
pelleted by centrifugation at 14000 g at 4 °C for 30 min. following PCR 
amplification as described in section 2.1.17 using 0.5 μl of the gDNA and 
L and R Hax1TalRE primers, 0.5 μl of BspHI restriction enzyme was 
added to each PCR reaction, digestion products were resolved by 
agarose gel electrophoresis. A representative gel image of PCR and 
BspHI analysis of F1 fin clip gDNA is shown in Fig. 5.22 a.  
 
Heterozygous hax1 mutants were partially resistant to BspHI cleavage. 
Sanger sequencing of PCR products from caudal fin clips of 
heterozygous hax1 mutants revealed numerous changes in the hax1 
target sequence (Fig. 5.22 b.). Regions of the sequencing traces 
containing double peaks were composed of WT and modified sequence. 
The sequencing traces from each individual heterozygous mutant were 
decoded. This revealed four main different TALEN induced changes in 
the hax1 target sequence (Fig. 5.22). These were all deletion mutations 
termed Δ1-4. 
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Figure 5.22 Genotyping of the F1 generation by BspHI restriction 
digest and sequence analysis of TALEN induced germline 
transmitted mutations 
a.) Adult F1 zebrafish resulting from the Tg(mpx:GFP)i114 nacre outcross 
were fin clipped and gDNA extracted. Following PCR using L and R 
hax1TalRE primers, the PCR products were subjected to a BspHI restriction 
digest and digests analysed by agarose gel electrophoresis using a 1.8 % 
agarose gel. A representative gel image is shown. Each lane represents a 
BspHI digest of gDNA from the fin-clip of a single fish. Heterozygous mutant 
PCR product is indicated by red numbering of lanes. b.) PCR product from 
each individually genotyped heterozygous mutant was subjected to Sanger 
sequencing. Representative sequencing traces from PCR samples of a 
hax1 WT fish and four mutant fish (harbouring mutations termed changes 1-
4, Δ1-4) are shown. The highlighted nucleotide region (pink) on the WT 
sequencing trace indicates the BspHI restriction site (TCATGA). 
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Figure 5.23 Sequence analysis hax1 heterozygous F1 mutants 
The nucleotide sequence of each of the 1-4 different indel mutations (Δ1- Δ4) in the heterozygous F1 mutants was deciphered by reading 
the nucleotides from each double peak from the sequencing traces. Mutant sequences were then compared to the WT hax1 sequence 
using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). The BspHI restriction site is also shown.  
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In silico expression of each mutant gene sequence using the Hax1 001 
isoform ATG site (Fig. 5.24) showed that the putative protein sequences 
were likely to contain numerous premature stop codons with the 
exception of Δ1 which would result in the deletion of 4 amino acids 
(amino acids 30-33) but otherwise an intact protein sequence. Mutations 
Δ2 and Δ4 (Fig. 5.24 b. and d.) occurred in the same region of the DNA 
and would result in the expression of almost identical putative hax1 001 
proteins with numerous premature stop codons in the sequence.  
 
 5.2.7  Phenotypic analyses of heterozygous and homozygous F2 
mutants 
In order to permit phenotypic analysis of hax1 mutant F2 embryos 
generated from a tg(mpx:GFP)i114; nacre in-cross, F2 embryos were 
subjected to gDNA extraction, PCR using L and R Hax1TalRE primers and 1 
μl of gDNA followed by BspHI cleavage as described in section 2.1.23 and 
2.1.17. In addition to embryos with GFP +ve PMN the in-cross would also 
generate embryos lacking a GFP signal in PMN cells (GFP -ve). In order to 
test whether the lack of GFP signal is a direct result of the in-cross or due to 
the lack of PMN in the embryos, gDNA was extracted from GFP +ve and 
GFP -ve individual embryos. Analysis of BspHI digestion product by agarose 
gel electrophoresis shows that the TALEN induced mutation Δ1 does not 
result in embryos with GFP -ve PMN as both GFP +ve and GFP -ve 
embryos harbour WT hax1, heterozygous and homozygous hax1 Δ1 
mutations (Fig. 5.25 a. and b.). Similar observations were made for hax1 
Δ2, Δ3 and Δ4 mutants (data not shown). The genotyping of the 
homozygous F2 hax1 mutants revealed that the L and R Hax1TalenRE 
primers occasionally produced two additional bands at ~350 bp and ~ 
200 bp which could result in incorrect genotyping of embryos and adult 
fish. A second pair of hax1 TALEN target region specific primers termed L 
and R Hax1TalenRE(01) (Appendix 7.19) was designed generating an 
amplicon of 367 bp. BspHI digestion of this resulted in two bands of 199 
bp and 168 bp (Fig. 5.25 c.). Fig. 5.25 c. shows that amplification of the 
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Figure 5.24 The effect of TALEN induced hax1 mutations on the 
putative hax1 001 protein sequence 
The hax1 genomic DNA sequences generated from the sequencing traces 
of the mutant heterozygous fish containing Δ1 (a.) and Δ2 (b.) were in silico 
expressed using the online Expasy translate tool (http://web.expasy.org/ 
translate/). The generated putative mutant sequences (aberrant) were 
compared to the wild type (WT) hax1 001 sequence using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). An asterisk within the amino acid 
sequence denotes a stop codon. 
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Figure 5.24 The effect of TALEN induced hax1 mutations on the 
putative hax1 001 protein sequence 
The hax1 genomic DNA sequences generated from the sequencing traces 
of the mutant heterozygous fish containing Δ3 (c.) and Δ4 (d.) were in silico 
expressed using the online Expasy translate tool (http://web.expasy.org/ 
translate/). The generated putative mutant sequences (aberrant) were 
compared to the wild type (WT) hax1 001 sequence using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). An asterisk within the amino acid 
sequence denotes a stop codon. 
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Figure 5.25 Analysis of F2 embryos generated from hax1 
heterozygous mutant incrosses using PCR and BspHI restriction 
digestion 
Heterozygous F1 mutants were incrossed. Each F2 embryo was lysed and 
gDNA extracted at 72 hpf. PCR was carried out using L and R Hax1TalRE 
primers and PCR products were subjected to a BspHI digest. The digestion 
products were resolved by agarose gel electrophoresis. Representative gel 
images are shown. Lanes containing homozygous (red), heterozygous 
(black) and WT (green) embryo PCR products  are colour coded. Restriction 
digest analysis was carried out in GFP +ve (a.) and GFP -ve PMN embryos 
(b.). Note not all NEB 100 bp ladder band sizes are shown. c.) PCR and 
BspHI restriction digest analysis using L and R Hax1TalRE(2) primers. gDNA 
was extracted from single embryos at 72 hpf. Following BspHI digestion of 
the amplicon, digestion products were resolved by agarose gel (1.8 %) 
electrophoresis. d.) Analysis of hax1 F2 hax1 Δ2/ Δ4 mutants fin clip hax1 
gDNA by Sanger sequencing. The arrow indicates the location of the A 
nucleotide.
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hax1 gene using the L and R Hax1TalenRE(1) primers did not result in 
the appearance of any additional bands. From hereon, genotyping was 
carried out using the L and R Hax1TalenRE(1). Sequencing of the 
homozygous adult zebrafish fin clip gDNA using these primers validated 
the homozygous mutant sequences (Fig. 5.25 d.). 
 
5.2.7.1 The effect of the hax1 Δ1 mutation on PMN number   
In order to investigate the effect of the hax1 Δ1 mutation on total embryo 
PMN number, a pair of heterozygous hax1 Δ1 tg(mpx:GFP)i114; nacre 
fish were in-crossed and the resulting F2 progeny visualised under a 2x 
objective on a Nikon Eclipse TE2000U inverted microscope. Micrographs 
of embryos with GFP labeled PMN were taken at 48 and 72 hpf and PMN 
counted at the relevant time point (Fig. 5.26 a. and b.). In comparison to 
the WT control and heterozygous Δ1 mutants, homozygous Δ1 mutations 
did not appear to have the expected negative effect on the PMN number 
at either 48 and 72 hpf. There also does not appear to be a major 
difference between the groups in the increase in PMN number from 48 to 
72 hpf (Fig. 5.26 c.).  
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Figure 5.26 The effect of the homozygous hax1 Δ1 mutation on 
PMN number   
F2 embryos generated from a single incross of a pair of heterozygous 
hax1 Δ1 mutants were sorted into GFP +ve and GFP -ve groups. 
Micrographs of GFP +ve embryos were taken using a 2x objective on a 
Nikon Eclipse TE2000U inverted microscope. Total PMN counts were 
carried out on images taken using the GFP channel. PMN were counted 
from 23 embryos at 48 (a.) and 72 (b.) hpf. The increase in PMN number 
from 48 to 72 hpf was also calculated and is shown (c.). Bars represent 
mean number of PMN. Following this, each individual embryo was 
genotyped by PCR and BspHI restriction digest as shown in Fig. 5.25. 
PMN counts from WT: n=4, het: n=10, hax1 Δ1/ Δ1: n=9, performed as a 
single experiment, were analysed using a one way ANOVA with Bonferroni's 
post test (ns- indicates not significant). 
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5.2.7.2 The effect of the homozygous hax1 Δ2/Δ4 mutation on PMN 
number   
In order to assess the effect of the hax1 Δ2/ Δ4 mutation on total embryo 
PMN number, a heterozygous hax1 Δ2 tg(mpx:GFP)i114; nacre fish was 
crossed with a heterozygous Δ4 tg(mpx:GFP)i114; nacre. During the course 
of these studies, it was not possible to generate true Δ2 and Δ4 mutants a 
result of a gender skew in the Δ2 and Δ4 heterozygous F1 mutant 
populations however, the two mutations differed only by three nucleotides 
and were located in the same region. The hax1 Δ2/Δ4 F2 progeny 
embryos were visualised under a 2x objective on a Nikon Eclipse TE2000U 
inverted microscope (Fig. 5.27 a.). Homozygous hax1 Δ2/Δ4 had normal 
morphology when compared to hax1 WT tg(mpx:GFP)i114 embryos. The 
total number of PMN was counted from GFP +ve embryos at 48 and 72 hpf. 
Although the number of WT embryos was low there appeared to be no 
major differences in the total PMN numbers between any of the WT 
embryos, heterozygous (hax1 Δ2 or hax1 Δ4) and hax1 Δ2/ Δ4 
homozygous mutants (Fig. 5.27 b.). No major differences were visible in 
the increase in PMN number from 48 to 72 hpf (Fig. 5.27 c.) and the 
number of PMN at the caudal hematopoietic tissue (CHT) (Fig. 5.27 d.).       
 
The F2 hax1 Δ2/ Δ4 homozygous mutants were generated from 
heterozygous F1 parents, which contain a copy of WT hax1. In order to 
test whether maternal hax1 mRNA protects the early embryos from 
harbouring a specific phenotype, hax1 splice MO and ATG MO was co-
injected into WT embryos, heterozygous and homozygous hax1 Δ2/Δ4 
embryos at the single cell stage. The MO co-injection resulted in a 
decrease in total PMN number in WT, heterozygous and homozygous 
hax1 mutant embryos in comparison to the uninjected group at 48 and 72 
hpf (Fig. 5.28 a. and b.). At 48 and 72 hpf, MO co-injected the 
heterozygous and homozygous hax1 mutant embryos contained a slightly 
higher total PMN number than the MO co-injected WT embryos. It is 
important to note that the genotyping of the F2 embryos showed that there 
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Figure 5.27 The effect of the homozygous hax1 Δ2/ Δ4 mutation on PMN number   
F2 embryos generated from heterozygous hax1 TALEN mutants were sorted into GFP +ve and GFP -ve groups. a.) Representative 
micrographs of a WT Tg(mpx:GFP)i114 and homozygous hax1 Δ2/ Δ4 embryos. PMN were counted at 48 hpf  (WT: n=4, het =15, hax1 
Δ2/ Δ4: n=13) and 72 hpf from 33 embryos generated from a heterozygous Δ2/ Δ4 mutant cross (WT: n=4, het =15, hax1 Δ2/ Δ4: n=12) 
(b.).c.) Increase in PMN number from 48 hpf and 72 hpf was calculated. d.) The number of PMN present at the CHT at 48 hpf was also 
counted. Following this, each individual embryo was genotyped by PCR and BspHI restriction digest. Images and counts are 
representative of a single experiment. Bars represent the mean ±SEM PMN number. PMN counts performed in single experiments were 
analysed using a one way ANOVA with Bonferroni's post test (ns- indicates not significant). 
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Figure 5.28 The effect of hax1 MO microinjection in F2 hax1 Δ 2/ Δ4 
mutants on total PMN number  
F2 embryos were co-injected with 1 nl of 0.5 mM splice 0.2 mM ATG MOs at 
the single cell stage. Control uninjected (uninj-15) and MO injected (MO inj) 
embryos (30) were visualised using a 2x objective on a Nikon Eclipse 
TE2000U inverted microscope. Micrographs of each embryo were taken 
using the GFP channel at 48 (a.) and 72 (b.) hpf. Total PMN numbers were 
then counted from each embryo. Each individual embryo was then 
genotyped by PCR and BspHI restriction digest of the gDNA. Note the 
uninjected group of 15 did not contain any WT embryos. 
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were no WT control embryos in the uninjected group and only 4 hax1 WT 
embryos in the MO injected embryos.  
 
5.2.8  Phenotypic analyses of heterozygous and homozygous F3 
hax1 Δ2/Δ4 mutants 
In order to generate hax1 Δ2/Δ4 mutant embryos lacking maternal mRNA, 
the GFP +ve F2 embryos were genotyped by caudal fin clipping at 3 dpf 
and grouped into heterozygous Δ2 or Δ4 embryos and homozygous hax1 
Δ2/Δ4.  
 
5.2.8.1 Genotyping of F2 embryos by Caudal fin clipping at 3 dpf, 
PCR and BspHI restriction digest analysis 
Fin clipping at 3 dpf was carried out by adding 3 μl of 25 % Tween-20 to 
anaesthetised embryos in a petri dish. The embryos were fin-clipped 
using a scalpel and the fin clip transferred to a 96 well PCR plate. Excess 
media was removed and the fin clip lysed in 15 μl of digestion buffer (10 
mM Tris Hcl pH8, 1 mM EDTA, 0.3 % Tween-20, 0.3 % NP-40) followed 
by a 10 min incubation at 98 °C. The plate was then transferred to ice and 
2 μl of Proteinase K (25 mg/ml) were added to fin clip. This was followed 
by incubation for a further 1.5 h at 55 °C followed by a 10 min incubation 
at 98 °C. The hax1 target region was amplified using the L and R 
Hax1TalRE primers with 2 μl of the 3 dpf fin clip gDNA. The amplicon was 
then subjected to BspHI digestion followed by agarose gel 
electrophoresis (data not shown).  
 
5.2.8.2 The effect of Genotyping of maternal hax1 Δ2/Δ4 mutations 
on PMN number and chemotaxis 
Adult F2 embryos were in-crossed and the total PMN number of progeny 
embryos analysed at 48 (Fig. 5.29 a.). Micrographs of 12 embryos from a 
single heterozygous and homozygous Δ2/Δ4 in-cross each were taken at 
48 h 2x objective on a Nikon Eclipse TE2000U inverted microscope. The 
graph in Fig. 2.29 a. appears to show that there was no difference in the 
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total number of PMN between the progeny of the hax1 heterozygous and 
homozygous hax1 Δ2/Δ4 in-crosses. In order to test the effect of the hax1 
Δ2/Δ4 mutation in PMN migration during recruitment and resolution 
towards a wound site, tail fin transections were carried out on embryos at 
2 dpf. The PMN number at the site of injury was then counted at 6 
(recruitment- Fig. 5.29 b.) and 24 h (resolution- Fig. 5.29 c.) post injury. 
There were no significant differences in the percentages of PMN at the 
site of injury between the progeny of the hax1 Δ2/Δ4 homozygous in-
cross and that of the het in-cross, at both the recruitment and resolution 
phases. In order to visualise the PMN cell migration over time, average 
PMN track speed and meandering index (displacement divided by path 
length) plots were generated by tracking PMN movement for 3 h. The 
micrographs in Fig. 5.30 a. show the tail end of the zebrafish embryos 
with each PMN path indicated in a different coloured line. Mean 
calculations of meandering index and track velocity (mean neutrophil 
speed/time, μ/s) did not reveal any expected differences in the PMN of 
maternal homozygous F3 Δ2/Δ4 mutants in comparison to the progeny of 
the F2 heterozygous (hax1 Δ2/+ x hax1 Δ4/+) in-cross during the 
recruitment phase as indicated by Fig. 5.30. In order to quantify the 
directionality or the ability of PMN to migrate towards the site of injury, a 
bearing angle was calculated for each PMN cell using Volocity®. Fig. 
5.31 demonstrates that the bearing plots showing PMN from the maternal 
homozygous F3 Δ2/Δ4 mutants were comparable to those of F2 
heterozygous (hax1 Δ2/+ x hax1 Δ4/+) where most PMN migrated towards 
the site of injury (right hand side) within the first 3 h post injury. 
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Figure 5.29 The Δ2/ Δ4 mutation does not affect PMN number  
Heterozygous and homozygous F2 embryos generated from a Δ2 Δ4 
cross were raised to adulthood. A pair of heterozygous (het inx) and 
homozygous (hax1 Δ2/ Δ4 inx) F2 fish was in-crossed. Micrographs of 
the embryos were taken at 48 and 72 hpf using a 2x objective on a Nikon 
Eclipse TE2000U inverted microscope. Total PMN numbers of F3 
generation were then counted from each embryo at 48 hpf (a.). b.) 
Embryos were injured at 2 dpf and PMN number at site of injury at 6 h 
post injury (recruitment phase) was counted. c.) F3 generation embryos 
were injured at 2 dpf and PMN number at site of injury at 24 h post injury 
(resolution phase) was counted. Bars represent mean PMN number ±SEM 
or mean % ±SEM PMN at the site of injury. PMN counts and calculated 
percentages (n=12) generated from a single experiment were analysed 
using an unpaired student's t-test. 
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Figure 5.30 The effect of hax1 Δ2/ Δ4 homozygous mutations on 
PMN chemotaxis 
a.) Embryos generated from a single F2 heterozygous (hax1 Δ2/+ x hax1 
Δ4/+) and a homozygous (hax1 Δ2/ Δ4 x hax1 Δ2/ Δ4 ) incross were injured 
at 2 dpf and a time-lapse sequence taken for 3 h and analysis of PMN 
chemotaxis performed  using Volocity® software. Representative PMN 
tracks over the course of the 3 h period are shown in different colours. The 
mean meandering index (b.) and the track velocity (c.) of six embryos in 
each group is shown. The bars represent the mean value ±SEM for each 
group of embryos. Values (n=6 performed in a single experiment) were 
analysed using an unpaired student's t-test. 
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Figure 5.31 The effect of hax1 Δ2/ Δ4 homozygous mutations on 
PMN chemotaxis 
Embryos generated from a single F2 heterozygous (hax1 Δ2/+ x hax1 Δ4/+) 
and a homozygous (hax1 Δ2/ Δ4 x hax1 Δ2/ Δ4) incross were injured at 2 
dpf and a time-lapse sequence taken for 3 h and analysis of PMN 
chemotaxis performed using Volocity® software. The direction of PMN 
movement is shown in the form of bearing plots. Representative images are 
shown from three embryos in each condition. 
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5.2.9 Summary 
The aim of this chapter was to generate stable zebrafish hax1 knockout 
lines using zinc finger and TALEN nuclease technology. I have 
demonstrated targeted hax1 gene disruption in the zebrafish using both 
ZFN and TALEN nucleases. A zinc finger nuclease targeting exon 3 of 
the hax1 gene was engineered and injected into single cell zebrafish 
embryos. I have shown that the injected zing finger nuclease mRNA 
induced single base changes in the hax1 gene, which would not permit 
screening of mutants by restriction digest. Embryos injected with a TALE 
nuclease targeting exon 2 of the hax1 gene carried a number of different 
deletions at the target site. Furthermore, the TALEN induced germline 
mutations were transmitted to progeny. Preliminary phenotypic analysis 
of heterozygous and homozygous hax1 mutants generated using the 
TALEN technology demonstrate that the hax1 exon 2 deletion mutations 
did not appear to have an effect on PMN number and chemotaxis.  
 
5.3 Discussion 
5.3.1 Targeting zebrafish hax1 using ZFN technology  
Injection of ZFN mRNA into zebrafish embryos is a well-established 
technique shown to result in efficient ZFN-induced mutagenesis of 
numerous genes in several model organisms (Doyon et al. 2008; Meng et 
al. 2008; Foley et al. 2009). The CoDA ZFN approach is one of numerous 
methods described in the literature for engineering ZFNs (Maeder et al. 
2008; Doyon et al. 2008; Kim et al. 2010; Lee et al. 2010; Sander et al. 
2011). This approach has been described as the least labour intensive 
and simple to practice with a high success rate of ZFN activity when 
compared to selection based methods such as oligomerized pool 
engineering (OPEN) (Sander et al. 2011).  
 
However, there are also several disadvantages of using the ZFN CoDA 
approach. Firstly, in comparison to existing methods, CoDA limits the 
number of target sites within a gene (Kim et al. 2009; Lee et al. 2010; 
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Sander et al. 2011). Sander et al reported that a CoDA site is found 
approximately every 500 bp of random sequence with a potential 
increase in target range depending on genomic sequence (Handel et al. 
2009). Secondly, although the approach is context-dependent, the 
identity of the F2 unit in the three-finger array is constrained which could 
imbalance the affinity of the finger array and have a negative effect on the 
overall specificity (Bibikova et al. 2001). 
 
Although the hax1 targeting ZFN generated did not appear to be 
completely inactive, it was only able to induce single nucleotide changes 
in the hax1 DNA sequence. Sanger sequencing did not detect these 
changes. The limitations of Sanger sequencing to assess nuclease 
activity have been noted in a study by Moore et al. who found that Sanger 
sequencing could not detect somatic DNA mutations in zebrafish targeted 
at three different loci previously reported to induce mutation rates ranging 
from 0.9- 3.3%. The single nucleotide changes did not appear to be 
Roche Titanium 454 sequencing errors since they do not relate to 
homopolymers (consecutive occurrences of the same base), a major 
limitation of 454 sequencing (Shendure & Ji 2008). In addition, due to the 
lack of flexibility in the hax1 CoDA target sites, only a single restriction 
enzyme (HpyAV) was identified which could be used for mutation 
screening. It in turn only partially spanned the spacer region. This would 
render mutant screening difficult and was likely to omit most mutations 
affecting the central spacer region.  
 
It has been reported that injection of highly concentrated ZFN mRNA into 
the zebrafish and other model systems can cause non-specific 
developmental abnormalities likely to occur as a result of cleavage at off-
target sites (Bibikova et al. 2002; Beumer et al. 2006; Miller et al. 2007; 
Meng et al. 2008). This suggests that ZFNs exhibit imperfect target site 
recognition. In this chapter, the embryos that were injected with high 
doses of hax1 ZFN mRNA displayed lethality at 1 dpf. This limited the 
amount of ZFN to be injected per single embryo to ~40 pg.  The lowered 
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ZFN dose could have had a negative effect on the success of the hax1 
mutation rate. In a study carried out by Cathomen et al., it was shown that 
for a given target DNA site, ZFNs with higher binding specificity exhibit 
higher activity, which in turn correlates with lower ZFN-induced 
cytotoxicity (Cornu et al. 2008). This may suggest that the ZFN generated 
in this chapter did not have a high DNA-binding specificity for the 
zebrafish hax1 gene. A low hax1 binding specificity of the ZFN could also 
support our finding of lack of multiple base deletions and insertions in the 
hax1 target sequence.  
 
ZFN toxicity may be partly due to the lack of regulation of the DNA 
cleavage by the ZFN (Szczepek et al. 2007). In addition to the expected 
FokI heterodimer formation, uncontrolled ZFN cleavage has been shown 
to result in generation of FokI nuclease homodimers due to the 
monomers binding at appropriately spaced off-target sites. This in turn 
leads to cleavage at off-target sites (Szczepek et al. 2007). In this chapter 
I have indicated that the DD-RR FokI variant was utilised in the 
construction of the hax1 targeting ZFN. Using computer analysis and a 
chromosomal homologous recombination assay, Szczepek et al. 
demonstrated that the DD-RR performed better than the EE-QK FokI 
variant due to less favourable homodimerisation of the DD and RR 
domains (Szczepek et al. 2007). This appears to have not been the case 
for the hax1 targeting ZFN. 
 
The length of the spacer region is another factor likely to have affected 
the hax1 targeting ZFN nuclease activity. In this chapter, I have shown 
that binding of the hax1 ZFN to the target sequence would generate a 5 
bp spacer region. Numerous studies have demonstrated that a ZFN 
arrangement producing a short spacer region (5-7 bp) between the two 
binding sites of the left and right subunits results in increased ZFN 
function (Bibikova et al. 2001; Handel et al. 2009; Shimizu et al. 2009). 
This did not appear to apply to the hax1 targeting ZFN described in this 
chapter. It is important to note that each ZFN is likely to have a different 
affinity and specificity for the intended target site. Therefore, the activity of 
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one ZFN cannot directly be compared to the activities of existing ZFNs. 
Some ZFNs have been shown to remain inactive and it has been 
suggested that this is due to an unfavourable chromatin environment at 
the target site (Bhakta et al. 2013). 
 
The lack of deletion and insertion mutations comparative to published 
data (Foley et al. 2009) combined with the relatively low single nucleotide 
change frequency (4.2 %) of the generated hax1 ZFN was likely to result 
in unsuccessful mutant screening by restriction digest analysis. To 
circumvent this, I next went on to utilise a new approach using TALEN 
technology in an attempt to induce high frequency hax1 mutations and in 
turn generate a hax1 knockout line.  
 
5.3.2 Targeting zebrafish hax1 using TALEN technology  
The injection of hax1 Golden Gate TALEN mRNA into single cell 
zebrafish embryos generated a high enough mutation rate allowing 
screening by BspHI restriction digest. Although incomparable to the hax1 
ZFN generated due to the use of a different target site, this finding is in 
agreement with published literature, which has demonstrated a higher 
success rate of TALEN mutagenesis in multiple model systems (Cermak 
et al. 2011; Miller et al. 2011; Moore et al. 2012; Cade et al. 2012). 
 
One of the limitations of using ZFNs and TALENs to induce mutations in 
the zebrafish is that the indel mutations are random and cannot be pre-
determined.  In comparison to the ZFN mutagenesis approach, the 
TALEN technology is a faster, cost-effective simpler technique. One of 
the main advantages of TALENs is their increased flexibility in targeting 
range. This is a due to their utilisation of a simple binding code whereby 
each individual RVD recognises a single nucleotide at the target locus. In 
addition, the longer TALEN recognition sites may play a role in the 
increased specificity and in turn reduced toxicity in comparison to ZFN. 
Guidelines based on natural occurring TAL effectors have been published 
by Cermak et al. who demonstrated that when applying these guidelines 
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a candidate cleavage site was found on average every 35 bp (Cermak et 
al. 2011). The lack of detectable TALEN induced toxicity in the hax1 
TALEN injected embryos supports previous findings showing that most 
TALE nucleases cause no detectable cytotoxicity (Li et al. 2011).  
 
Multiple TALEN scaffolds have been described differing in the N and C 
terminal length, FokI nuclease linker as well as nuclear localisation 
sequences (Cermak et al. 2011; Mussolino et al. 2011; Miller et al. 2011). 
In agreement with published data, the hax1 left and right TALEN 
constructs containing the 147 bp long N-terminal region, a wild type 
homodimeric FokI nuclease domain and the +63 bp long C-terminal 
successfully cleaved the hax1 target site although it has been 
demonstrated that both hetero- and homodimeric nuclease domains 
induce mutation with comparable efficiency (Cade et al. 2012). Miller et al 
have demonstrated that a 19 bp spacer generated ~15 % of endogenous 
human CCR5 modification activity using the +63 bp C-terminal domain 
compared to a 2% of a TALEN containing a truncated C-terminus (+28 
bp) targeting the same region (Miller et al. 2011). Increased 
understanding of these parameters can lead to elevated target specificity 
and affinity in turn increasing the mutation frequencies for a specified 
gene.  
 
5.3.3 Validation of hax1 TALEN induced mutant sequences 
In this chapter, the sequence analysis of the TALEN induced mutations 
from the heterozygous and homozygous zebrafish provides considerable 
evidence for the generation of premature Hax1 protein. However, it 
should be noted that in order to fully validate the mutant sequence, 
genomic DNA from mutant embryos should first be amplified using hax1 
specific primers. Following this, the PCR product could be TOPO cloned 
into competent E. coli cells and colony PCR carried out. Each colony 
would then contain a single allele which would be Sanger sequenced and 
compared to the wild type hax1 sequence. Therefore, caution should be 
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taken when interpreting the preliminary phenotypic data generated in this 
chapter. 
 
5.3.4 The effects of hax1 exon 2 TALEN induced deletion mutations 
on zebrafish PMN number and chemotaxis 
The TALEN mutagenesis data generated in this chapter suggest that 
mutation in the exon 2 of the zebrafish hax1 gene do not affect PMN 
number. Furthermore, analysis of migration during recruitment and 
resolution from a wound site indicated that there was no difference 
between wild type and homozygous knockout mutants in PMN 
chemotaxis. This does not support previous findings demonstrated from 
human patient samples and mammalian cell culture models (Klein et al. 
2007; Cavnar et al. 2011; Morishima et al. 2013). These results raise 
interesting questions as to how disruption of the 5’ site of hax1 exon 2 
does not recapitulate the human phenotype. There are a number of 
reasons, which could explain this phenomenon. Firstly, the genetic 
organisation of the HAX1 gene is extremely complex due to its differential 
splicing pattern. The TALEN only targeted exon 2 of the zebrafish gene, 
however, in chapter 4 I have demonstrated the expression of multiple 
hax1 variants. Splicing out of exon 2 could occur to generate alternative 
functional hax1 isoforms. The evidence for alternative splicing in the 
zebrafish may also support my findings on co-injected hax1 TALEN 
embryos with the hax1 start MO and hax1 splice MO where PMN levels 
were reduced but not abolished.  
 
Secondly, the mechanisms of hax1 function in the zebrafish are unknown 
and may differ to the human counterpart. In light of this, it is important to 
note that in humans, PMN are produced in the bone marrow, a tissue 
type which zebrafish lack (Charbord et al. 1996). The mechanisms of 
PMN onset in the bone marrow are not understood. In the zebrafish, PMN 
are first produced at ~30 h in the posterior intermediate cell mass and 
anterior yolk sack (Bennett et al. 2001). During later stages of zebrafish 
development and adulthood, most of the haematopoiesis occurs in kidney 
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(Bennett et al. 2001). In a single study, it has been shown that the bone 
marrow is likely to play a crucial role in PMN clearance under 
homeostatic conditions. This difference between human and the zebrafish 
model in the PMN ‘niche’ may represent dissimilar functions of HAX1 in 
the two organisms and could lead to the lack of recapitulation of the 
human phenotype. Lastly, the loss of the multifunctional Hax1 protein 
may be detrimental to the zebrafish embryos and consequently the 
zebrafish may have a compensatory switch utilizing unknown factor/s to 
counteract the lack of Hax1 expression.  
 
5.5 Conclusion 
In conclusion, I provide novel evidence for hax1 gene disruption in the 
zebrafish. In addition, I have shown that TALEN induced hax1 mutations 
were maintained in the germline up to F3. Homozygous knockout 
mutations predicted to result in premature truncation of the Hax1 protein 
did not appear to have an effect on PMN number and chemotaxis. The 
lack of recapitulation of the human phenotype was discussed and the 
differences in PMN sites of production in human and zebrafish were 
highlighted. 
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6 Final Discussion 
6.1 Aims of the study 
The aim of this thesis was to investigate the function of HAX1 in regulating PMN 
function during inflammation. To this end I studied expression patterns and 
regulation of HAX1 in human PMN and the myeloid cell line PLB-985. In 
addition, in order to generate an in vivo working model for hax1 study, I aimed 
to explore hax1 expression in zebrafish embryos and the effects of its 
mutagenesis in the context of PMN biology.  
 
6.2 Discussion and future work 
PMN survival and homeostasis play an important role in inflammation and 
defence against host pathogens. Defects in the apoptotic pathway of PMN 
result in numerous chronic inflammatory diseases (Kotecha et al. 2003; Brown 
et al. 2009; Moriceau et al. 2010). The finding by Klein et al revealing that HAX1 
deficiency in human results in SCN implicated a role for this gene in PMN 
survival and homeostasis (Klein et al. 2007). To date, the molecular mechanism 
underlying neutropenia in HAX1 deficiency is unknown. Elucidation of the 
pathways in which HAX1 is involved is essential for our understanding of how 
HAX1 regulates PMN survival and homeostasis and could allow identification of 
novel therapeutic targets for chronic inflammatory diseases where dysregulated 
PMN survival is central to pathogenesis.  
 
I began my research with an investigation into HAX1 expression at the 
transcript and protein level in primary human PMN and a number of cell lines 
including PLB-985. I have shown that although numerous transcript variants are 
expressed in PMN, based on the expression of previously identified variants 
these cells did not appear to have a specific hax1 transcription profile. Several 
other unidentified hax1 variants were visible in the PMN PCRs amplified using 
hax1 specific primers and have also been described in other cell types (Lees et 
al. 2008). Identification through 3’ and 5’ rapid amplification of cDNA ends 
(RACE) and sequencing of hax1 transcript variants may result in the detection 
of novel cell specific isoforms. qPCR is more quantitative than the RT-PCR 
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used in this thesis, which only detects dramatic changes in transcript levels. 
Further analysis therefore, by qPCR of previously and newly identified variants 
could also indicate whether hax1 is transcriptionally regulated and allow 
complete characterisation of the hax1 transcript expression patterns in PMN in 
both health and disease.  
 
Numerous studies have highlighted the anti-apoptotic properties of HAX1. 
Overexpression of HAX1 in cardiac myocytes, HeLa and HEK293 cells was 
shown to suppress apoptosis (Yedavalli et al. 2005; Han et al. 2006; Vafiadaki 
et al. 2007). In cardiac myocytes, the anti-apoptotic effects of HAX1 are exerted 
through caspase-9 inhibition (Han et al. 2006). Other studies have also linked 
HAX1 to the mitochondrial apoptotic machinery. To date it is not known whether 
HAX1 is also regulated in this way in the PMN. I have shown that full-length 
HAX1 protein levels (isoform 001) are degraded over time in PMN. The HAX1 
degradation is likely to correspond to breakdown by caspase activity during 
apoptosis since inhibition of caspases by qVD-OPh resulted in an increase in 
HAX1 levels. However, in order to fully establish the link between HAX1 
degradation and caspase activity, HAX1 levels of freshly isolated PMN could be 
compared to those of cells treated with different stimuli and analysed by 
western blotting. If HAX1 levels were upregulated in response to the stimuli then 
this would suggest that HAX1 is an upstream regulator of the PMN apoptotic 
pathway. Attempts during my studies to identify HAX1 protein binding partners 
and in turn potentially shed light into HAX1 anti-apoptotic effects through co-
immunoprecipitation assays were unsuccessful.   
 
A recent study claims that HAX1 splicing in the rat heart results in the 
expression of anti- and pro-apoptotic isoforms (Koontz & Kontrogianni-
Konstantopoulos 2014). The anti- and pro-apoptotic HAX1 forms in the rat were 
shown to modulate apoptosis through the formation of homo- and heterodimers 
(Koontz & Kontrogianni-Konstantopoulos 2014). In PMN, in addition to the full-
length isoform (001) several immunoreactive bands were detected using both 
HAX1 antibodies. Although full-length HAX1 levels decreased during PMN 
ageing, I have shown that the expression of some of the HAX1 specific bands 
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remained unchanged and, although speculative, these may represent novel pro-
apoptotic forms of the protein.  
 
In PLB-985 cells CHX and STSP induced the expression of several HAX1 
specific species <30 kDa in size. This work raises interesting questions as to 
whether the additional bands detected in my studies are a result of HAX1 
cleavage or pro-apoptotic forms of the protein, although the use of CHX 
indicates are unlikely to be newly expressed isoforms. Further work in this field 
could involve characterisation of HAX1 specific bands by protein sequencing 
and investigation into the dimerization states of HAX1 isoforms in healthy and 
aged PMN.  
 
I hypothesised that HAX1 plays a role in the mitochondrial stability of myeloid 
cells. My work on the PLB-985 cell line using siRNA to knockdown the HAX1 
gene does not support this hypothesis. HAX1 knockdown in PLB-985 cells had 
no effect on basal mitochondrial membrane stability or cell death. These results 
are in disagreement with previous literature of HAX1 involvement in the 
regulation of apoptosis. Conversely, a very recent study found that Hax1 
deficiency did not increase cytokine deprivation-induced apoptosis in primary 
murine bone marrow-derived mast cells but that HAX1 does in part, mediate 
calcium-dependent survival (Trebinska et al. 2014). These data provide further 
support for HAX1 cell type- and stimulus specific roles and highlight that careful 
consideration should be taken into the type of stimulus utilised when devising 
HAX1 studies. Canvar et al showed that HAX1 deficiency using siRNA had no 
significant effect on PLB-985 apoptosis induced by hydrogen peroxide, but 
instead affected cell adhesion and chemotaxis (Cavnar et al. 2011). Perhaps 
these results would have differed in calcium-dependent triggered apoptosis. 
 
One of the main problems of working with primary PMN is that they are short-
lived in culture and genetically intractable. Attempts to knockdown HAX1 using 
novel polymerosome technology in PMN and test the effects on PMN survival 
were unsuccessful, as shown in Chapter 3. The use of the PLB-985 cell line as 
a model is also not ideal since these cells differ to PMN in many ways. In 
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addition, although the HAX1 knockdown efficiency using siRNA in PLB-985 was 
high, it should be noted that it is only a transient change and some HAX1 
protein remained in the HAX1 siRNA transfected cells at both of the timepoints 
tested. The small pool of HAX1 protein may have been sufficient for its 
functional purpose. These limitations in combination with the lethality of the 
Hax1 homozygous knockout mutation in mice resulted in a search for an 
alternative in vivo model.  
 
The genetic tractability of the zebrafish makes it an ideal model system for the 
study of monogenic disease. The utilisation of recently developed nuclease-
targeted mutagenesis techniques can provide insight into the molecular 
pathophysiology of human mutations. In addition, the generated knockout 
zebrafish lines can be utilised to validate MO knockdown data. My research 
revealed that zebrafish express the hax1 gene and, similarly to the human 
gene, the zebrafish gene is also alternatively spliced resulting in multiple splice-
variants. Disruption of the hax1 gene using MOs resulted in reduced PMN 
number, which may be due either to the loss of Hax1 in the embryo or the 
concomitant developmental delay. The reduction in PMN numbers following MO 
induced knockdown supports a role for Hax1 in PMN homeostasis and cell 
survival and shows resemblance to the human phenotype of HAX1 deficiency. 
However, the effects of the MOs should be interpreted with caution due to 
potential off-target effects (Robu et al. 2007). Attempts to reduce or overcome 
any off-target effects using a p53 MO, and to rescue the MO phenotype using 
full-length hax1 were unsuccessful. This reduces our confidence in the MO 
data.  
 
In this thesis, I have shown that a hax1 targeting ZFN did not result in the 
effective mutagenesis of the hax1 gene. Conversely, a hax1 exon 2 targeting 
TALEN efficiently modified the gene and the mutations were successfully 
transmitted through the germline. This further demonstrates that TALENs are a 
simple, robust and efficient technology to perform heritable targeted gene 
mutations in the zebrafish. Contrary to our expectations, the hax1 homozygous 
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knockout mutation in exon 2 did not have an effect on zebrafish PMN number. 
Preliminary data also showed that it did not appear to affect PMN chemotaxis.  
 
The recent findings suggesting HAX1 exists in pro- and anti- apoptotic forms, 
could help to justify the lack of a PMN specific phenotype of the hax1 TALEN 
targeting exon 2. As shown in the zebrafish hax1 variant expression profile in 
Chapter 4, exon 2 is likely to be expressed in numerous hax1 variants and so 
may be found in both pro- and anti-apoptotic isoforms. Targeting of this region 
could therefore, have resulted in the deficiency of both pro- and anti-apoptotic 
forms that in turn could have lead to a neutralisation of the phenotype. It may be 
that unidentified PMN specific isoforms exist that were not affected by the 
siRNA in PLB-985 and the TALEN in zebrafish, respectively.  
 
It is important to note that our understanding of PMN development in the 
zebrafish is very limited and species differences could reflect differences in the 
HAX1 deficiency PMN specific phenotypes. One could speculate that the lack of 
a hax1 knockout phenotype in the zebrafish could reflect the differences in the 
PMN production and/or PMN differentiation niches. The data generated on PLB-
985 in this thesis suggest that HAX1 may not be playing a role in apoptosis. It 
may be that the protein is involved in PMN mobilisation out of the bone marrow 
and since this tissue is absent in the zebrafish, this difference could have 
resulted in a lack of phenotype. This could explain the lack of differences in 
PMN number between the wild type and the hax1 knockout zebrafish embryos. 
Genetic redundancy of hax1 with other pathway members in the zebrafish could 
also have accounted for the absence of a phenotype. The presence of an 
unsuspected hax1 paralogue in zebrafish that could have concealed the effects 
of the hax1 exon 2 TALEN induced mutation should not be disregarded. 
Conversely, the TALEN induced hax1 exon 2 mutation could have resulted in 
the synthesis of a functionally active splice form that restored the phenotype.  
 
In order to verify the MO data, the same hax1 region targeted by the splice site 
MO could be targeted by a nuclease to investigate whether the effects on PMN 
number and development are recapitulated. Novel technology using a bacterial 
 254 
type II CRISPR (clustered, regularly interspaced, short palindromic repeats) 
system and Cas9 endonuclease has been shown to exert even more flexibility 
with the target site than the TALENs and could be used to induce mutations in 
the hax1 exon 3 region targeted by the splice site MO (Hwang et al. 2013). 
TALEN or CRISPR/Cas9 technology could also be used to induce mutations in 
other regions of the gene and test whether the effects of this on PMN survival 
and chemotaxis differ from the exon 2 homozygous mutation.  
 
Following further characterization of the zebrafish hax1 variants, the different 
hax1 transcripts could be overexpressed in PMN and tagged with fluorescent 
protein in order to determine their subcellular localisation and effects on PMN 
survival. PMN specific promoters and the viral 2A peptide could be used to 
allow cell-specific expression (Provost et al. 2007). If the findings of the recent 
study suggesting the presence of pro-apoptotic HAX1 isoforms were to be true 
for PMN, then the overexpression of certain isoforms in PMN would be 
expected to result in increased apoptosis (Koontz & Kontrogianni-
Konstantopoulos 2014). This would allow investigation into the possible 
mechanisms of hax1 function in vivo. Known published interactions of HAX1 in 
other cell types could then be explored in zebrafish PMN.  
 
6.3 HAX1 as a potential therapeutic target 
In chronic inflammatory disease, PMN are recruited to sites of lesions resulting 
in uncontrolled amplification of inflammation. Airway diseases such as asthma 
and COPD are characterised by systemic and chronic localised inflammation. 
They are among the world’s most prevalent diseases and studies show they are 
on the increase. To date, strategies for selective targeting of persistent 
neutrophilic inflammation are lacking. Many of the prescribed drug treatments 
for these diseases lack efficacy and have adverse effects highlighting a need for 
the identification of novel therapeutic targets.  
 
The PMN specific phenotype of HAX1 deficiency in humans highlights a cell 
specific role for this protein and suggests that treatment of inflammatory disease 
by targeting of HAX1 would be selective for PMN and result in reduced adverse 
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effects. My research has highlighted that an understanding of the HAX1 isoform 
specific functions will be key for selective drug target generation. A better 
understanding of HAX1 function may also prove valuable in the treatment of 
other disorders since HAX1 overexpression has also been implicated in 
numerous other diseases including melanoma, psoriasis, lung and breast 
cancer (Mirmohammadsadegh et al. 2003; Trebinska et al. 2010).  
 
6.4 Summary 
This thesis has explored the expression and roles of HAX1 in human PMN and 
the zebrafish. This is the first description of HAX1 transcript variant 
characterisation in human PMN and PLB-985 showing that PMN do not appear 
to have a distinct transcriptional profile from other cell types. HAX1 levels were 
shown to be degraded during apoptotic cell death and the use of pro- and anti-
apoptotic stimuli demonstrated that HAX1 is modulated in PMN. Further work is 
required to determine whether this was a result of caspase inhibition or if HAX1 
acts upstream of caspase activation. In zebrafish, I have shown that multiple 
isoforms of hax1 are expressed, providing novel evidence for the expression 
and alternative splicing of hax1 in the model organism. These data enabled me 
to use MO and TALEN technology in order to investigate the effects of hax1 
mutagenesis in zebrafish embryos. To our knowledge, this is the first study 
describing hax1 mutagenesis through the use of both MO and TALEN 
technologies. The reduction of PMN following MO induced knockdown of hax1 
supports a role for hax1 in PMN homeostasis and/or cell survival. Contrary to 
our expectations however, preliminary data generated utilising a hax1 deficient 
zebrafish line created using TALEN technology showed that the hax1 exon 2 
mutation did not affect PMN number and chemotaxis. These findings along with 
previously generated data suggest that HAX1 isoforms are likely to exert their 
pro- and/or anti-apoptotic functions in a cell and stimulus specific manner. 
Collectively my data highlight the complexity of the HAX1 genetic organization 
in human and zebrafish and a need for further study of HAX1. Understanding 
the function of HAX1 in the regulation of PMN survival and homeostasis may 
offer a potential therapeutic opportunity for the treatment of inflammatory 
diseases.  
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7 Appendices 
7.1 Appendix 1:  Buffers for whole cell lysate preparation 
and western blotting 
7.1.1 SDS-PAGE loading buffer (10 ml) 
Reagent Concentration 
in buffer 
Volume 
1 M Dithiothreitol (DTT) 0.1 M 1 ml 
10 % SDS 4 % 4 ml 
Glycerol 20 % 2 ml 
1 M Tris HCl (pH 6.8) 0.0625 M 625 µl 
0.2 % Bromophenol Blue 0.004 % 200 µl 
dH2O   2.175 
 
7.1.2 Resolving Gels (1.5 mm gel plates) 
% Resolving gel: 12% 15% 
 1 gel 2 gels 1 gel 2 gels 
dH2O 6.6 ml 9.9 ml 5.4 ml 8.1 ml 
40 % Acrylamide 4.4 ml 6.8 ml 5.6 ml 8.4 ml 
1.5 M Tris pH 8 3.8 ml 5.7 ml 3.8 ml 5.7 ml 
20 % SDS 75 µl 112.5 µl 75 µl 112.5 µl 
20 % APS 150 µl 225 µl 150 µl 225 µl 
TEMED 6 µl 9 µ 9 µl 9 µl 
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7.1.3 Stacking Gels (1.5 mm gel plates) 
Reagent 1 gel 2 gels 
dH2O 3 ml 6 ml 
40 % Acrylamide 620 µl 1240 µl 
0.5 M Tris pH 6.8 1260 µl 2520 µl 
20 % SDS 25 µl 50 µl 
20 % APS 50 µl 100 µl 
TEMED 5 µl 10 µl 
 
7.1.4 10X Running Buffer (1 l) 
10X stock solution (1 l) 
Reagent 
 Mass 
Tris/Trizma base 30.3 g 
Glycine 144 g 
SDS 10 g 
1 l of 10X stock solution was made up by adding 1 l of dH2O to the above 
reagents. For 1 working buffer (pH ~ 8.3), 100 ml of 10X stock was diluted with 
900 ml of dH2O.  
7.1.5 10X Transfer Buffer (1 l) 
10X stock solution (800 ml)  Volume/Mass 
Tris/Trizma base 29 g 
Glycine 145 g 
dH2O 800 ml 
For 1X working buffer (1 l) 80 ml of 10X stock were added to 200 ml of 
methanol and 720 ml of dH2O.  
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7.1.6 10 X Tris Buffered Saline (TBS) (1 l) 
Reagent Volume/Mass 
Tris-HCl 1M pH 8.0 100 ml 
NaCl 97.3 g 
dH2O to 1000 ml 
For 1X working buffer (1 l) 100 ml of 10X stock were added to 900 of dH2O.  
7.1.7 10X Tris Buffered Saline (TBS) -Tween (1 l) 
Reagent Volume/Mass 
Tris-HCl 1M pH 8.0 M  100 ml 
NaCl 97.3 g 
Tween-20 5 ml 
dH2O to 1000 ml 
For 1X working buffer (1 l) 100 ml of 10X stock were added to 900 of dH2O.  
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7.2 Appendix 2: Primary and Secondary Antibodies 
7.2.1 Primary Antibodies 
Protein target  Size of 
target 
protein 
Conc.  
(µg/ml) 
Required 
working 
dilution 
Required 
Secondary 
Antibody (IgG) 
β- actin (Sigma) 40 kDa 400  1:4000 Goat anti-rabbit HRP 
HAX1 (BD) (Cat ♯: 
610824) 
35 kDa 250  1:800 Goat anti-mouse 
HRP 
HAX1 (GenTex) 
(Cat ♯: GTX101992) 
35 kDa 250  1:1500 Goat anti-rabbit HRP 
Mcl-1(Santa Cruz) 
(Cat ♯: Sc818) 
40 kDa 200 1:1000 Goat anti-rabbit HRP 
 
 
7.2.2 Secondary Antibodies 
Secondary Antibody Conc. (µg/ml) Required working 
dilution 
Goat anti- Mouse (Dako) 200 1:2000 
Goat anti-Rabbit HRP conjugate 
(Dako) 
200 1:2000 
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7.3 Appendix 3:  
7.3.1 RT-PCR primers for amplification and sequencing of D. rerio hax1 
isoforms 
Target Sequence Expecte
d size 
(bp) 
Annealing 
temp. (°C) 
hax1 001 Forward 5’-ATGGTGGCATTTTGTGAAGG-3’ 
Reverse 5’-ATTGTGATCGTGGTGGGTTT-3’ 
964 60 
hax1 002 Forward 5’-GAGTGGTCTGACAATTTGAATC-3’ 
Reverse 5’-
CAATTCATGAGACCGTAAGGCAGAC-3’ 
1150 58 
hax1 003 
& 005 
Forward 5’-GGCACGCTTTGAAGAGCCTCAG-
3’ 
Reverse 5’-
CGGGAAACCTGATGGGAAGAAGC-3’ 
003 -
1625 
005 -130 
58 
 
hax1 007 Forward 5’-
CCTACTTAACGAAGGATAGCGCGC-3’ 
Reverse 5’-
CAATTCATGAGACCGTAAGGCAGAC-3’ 
907 58 
hax1 008 Forward 5’-CAGGCTGTAAATATGCTCTGC-3’ 
Reverse 5’-
CAATTCATGAGACCGTAAGGCAGAC-3’ 
592 58 
hax1  Forward  5’-GGCACGCTTTGAAGAGCCTCAG-
3’ 
Reverse 5’-
CAATTCATGAGACCGTAAGGCAGAC-3’ 
984 60 
hax1 x Forward 5’-GTTCCCGGAGGTCATTATCGAG-3’ 
Reverse 5’-CGAAAGCCTCTGAAGAACTTGG-
3’ 
818 (full 
length 
hax1) 
60 
hax1 MO 
intron 3-4 
R 
Reverse 5’- CTGGCAGACCTCGATTTACC-3’ - Sequencing 
primer 
EF1-α Forward 5’ TACGCCTGGGTGTTGGACAAA 3’ 
Reverse 5’ TCTTCTTGATGTATCCGCTGAC 3’ 
470 60 
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 7.3.2 RT-PCR primers for amplification of human HAX1 isoforms 
Target Sequence Expected 
product 
size (bp) 
Annealing 
temp. (°C) 
HAX1 001 Forward 5’-AGGAATTTGGCTTCGGCTTC-3’ 
Reverse 5’-CTGGAAGTTCAGGAGGATGG-
3’ 
151 60 
HAX1 002 Forward 5’-GAGCTGAGGTCTGACTTTGA-3’ 
Reverse 5’-TGAGGGTTAACAAGGCTACC-3’ 
1009 60 
HAX1 003 
& 005 
Forward 5’-AGGAATTTGGCTTCGGCTTC-3’ 
Reverse 5’-TGAGGGTTAACAAGGCTACC-3’ 
003- 316 
005- 165  
60 
 
HAX1 004 Forward 5’-
ACCTCGGAGCTTCAGCCCAGGA-3’ 
Reverse 5’-TGAGGGTTAACAAGGCTACC-3’ 
667 60 
HAX1 006 Forward 5’-GATGACCTAAACTTCCAGGTC-
3’ 
Reverse 5’-TGAGGGTTAACAAGGCTACC-3’ 
548 60 
HAX1 007 Forward  5’-ATGGTAAGTCTGGAGGAAGG-
3’ 
Reverse 5’-TGAGGGTTAACAAGGCTACC-3’ 
454 58 
HAX1 008 Forward 5’-AGTATGGCCAGGGAACGAAT-3’ 
Reverse 5’-TGAGGGTTAACAAGGCTACC-3’ 
297 60 
HAX1  Forward 5’-TGGAGGGGTTCAAAGGTTCG-
3’ 
Reverse 5’-
AAGTTCAGGAGGATGGGAAGGC-3’ 
356 57.8 
GAPDH Forward 5’-ACTTTGGTATCGTGGAAGGAC-
3’ 
Reverse 5’-TGGTCGTTGAGGGCAATG-3’ 
 
420 
 
50 
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7.4 Appendix 4: D. Rerio Hax1 genetic sequence 
indicating primer binding regions 
Gene: zgc:92196 (ENSDARG00000036764), HCLS1 associated protein X-1 
[Source:RefSeqpeptide;Acc:NP_001002337]   (Exons: orange) 
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7.4 Appendix 4: D. Rerio Hax1 genetic sequence 
indicating primer binding regions 
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7.5 Appendix 5: PCR gel electrophoresis 
7.5.1 50X TAE buffer (1 l) 
Reagent M 
Volume/mass 
Tris Base 242 g 
EDTA 37.2 g 
 Acetic acid 57.1 ml 
dH2O to 1000 ml 
For 1X TAE 200 ml of 50 X buffer were added to 800 ml of dH2O.  
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7.6 Appendix 6: pCR-Blunt II- TOPO vector and pCS2+ 
plasmid vector maps 
 
pCS2+ 
(http://www.xenbase.org/reagents/vectorAction.do?method=displayVectorSumm
ary&vectorId=1221270) 
Antibiotic resistance: 
Ampicillin 
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7.7 Appendix 7: Whole mount in situ Hybridization (WISH) buffers 
7.7.1 Pre-Hybridization buffer (50 ml) 
Reagent M  Volume/mass required to make 50 ml of 
buffer 
50 % Formamide 25 ml 
5X SSC 12.5 ml of 20X 
0.1 % Tween 20 50 μl 
Citric Acid to pH6 460 μl of 1M  
50 μg/ml heparin 50 ul of 500 mg/ml stock 
500 μg tRNA 20 μl of 24.75 μg/ μl stock 
dH2O 12 ml 
 
7.7.2 20X Saline-sodium citrate (SSC) buffer (200 ml) 
Reagent M  Volume/mass required to make 200 ml of 
buffer 
NaCl 35.06 g 
Sodium citrate 17.64 g 
Adjust to pH 7 using citric acid  
dH2O to 200 ml 
 
7.7.3 HybWash buffer (50 ml) 
Reagent M  Volume/mass required to make 50 
ml of buffer 
50 % Formamide 25 ml 
5 x SSC 12.5 of 20X stock 
0.1 % Tween 50 μl 
 Adjust to pH 6 using citric acid 460 μl 
dH2O 12 ml 
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7.7.4 Staining wash (50 ml) 
Reagent M  Volume/mass required to make 50 
ml of buffer 
100 mM Tris HCl pH9.5 to 50 ml 
50 mM MgCl2 0.51 g 
100 mM NaCl 0.292 
  0.1 % Tween 50 μl 
To make up the staining solution 112.5 μl of NBT (50 mg/ml) and 175 μl of BCIP 
(50 mg/ml) were added to 50 ml of staining wash.
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7.8 Appendix 8: Egg medium for zebrafish embryos (E3) 
7.8.1 60X E3 medium (2 l) 
Reagent M  Volume/mass required to make 2 l of 
buffer 
NaCl 34.8 g 
KCl 1.6 g 
CaCl2 5.8 g 
  MgCl4 9.78 g 
 dH2O to 2000 ml 
 
7.8.2 1X E3 medium (1 l) 
Reagent M  Volume/mass required to make 1l of 
buffer 
60 X E3 16.7 ml 
1% Methylene Blue 100 μl 
dH2O to 1000 ml 
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7.9 Appendix 9: Sanger sequencing analysis of D. rerio hax1 
008 
Green arrows indicate hax1 008 primer annealing sites. 
  
Exon 6 Exon 7
intron 5-6
D. rerio hax1 008 
 76543
Query- expected hax1 008 sequence amplified using primers for isoform 008
Subject- Sanger sequencing output using hax1 008 forward primer
Exon number:
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7.10 Appendix 10: Sanger sequencing analysis of PCR band 
amplified using the D. rerio hax1 x primer pair reveals the band 
is hax1 001 
 
  
D. rerio hax1 001
Red arrows indicate hax1 x primer annealing sites
Query- hax1 001 sequence deduced from the Ensebl sequencing 
data
Subject- Sanger sequencing output using hax1 x forward primer
Exon 2
Exon 2
Exon 2
Exon 2 Exon 3
Exon 3
Exon 3
Exon 3 Exon 4
Exon 5
Exon 5
Exon 5 Exon 6
Exon 6
Exon 4
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7.11 Appendix 11: Sanger sequencing analysis of TOPO 
cloned 
hax1 MO 
induced 
2.5 kb 
PCR band 
pair  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 2.5 kb 
PCR band induced by splice MO injection and amplified using the hax1 primer 
pair was TOPO cloned into the pCR-BLUNT II-TOPO vector. Sanger 
sequencing of the PCR band using an M13 Forward primer (green arrow) 
resulted in sequence identical to the 3’ of exon 2 and most of intron 2-3 (from 
the 5’ end). Query: D. rerio hax1 gene sequence deduced from the Ensembl 
website. Subject: Sanger sequencing output.   
Exon 2 Intron 2-3
D. rerio hax1 gene
splice MO induced splicing
normal splicing (hax1 primer pair)
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7.11 Appendix 11: Sanger sequencing analysis of cloned hax1 
MO induced 2.5 kb band amplified using the D. rerio hax1 
primer pair (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequencing of PCR band using the hax1 MO intron 3-4 R primer (black 
arrow) resulted in sequence identical to most of intron 2-3 (from the 3 ‘ end) and 
most of exon 3 (from the 5 ‘ end). Query: D. rerio hax1 gene sequence deduced 
from the Ensembl website. Subject: Sanger sequencing output.  
Intron 2-3 exon 3
D. rerio hax1 gene
normal splicing (hax1 primer pair)
splice MO induced splicing
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7.11 Appendix 11: Sanger sequencing analysis of cloned hax1 
MO induced 2.5 kb band amplified using the D. rerio hax1 
primer pair (cont.) 
 
Sanger sequencing of PCR band using an M13 Reverse primer (green arrow) 
resulted in sequence identical to exons 4-7. Query: D. rerio hax1 gene 
sequence deduced from the Ensembl website. Subject: Sanger sequencing 
output. 
Exon 7
Exon 6
Exon 5
Exon 4
D. rerio hax1 gene
normal splicing (hax1 primer pair)
splice MO induced splicing
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 7.12 Appendix 12: Determining the insert orientation by Sanger 
sequencing of the cloned hax1 001 cds in pCS2+ 
 
Sequencing of pCS2+ hax1 001 using the M13 Reverse primer revealed that 
the full length cds insert is in the 5’-3’ direction. Therefore, the hax1 coding 
sequence is in the correct orientation for in vitro transcription to generate full 
length hax1 capped RNA for injection into single cell zebrafish embryos.   
Exon 7
Exon 7
Exon 6
Exon 6
Exon 5
Exon 5
Exon 5 Exon 4
Exon 4 Exon 3
Exon 3
Exon 3
Exon 3 Exon 2
Sp6 promoter
pCS2+ hax1 001
hax1 001 cds
Sv40 PolyA tail
M13 Rev
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7.13 Appendix 13: PCR primers for generation, amplification 
and sequencing of ZFN constructs 
7.13.1 Left ZFN subunit F1 and F2F3 primers: 
GoodF1Hax1aL  
 5'-ggccACCGGTATGAGTACGGGTATGACGGTCCAAAATATGACGACGCGA 
AAAGTTCCGCATGCAAAT-3' 
GoodF2F3Hax1aL 
5'-ggccACCGGTGAAAAACCGTTTCAGTGTCGGATCTGTATGCGAAATTTCT 
CCCGTCAGGACAACTTGGGTCGTCATCTACGTACGCACACCGGCGAGAAG
CCATTCCAATGCCGAATATGCATGCGCAACTTCAGTCGTAACGTTAACTTG
GTTACCCACCTAAAAACCCACCTGAG-3' 
Right ZFN subunit F1 and F2F3 primers: 
GoodF1Hax1aR  
5'-ggccACCGGTATGAGTACGGGTATGACGCAACAAGTTATGTGGACGCGA 
AAAGTTCCGCATGCAAAT-3' 
GoodF2F3Hax1aR  
5'-ggccACCGGTGAAAAACCGTTTCAGTGTCGGATCTGTATGCGAAATTTCT 
CCCATAAATCTTCTTTGACCCGTCATCTACGTACGCACACCGGCGAGAAGC
CATTCCAATGCCGAATATGCATGCGCAACTTCAGTCAGACCACCCATTTGT
CTCGTCACCTAAAAACCCACCTGAG-3' 
 
The F1 and F2F3 primers (4 nmole ultramer synthesis) for each the left and 
right subunits were purchased from Integrated DNA Technologies, Coraville, IA.  
 277 
7.13.2 PCR primers for ZFN construct amplification and sequencing 
 Sequence Product 
size (bp) 
Annealing 
temp. 
(°C) 
LCS2 
goodRCS2 
5’-GAAAAGTTCCGCATGCAAAT-3’ 
5’-CACCTAAAAACCCACCTGAG-3’ 
4867 50 
LseqC2 
RseqCS2 
5’-TGCAGGATCTGCCACCAT-3’ 
5’-TCCTTGATCCACCCAAATGT-3’ 
602 50-60 
LseqFok 
RseqFok 
5’-GCCAGAAATTCCACTCAGGA-3’ 
5’-CCCCCTGAACCTGAAACATA-3’ 
705 50-60 
LHax1ZFN 
RHax1ZFN 
5’-AGTCAGCCTTCAACTGTGTGT -3’ 
5’-TGGCAGACCTCGATTTACCT-3’ 
305 50-60 
LHax1ZF454 
RHax1ZF454 
5’-CGTATCGCCTCCCTCGCGCCATCAG 
acgagtgcgtAGTCAGCCTTCAACTGTGTGT-
3’ 
5’-CTATGCGCCTTGCCAGCCCGCTCAG 
cgagagatacTGGCAGACCTCGATTTACCT-
3’ 
375  
atitanium 
btitanium 
5’- CGTATCGCCTCCCTCGCGCCATCAG -
3’ 
5’- CTATGCGCCTTGCCAGCCCGCTCAG -
3’ 
375  
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7.14 Appendix 14: Validation of the ZF (F1-F3 array) and 
nuclease domain sequences of the left and right hax1 targeting 
ZFN expression vectors  
7.14.1 Validation of the Left ZFN ZF sequence (Colony L12) 
a.) 
 
 
 
 
 
 
 
b.) 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequence of the Left ZFN subunit expressing colony L12 using 
LseqCS2 (a.) and RseqCS2 (b.). Query: Expected 569 bp PCR product. 
Subject: Sanger sequencing output. 
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7.14.2 Validation of the Right ZFN ZF sequence (Colony R3) 
a.) 
 
 
 
 
 
 
b.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequence of the Right ZFN subunit expressing colony R3 using 
LseqCS2 (a.) and RseqCS2 (b.). Query: Expected 599 bp PCR product. 
Subject: Sanger sequencing output. 
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7.14.3 Validation of the Left ZFN FokI sequence (Colony L12) 
a.)  
 
 
 
 
 
 
 
b.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequence of the Left ZFN subunit expressing colony L12 using LseqFok 
(a.) and RseqFok (b.). Query: Expected 705 bp PCR product. Subject: Sanger 
sequencing output. 
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7.14.4 Validation of the Right ZFN FokI sequence (Colony R3) 
a.)  
 
 
 
 
 
 
 
 
b.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sanger sequence of the Right ZFN subunit expressing colony R3 using 
LseqFok (a.) and RseqFok (b.). Query: Expected 705 bp PCR product. Subject: 
Sanger sequencing output. 
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7.15 Appendix 15: Roche Titanium 454 sequence comparison 
analysis of the hax1 amplicon generated from gDNA of hax1 
ZFN injected embryos  
 
Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
 284 
 
Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
 
 285 
 
Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
 297 
 
Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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Amplicon identity- x (number of occurrences) (sequence size). Red letters 
denote changes in the sequence. ZFN spacer region:218-222. 
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7.16 hax1 gene sequence input into the TALEN Targeter 2.0 
tool for identification of TALEN sites and hax1 exon 2 specific 
TALEN RVD sequences 
aatcatggttttttttaatacagGGACCCCTTCTTTGATGGAATGATTCATGAAGATG
ATGATGATGAAGACGAGGATGACTTTAACAGACCCCATCGGG 
50 bp of DNA sequence 5’ and 3’ of the BspHI site (highlighted yellow) were 
inserted into the online tool. Lower and upper case sequences denote intronic 
region and exonic regions, respectively. 
 
LEFT TALEN RVD Sequence: NI, HD, NI, NN, NN, NN, NI, HD, HD, HD, HD, 
NG, NG, HD, NG, DNA sequence recognised: ACAGGGACCCCTTCT. 
 
RIGHT TALEN RVD Sequence: HD, NG, NG, HD, NI, NG, HD, NI, NG, HD, NI, 
NG, HD, NI, NG, HD, NG, DNA sequence recognised: AGATGATGATGATGA 
AG).  
 
Spacer region sequence: TTGATGGAATGATTCATGA.
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7.17 Appendix 17: Golden Gate TALEN assembly plasmids 
Adapted from (Cermak et al. 2011). Note not all of the available plasmids are shown.
RVD plasmid (Module)
Last half RVD repeat plasmid
Array plasmid
HD®C
NI®A
NG®T
NN®G
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7.18 Appendix 18: A map of the Golden Gate TALEN assembly generic backbone 
 302 
7.19 Appendix 19: Primers required for amplification and 
sequencing of the TALEN constructs and hax1 specific 
TALEN target site 
Target Sequence Expecte
d size 
(bp) 
Annealing 
temp. (°C) 
TAL_R2 Forward 5’- ggcgacgaggtggtcgttgg -3’ - - 
SeqTALEN_5-
1 
Forward 5’- catcgcgcaatgcactgac -3’ 
 
- - 
Hax1TalRE Forward 5’-
GGTTAAAAATCCAACGGCACT -3’ 
Reverse 5’-
TGCTTCACCCATGTCACCTTA-3’ 
534 bp 55 
Hax1TalRE (1) Forward 5’-
AAGCACTTTTGGTGTAATGGTAATC-3’ 
Reverse 5’- 
CCAGCAAACATCTCCTCCATGTCTC-3’ 
367 bp 55 
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7.20 Annotation of left and right hax1 specific left and right 
TALEN encoding vector sequences 
7.20.1 Left TALEN subunit ((Lhax1pCAGT7-TALEN(Sangamo)) 
 
 
 304 
 
 
 305 
 
 
 
 306 
 
 
 
 307 
 
 
 
 
 
 308 
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7.20.2 Right TALEN subunit (Rhax1pCAGT7-TALEN(Sangamo)) 
 
 
 
 
 310 
 
  
 
 
 
 311 
 
 
  
 
 
 312 
 
 
  
 
 313 
 
 
 
 
 314 
 
 
 
 
 
 315 
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